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Summary
The debate regarding the contribution of adult stem/progenitor cells during
normal growth and beta-cell regeneration is far from being resolved. Therefore, we
addressed in two distinct situations the origin of new beta-cells. We exploited a
Cre/loxP lineage tracing system to efficiently label beta-cells in double transgenic
mice (Z/AP; RIPCreERTAM) to address the origin of new beta-cell during the beta-
cell mass expansion in response to one and two pregnancies. Similarly, we examined
origin of new beta-cell after diabetic recovery in triple transgenic mouse (Z/AP;
RIPCreERTAM; pIns-c-MycERTAM). Finally we evaluated the functionality of
regenerated beta-cells after diabetic recovery in the single pIns-c-MycERTAM mouse
model by microfluorimetry, in collaboration with Dr P. Squires. We showed that the
beta-cell functionality in the pIns-c-MycERTAM line was abnormal. Second, we
showed that the human placental alkaline phosphatase label (HPAP) in the double
and triple transgenic mice was 1) specific to beta-cells, 2) irreversible and heritable
and 3) tamoxifen dose-dependant. Third, the analysis of the proportion of beta-cells
labelled for HPAP in one pregnancy, showed that the HPAP labelling index of the
non-pregnant animals (0.44±0.05) was greater that in the pregnant group
(0.33±0.06),(paired two-tailed t-test, P-value 0.021), indicating a dilution of the label
in pregnant animal pancreata. Furthermore the combined results of the mean HPAP
labelling index in non-pregnant animals (0.44±0.12) and pregnant animals
(0.33±0.09) in one and two pregnancies reinforced our results above by indicating
that the difference between the two groups was considered extremely significant
(paired, two-sided student t-test, P-value 0.0007). Likewise, we showed that two to
three months after the tamoxifen pulse, beta-cells do not fully lose differentiation or
transdifferentiate into other lineages of either endocrine or exocrine compartment. In
conclusion, we demonstrated for the first time that non-beta-cell progenitors
contribute significantly to the increase of the beta-cell mass in response to pregnancy
in combination with pre-existing beta-cell self-duplication.
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Introduction
Diabetes mellitus is characterized by abnormal glucose homeostasis (namely
elevated blood glucose), which is associated with cardiovascular disease, retinopathy,
neuropathy and nephropathy. It is estimated to affect currently 150 million people
worldwide and this figure is predicted to double by year 2025 (Prentki and Nolan,
2006). Two major types of diabetes are recognised, type 1 results from autoimmune
destruction of beta-cells and type 2 (representing 90% of cases) resulting from a
combination of impaired peripheral action of insulin (insulin resistance) and
inadequate compensatory adaptation of beta-cells resulting at the later stage of the
disease to a significant decrease of beta-cell mass.
Currently available drugs do not prevent the decline in beta-cell mass and
function so that most patients will require increased doses of drugs and eventually
insulin to control their blood glucose levels. In fact, at present the only hope is to
prevent diabetes by encouraging healthy eating, weight control and exercise or, in
established diabetes, to replace missing beta-cells by transplantation. Islet
transplantation is proven to normalize patient’s blood glucose level for several years.
Unfortunately the shortage of donor human pancreatic islets severely limits the
number of diabetic people able to benefit from it.
Therefore, faced with such a rising problem, a large research effort is directed
at developing alternative sources of beta-cells for transplantation or to develop new
strategies to maintain/restore the endogenous pancreas beta-cell mass. At least in
some respects, regeneration of beta-cells in the adult recapitulates elements of beta-
cell developmental ontogeny. So first, I will describe what is known about pancreas
development and second how this knowledge can be translated to ex and in vivo
strategies to artificially yield unlimited sources for new beta-cells. Finally, I will
introduce the relevance of my research in relation to the debate concerning the
elusive adult pancreatic progenitor or stem cell.
1.1 Mouse pancreas and beta-cell development
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The growing interest for pancreas development derives from diseases related
to this organ such as diabetes and to a lesser extent, cancer. Pancreas development
represents an experimental system to investigate cellular and molecular pathways
involved in pancreas and beta-cell ontology during normal conditions. Knowledge
gained from this model could be applied to regenerate or stimulate an endogenous
functional beta-cell mass in patients, to direct glucose-responsiveness beta-cell-like
phenotype formation from embryonic cells or other cell types. Likewise, it could
allow understanding mechanisms responsible for pancreas homeostasis or beta-cell
regulation during development and postnatal life. Because Piper et al. (Piper et al.,
2004) reported that human pancreas development resembles that of mouse, we will
describe processes regulating pancreas development specifically in the mouse owing
to the great amount of available information provided from this species in this field.
Even though, Bonner-Weir et al. (Bonner-Weir et al., 2004) mentioned some
differences in major pathways in mouse and human for new beta-cells in postnatal
life.
1.1.1 Pancreas anatomy and function
The pancreas is composed of three integrated tissue-types, which are the
exocrine, endocrine and ductal components. The exocrine compartment forms the
bulk of this organ, around ninety to ninety-five percent of the pancreatic mass, and it
is organized into acini which develop at the termini of ducts. The exocrine
compartment is a branched, lobulated organ in which cells grouped in the acinus
secrete digestive enzymes important for food processing in the gut (lipases, proteases,
nucleases) in an inactive form in the intestine via an elaborated pancreatic ductal
network. Duct cells secrete bicarbonate ions and electrolytes. These enzymes
become active only in the digestive tract, and the secretory process of the acini is
tightly regulated by hormone stimulation. The endocrine gland, by contrast,
represents one to two percent of the organ, is organized into islets of Langerhans
which are compact globular clusters of cells embedded in the exocrine component.
Five endocrine cell-types compose the islets of Langherans: beta-cells, secreting
insulin and also an insulin antagonist amylin, alpha-cells, secreting glucagon, delta-
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cells, secreting somatostatin, PP-cells, secreting pancreatic polypeptide (PP), and the
recently described epsilon-cells producing ghrelin. Overall, beta-cells form the core
of the islets, alpha-cells are located at the periphery of the islets, while somatostatin
and PP-cells are scattered within or at the mantle of islets. Insulin has a binary action,
it possesses both mitogenic and metabolic (specifically by promoting glucose uptake)
effects on its target tissues (Slack, 1995, Murtaugh, 2007, Collombat et al., 2006).
1.1.2 Pancreas ontology
The pancreas is a complex organ composed of exocrine and endocrine tissues
that fulfil distinct functions. The processes coordinating pancreagenesis imply
complex molecular interplays which are becoming understood due to identification
of key signalling pathways and transcription factors controlling pancreatic
development.
1.1.2.1 Outline of mouse pancreas development
During mammalian development (Figure 1), the definitive endoderm, in
addition to the two others germ layers (i.e. ectoderm and mesoderm) is formed and
specified during gastrulation, in an area named the primitive streak. Molecular
factors such as Wnt/beta-catenin, Nodal, GATA-4/6, FoxA2 (forkhead box A2),
Sox17 (SRY-box containing gene 17), and Mix are required for definitive endoderm
formation. The definitive endoderm subsequently develops into the primitive foregut
epithelium which will become committed to a pancreatic fate around E.8.5
(embryonic day eight) with the expression of the pancreatic duodenal homeobox 1
(Pdx1) transcription factor. The thickening region of the posterior foregut endoderm,
around E.9-9.5, gives rise dorsally and ventrally to one and two buds respectively in
the mouse embryo. But later, one of the ventral primordia will regress. Subsequently
as embryogenesis proceeds, the two pancreatic buds expand, and branch into the
surrounding mesenchyme. Then consecutive rounds of branching, further growth and
differentiation result in the formation of a fully mature single organ prior to birth, the
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Figure 1 Overview of mouse pancreatic organogenesis. Mouse embryonic
development is shown from early primitive streak stage (E.7) through endoderm
migration and specification, pancreatic budding, branching morphogenesis, and
differentiation of pancreatic lineages. Multipotent progenitors that give rise to all
pancreatic lineages express Pdx1, Ptf1a, CPA, and c-Myc in early pancreas
development, while exocrine progenitors express CPA during mid-pancreatic
development. At all stages, endocrine progenitors express Ngn3. (Oliver-Krasinski
and Stoffers, 2008).
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ventral and dorsal pancreas having been brought into contact by the rotation of the
stomach and duodenal region at E.12.5 (Slack, 1995, Murtaugh, 2007, Zhou et al.,
2007, Murtaugh and Melton, 2003, Offield et al., 1996, Jensen, 2004, Oliver-
Krasinski and Stoffers, 2008, Guo and Hebrok, 2009, Ackermann and Gannon, 2007)
At the earliest stage of pancreagenesis called “the primary transition”, around
E.9.5, epithelial cells express endocrine hormones but the glucagon secreting-cells
are certainly the most predominant. We note in passing that the order of appearance
of the endocrine lineages during the early stage of pancreatic development is still
uncertain (Herrera et al., 1991, Gittes and Rutter, 1992, Herrera, 2000).
Subsequently, during the period called “the second transition”, around E13.5-15.5,
endocrine cells of the five endocrine lineages differentiate and proliferate
exponentially, and beta-cells secreting insulin become the majority lineage from this
stage onwards. Then, the new endocrine cells detach from the epithelium to
aggregate into islet clusters. Deltour et al. (Deltour et al., 1991) have demonstrated
that these endocrine cells composing the islets are of polyclonal origin. What’s more,
during this time-window, amylase-expressing acinar cells begin to differentiate. At
the final stage of islet formation and maturation, vascularisation and innervation of
the islets are observed. In addition to key transcription factors required for pancreatic
growth, morphogenesis and differentiation during development, soluble and
membrane-bound factors from the surrounding tissue are crucial for directing these
cascades of events; particularly the interplays between the mesenchyme and the
pancreatic epithelium (Zhou et al., 2007, Murtaugh and Melton, 2003, Maestro et al.,
2003, Oliver-Krasinski and Stoffers, 2008, Guo and Hebrok, 2009, Edlund, 2002).
A recent study from Zhou and collaborators (Zhou et al., 2007)
reported multipotent progenitors positive for Pdx1, Ptf1a, c-Myc and
carboxipeptidase A1 (CPA1). They are localized at the tips of the epithelium
branches within the early pancreatic primordia, while the trunks of the branches are
formed of endocrine and ductal cells (Figure 1 and 2). The authors have shown, by
cell-lineage tracing, that this multipotent progenitor, positive for CPA1, gives rise to
all pancreatic cell types. Of note, CPA1 during postnatal life is restricted to acinar
cells. Subsequently, the proliferation of the multipotent progenitors positive for
CPA1 at the tips of branches, leads to the elongation of the finger-like epithelium
Chapter 1: Introduction
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Figure 2 Multipotent Progenitors Guide Pancreatic Organogenesis.(A) CPA1+
multipotent progenitors give rise to exocrine, endocrine, and duct cells in vivo and
may undergo limited self-renewal. (B) Early pancreatic buds are composed primarily
of multipotent progenitors. At the onset of branching morphogenesis (E.12), the
multipotent cells may divide asymmetrically such that they are propelled away from
the centre of the pancreatic buds, thus producing branches. Continued fast
proliferation and differentiation of these progenitors into endocrine and duct cells
generate the trunk of the branches. When the branching tip divides, CPA1 is down
regulated in the cleft region. Around E.14, CPA1+ tip cells restrict to exocrine fate
during the secondary transition (Zhou et al., 2007).
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(the branch) within the pancreatic anlagen, and the cells left behind the tips become
more differentiated and later will be converted into endocrine and ductal cells which
make up the trunks of the branches. Ultimately, the endocrine cells differentiate and
migrate away from the epithelium, leaving the trunks to be composed entirely of duct
cells. Then, during midgestation, at a developmental stage termed “second
transition”, the multipotent progenitors confined to the branch tips differentiate into
exocrine cells.
1.1.2.2 Pancreas and beta-cell development
Key transcription factors critical for pancreas organogenesis at different
stages of development have been defined by genetic lineage tracing methods and the
use of mutant animals for the loss and gain of function studies of these transcription
factor genes. Thus, it has been shown that the transcription factors Pdx1 and Ptf1a
are expressed in cells that are progenitors giving rise to all pancreatic cell types
(Offield et al., 1996, Kawaguchi et al., 2002, Ahlgren et al., 1996). Pdx1 and Ptf1a
are expressed at the early stage of pancreas development around E.8.5 and E.10.5
respectively and are important for pancreatic specification, and subsequently for
pancreatic growth and differentiation of all pancreatic lineages. Kawaguchi and
collaborators have shown, by lineage tracing, that Ptf1a is required not only for the
establishment of the exocrine lineage but for all pancreatic cell types. Likewise,
Offield et al. and Ahlgren et al. (Offield et al., 1996, Ahlgren et al., 1996) reported
that Pdx1 was not essential for the initial pancreatic bud formation since the Pdx1-/-
null mice displayed a rudimentary pancreatic anlage, but it is required rather for the
specification of the early pancreatic epithelium and subsequently for pancreatic
growth, proliferation and differentiation of all pancreatic lineages. Thus the
requirement of other factors upstream of Pdx1 is critical for the initiation of pancreas
organogenesis (Oliver-Krasinski and Stoffers, 2008, Edlund, 2002). These studies as
well suggest that the programs governing dorsal and ventral pancreatic formation
have distinct pathway requirements (Kumar and Melton, 2003, Guo and Hebrok,
2009).
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Examination of Ngn3-null mice combined with lineage tracing studies
has revealed that neurogenin3 (Ngn3) is a key transcription factor required for
endocrine cell differentiation (Guo and Hebrok, 2009, Gradwohl et al., 2000,
Schwitzgebel et al., 2000). It is transiently expressed during development (it peaks at
E.15.5), it is positively regulated by Hfn6 (Hepatic Nuclear Factor6) (Maestro et al.,
2003), and its expression marks endocrine precursor cells that give rise to all islet
cells, but this progenitor cell is not self-renewing. Ngn3-expressing cells characterize
the immediate precursors for the endocrine cells in the developing organ.
Experiments in which Ngn3 was misexpressed have demonstrated that this
transcription factor per se is not sufficient to induce the differentiation of beta-cells.
Therefore additional signals are required to induce the beta-cell lineage
(Schwitzgebel et al., 2000). Indeed, Ngn3 activates a set of genes including Isl1
(Lim homeodomain factor), neurod1 (neurogenic differentiation1) and Insm1/IA1
(insulinoma-associated1) that are essential for the development of islet cell lineages.
Then, a combination of additional factors expressed in endocrine precursors further
restricts the latter into a specific endocrine lineage. Pax4 (pair box gene 4) and Arx
(aristaless related homeobox) are Ngn3 target genes, and precursor cells that express
either Pax4 or Arx later will develop into beta-cells or alpha-cells respectively
(Collombat et al., 2003). Thus, beta-cell specification and maturation requires
additional transcription factors, including Pax4, Pax6, Nkx2.2 , Nkx6.1, MafB, Pdx1,
Hlxb9 reviewed by Murtaugh and Melton, 2003, Guo and Hebrok, 2009, Spence and
Wells, 2007, Collombat et al., 2006 and presented in figure 3. A model becomes
apparent regarding the role of the bi-potential Pdx1 progenitor cells. In the presence
of notch signalling and mitogenic signals, either the Pdx1 progenitor pool grows and
multiplies to be available later for endocrine and exocrine differentiation, or if it
escapes these factors, then Ngn3 is up-regulated and this progenitor undergoes
endocrine differentiation (Murtaugh and Melton, 2003, Ackermann and Gannon,
2007). Finally, Gu and colleagues (Gu et al., 2002) demonstrated by a lineage
tracing method, that Ngn3-expressing cells function also as islet-progenitors in adult
mice during renewal and maintenance, recapitulating in this respect the mechanism
used to produce endocrine cells during pancreas organogenesis.
Figure 3 Transcription f
endodermal derivatives.
each stage of differentiation. Factors initially expressed at a particular stage are
colour-coded as follows: gut endoderm (
(blue), early endocrine progenitor (black), endocrine progenitor
(Adapted from Oliver
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actor profile during stages of cell formation from
The diagram indicates transcription factors expressed at
purple), pancreatic endoderm progenitor
(orange),
-Krasinski and Stoffers, 2008).
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cell (red).
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1.1.3 Signalling pathways and transcription factors in the developing pancreas
Studies dedicated to the appreciation of events directing pancreagenesis have
demonstrated that the presence of signal transduction molecules and transcription
factors in tissues prefigure the processes that govern pancreas development. Thus,
spatio-temporal expression of key transcription factors and signalling pathways can
be an indicator predicting the fate of undifferentiated cells in the developing
pancreas. In the following, I will describe the main transcription factors and
transduction pathways important for pancreatic organogenesis because they could be
instrumental in understanding how to generate ex-vivo beta-cell-like cells.
1.1.3.1 Signalling pathways
Pancreas development is conducted by extracellular factors that are part of
signalling pathways, and which are secreted by the surrounding environment. Thus,
factors secreted by mesodermal tissues such as the notochord and, later, the dorsal
aorta are critical for dorsal pancreatic specification. The lateral plate mesoderm that
is positioned underneath the presumptive ventral pancreatic endoderm provides
factors that initiate the ventral pancreatic region, likewise the dorsal aorta or
endothelial cells (Kumar and Melton, 2003). Many signalling pathways including
Hedgehog, Fgf (fibroblast growth factor), Notch, Wnt/beta-catenin, and TGF-beta
(transforming growth factor) transduction pathways, regulate important phases of
pancreas development. I will describe succinctly their functions, although this list is
not exhaustive, reviewed by authors in brackets (Oliver-Krasinski and Stoffers, 2008,
Murtaugh and Melton, 2003, Guo and Hebrok, 2009, Edlund, 1998, Edlund, 2002,
Kim and Hebrok, 2001, Dhawan et al., 2007, Spence and Wells, 2007).
Hedgehog signalling
Studies of members of the Hedgehog family (interacting with the Patched
receptor), particularly sonic hedgehog, have shown that the expression of the latter is
excluded from the dorsal and ventral pancreatic anlagen. This exclusion by inhibition
of sonic hedgehog within the two anlagen is crucial for Pdx1 expression and the
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specification of both pancreatic primordia, at an early stage of pancreas
organogenesis. The dorsal endoderm at an early stage of gut formation is normally in
contact with the notochord, a transitory mesodermal structure that secretes soluble
factors such as members of TGF/ activin and Fgf family, before the two structures
will be separated around E.8.5 by the midline fusion of the paired dorsal aortas. And
these notochord-derived-signals (including activin beta B and Fgf2) prevent sonic
hedgehog expression. Since the notochord is not in close proximity to the ventral
part of the endoderm, these signals blocking hedgehog expression in the ventral part
of the primitive gut might be secreted by other tissues, such as the lateral plate
mesoderm. By repressing sonic hedgehog, activin and Fgf induce expression of
pancreatic genes. Thus the down regulation of sonic hedgehog before pancreas
organogenesis later inhibits intestinal differentiation and promotes pancreatic fate in
the posterior foregut endoderm.
Endothelial signals
Aorta-derived endothelial cells in contact with dorsal endoderm induce in this
region, the expression of Ptf1a and maintain Pdx1 expression. Thus, the endothelium
has a critical role for pancreatic specification and beta-cell differentiation and
proliferation.
Fgf signalling
In addition to Fgf2, members of the Fgf family play an active role in
initiating the pancreatic program. Fgf10 expressed by the dorsal and ventral
mesenchyme from E.9.5 to E.12.5 is also involved in pancreatic specification by
promoting expression of Pdx1 and the maintenance of Ptf1a. During later stages,
Fgf10 stimulates division of pancreatic progenitors positive for Pdx1, and
consequently inhibits their differentiation into endocrine cells, through activation of
Notch signalling and Hes1 (hairy and enhancer of split family) expression. Thus, this
preserves the pancreatic progenitor pool for early differentiation. Studies focused on
the Fgf signalling will help deciphering the mesenchyme-to-epithelium critical
signalling for pancreatic growth, morphogenesis and differentiation.
Notch signalling
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Interaction of the membrane-bound ligand Delta or Jagged/Serrate with the
Notch receptor on neighbouring cells leads to cleavage of the Notch intracellular
domain (NICD) resulting in its translocation in the nucleus where its transcription
factor property activates genes such as Hes1. In turn Hes1, by inhibiting Ptf1a
activity and Ngn3 expression in these cells, prevents early differentiation of
pancreatic progenitors into exocrine and endocrine cells respectively. Thus, Notch
signalling at the early stage of pancreas organogenesis has a critical role for
maintaining the pool of pancreatic progenitors in an undifferentiated state.
Wnt signalling
The Wnts bind to Frizzled receptors and LRP5/LRP6 coreceptor in the
plasma membrane. Upon translocation into the nucleus, beta-catenin cooperates with
transcription factors such as TCF/LEF to activate transcription of genes. Wnt/beta-
catenin signalling plays a role in the maintenance of Ptf1a-positive exocrine
progenitor cells. There is evidence that Wnt signalling plays a role in the endodermal
versus mesodermal fate choice.
TGF-beta signalling
TGF-beta signalling is required for specification and branching of the
pancreatic epithelium. Elements composing TGF-beta signalling were detected in
developing pancreatic epithelium and mesenchyme. Nodal, a member of this family,
plays a role in promoting endodermal and mesodermal formation, and high dose of
this factor might be important to direct an endodermal fate. Activin and growth
differentiation factor, also members of the TGF family, are involved in the endocrine
and exocrine lineage development. Other members are TGF-beta, inhibin, Bone
Morphogenetic Protein (BMP), ligand antagonist such as follastin, and the
intracellular mediators Smads. BMP regulates, with retinoic acid, global anterior-
posterior patterning of the gut and these signals and others specify the endoderm at
gastrulation to induce a pancreatic fate or make it competent to respond later to other
factors
1.1.3.2 Transcription factors during pancreas and beta-cell development
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Studies using genetically modified mouse technology have led to considerable
progress in understanding the sequential activation of signal transduction pathways and
the expression of transcription factors critical for pancreas development. Below is a
current list of transcription factors known to be involved in pancreas development and
elegantly reviewed by authors in brackets (Spence and Wells, 2007, Murtaugh and
Melton, 2003, Guo and Hebrok, 2009, Edlund, 1998, Edlund, 2002, Dhawan et al.,
2007, Jensen, 2004, Slack, 1995, Kim and Hebrok, 2001, Habener et al., 2005,
Chakrabarti and Mirmira, 2003). This list is of course not exhaustive.
Endodermal establishment and the core endodermal program
FoxA2 (HnF3β) is a key protein in endodermal development and required to 
generate midgut and foregut endoderm in most species. It is expressed at first in
embryo at E.6.5, then in the foregut endoderm, notochord and floor plate prior to
pancreas formation. In mature beta-cells it controls insulin secretion.
HnF4α is expressed throughout pancreatic development and is important for 
adult beta-cell function.
HnF1α is expressed at E.10.5, and important for mature beta-cell function 
and abundant in adult endocrine cells.
HnF1β seems to play a role in the establishment of the endodermal program, 
later in the epithelium of both pancreatic buds and it becomes restricted to ductal
cells cell by E.14, even though it continues to be express in endocrine cells at a low
and detectable level. Also it might be required for activating pancreatic (Ptf1a, Hfn6)
and endocrine (Ngn3) gene expression and for regulating the generation of endocrine
precursors. HnF1β positive cells may be the immediate precursors of Ngn3 positive 
progenitor cells.
GATA-6 is expressed at E.9.5, present in developing ducts, endocrine
precursors. Later it is restricted to endocrine cells.
HnF6 has a role in pancreatic determination and it is essential to the
generation of Ngn3 positive progenitor cells. It is expressed before Pdx1 activation
in the prospective pancreatic domains and it is capable of activating the Pdx1
promoter.
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Nrsa2 it is expressed in early endoderm development in liver and pancreas. It
is expressed in pancreatic ductal and exocrine cells in the mature organ.
Pancreatic determination and progenitors
Pdx1/IPF1 expression begins at E.8.5 in the dorsal and ventral gut epithelium
endoderm region that give rise to pancreatic primordia. Cell expressing Pdx1 and
Ptf1a are progenitors giving rise to all pancreatic cell types. The early glucagon
producing endocrine cells do not express Pdx1. Progressively Pdx1 becomes
restricted to beta-cells and a subset of delta and PP-cells. Its cofactors such as Pbx
and Meis2 in the pre-pancreatic domain by regulating the action of Pdx1, might
result in directing a subpopulation of the Pdx1-positive endoderm cells towards a
pancreatic fate. Pdx1 plays a role in several aspects of adult beta-cell function.
Ptf1a protein is detected in the early pancreatic epithelium at E.10.5 (Ptf1a
mRNA at E. 9.5). Cells expressing Ptf1a in the developing pancreas are progenitors
of all pancreatic cells and not only those of the acinar lineage. It is expressed only in
foregut cells that become devoted to pancreatic fate and decides whether cells
allocated to the pancreatic anlagen proceed towards pancreagenesis or revert back to
duodenal fate. Ptf1a determines which cells positive for Pdx1 in the wide Pdx1
population will undergo pancreatic differentiation. Later it is restricted to adult
acinar cells.
Sox17 is early marker of the definitive endoderm and it is required for
pancreas formation
Sox9 is detected in the pancreatic epithelium of progenitor cells expressing
Pdx1 at E.9-9.5. It plays a role in the maintenance of the pancreatic progenitor pool.
It is co-expressed with Ngn3 progenitor cells, and in vitro studies suggest that Sox9
positively regulates Ngn3 gene.
Hlxb9 (homeobox b9) it is expressed throughout the early dorsal and ventral
pancreatic domain and the notochord but its expression in the dorsal pancreatic
primordium precedes Pdx1. It is present in pancreatic progenitor cells. Later it has a
role in adult beta-cells.
Islet progenitors
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HnF1β function was described above. 
Ngn3 expression is detected first in the embryonic pancreatic epithelium at
E.9.5 at a high level, peaks at E.15.5, then, declines progressively so that it is no
longer detectable at birth and during the postnatal life. It is expressed in the
immediate precursors of endocrine cells, and cells expressing Ngn3 give rise to all
endocrine cells. It is positively regulated by Hnf6 and possibly by Sox9. HnF1β 
positive cells might be the immediate precursors of Ngn3 positive cells. In
progenitors expressing Ngn3, it is not sufficient to promote a beta-cell fate; other
competent factors are required. This suggests that the islet cell type decision is made
before the expression of the hormone.
Pax4 expression is visible at E.9.5 in both pancreatic anlagen but later it is
restricted to the developing beta-cells but not present in the adult. Lineage tracing
experiments have demonstrated that similar to Ngn3 positive cells, Pax4 positive
cells contribute to all endocrine lineages and might mark endocrine precursors. Ngn3
seems to activate Pax4 promoter directly and it is upstream of Pax4. Another Ngn3
target gene, the transcription factor Arx appears to co-express with Pax4. When both
Pax4 and Arx begin to repress the expression of the other, then two populations of
cells develop, one expressing Pax4 and the other Arx. Subsequently both cell
populations will differentiate into beta/delta-cell or alpha-cells respectively.
Lineage specification and beta-cells differentiation
Nkx2.2 it is detected around E.8.75-9.5 in the pancreatic epithelium and by
E.15.5 becomes restricted to endocrine alpha, beta and PP-cells. Nkx2.2 acts as a
repressor for alpha and beta-cells formation during development and as an activator
for beta-cell terminal differentiation. Later this transcription factor is expressed in
adult beta-cells and plays a role as activator in beta-cell function.
Nkx6.1: it is expressed in the dorsal and ventral pancreatic epithelium buds at
E.10.5. As development proceeds, Nkx6.1 is expressed in Ngn3 positive endocrine
precursors, and become restricted to the developing and adult beta-cells. Nkx.6.1
represses glucagon expression and regulates insulin secretion in adult beta-cells.
Also, Nkx.6.1 is required only for the second peak of beta-cell differentiation during
the period called “the second transition”, around E13.5-15.5.
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Maf A expression begins at E.13.5 in the beta-cell population and later is
expressed in adult beta-cells. Maf A is positioned downstream of Nkx6.1. In adult
beta-cells, Maf A promotes glucose-induced insulin released and interacts directly
with Pdx1 and NeuroD1/Beta2 to activate insulin gene transcription.
Maf B is expressed in both beta- and alpha-cells beginning at E.12.5 and is
restricted to alpha-cells during postnatal life. Maf B plays a role in beta and alpha-
cell differentiation and maturation.
Forkhead family transcription factors includes FoxA1 (Hfn3alpha), FoxA2
(Hfn3beta), FoxA3 (Hfn3gamma). In mature beta-cells FoxA2 regulate insulin
secretion.
Exocrine differentiation
PTF1a gene encodes P48 which plays a role in uncommitted pancreatic
precursors and does not program the exocrine fate simply by its expression.
MIST1 is strongly expressed in pancreas. It is required for maintaining
exocrine cell identity and it is restricted to exocrine cells.
In conclusion, during the last two decades, results from targeted gene
disruption and enrichment in mice, and from genetic lineage tracing experiments,
have established the role, and the spatial and temporal organization of transcription
factors and signals indispensable for pancreas organogenesis. By collective efforts
from different research groups, the cascade of events governing pancreas
development can be better understood. However, although a more coherent
description of the different phases of pancreagenesis has emerged, many important
questions in this area still have to be examined, such as the cross-regulation between
signalling pathways or transcription factors, to refine our understanding of the
overall mechanisms directing pancreas formation. Thus, the current understanding of
the genetic networks that govern pancreatic development can be applied to identify
the genetic signature of pancreatic or endocrine progenitors during development, and
as an instrumental tool to trace potential progenitors in postnatal pancreas. This
genetic network and signalling pathways may be also useful to transdifferentiate
non-beta-cell adult cells into functional beta-cell-like cells or to derive a glucose
responsiveness-beta-cell-like phenotype from embryonic stem cells.
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1.2 Human embryonic stem cells as a potential unlimited source for
beta-cells
Human embryonic stem cells (hESC) derived from the inner cell mass of
human blastocysts (Thomson et al., 1998) are capable of both unlimited self-renewal
and differentiation into all cell lineages of the body. Consequently differentiation of
hESCs into functional insulin-producing cell population, if achieved, could represent
a promising source of expandable surrogate beta-cells for cell-based therapies to
treat diabetes (Spence and Wells, 2007).
Progress in this fast moving field was made recently by developing protocols
in which the processes of hESC differentiation recapitulate in some aspect those of
embryonic pancreas development to generate hESC-derived insulin-producing cells.
In this regard D’Armour and colleagues (D'Amour et al., 2006) have proposed a cell
differentiation protocol that successfully converted hESC into endocrine islet cells.
Furthermore, the in vitro step-wise process conducting the hESC differentiation into
endocrine cells appeared to mimic the different stages of embryonic pancreagenesis.
Thus D’Armour’s protocol consists in converting first hESC into definitive
endoderm (DE). This was achieved by inducing the expression of Nodal expression
in those cells and other markers of embryonic definitive endoderm such as Sox17,
CXCRA (chemokine receptor), CER (the mouse Cerberus homolog) or FoxA2,
using a high concentration of activin A. One has to stress that the differentiation of
hESC into the DE is a critical step to later yield endocrine cells efficiently. The
second step is to differentiate the definitive endodermal cells into a phase that
resembles the embryonic primitive gut cells, this after activin A removal. At this
stage the hESC-derived cells are like primitive gut, expressing markers similar to the
embryonic primitive gut, such as Hnf1beta and Hnf4A. The third step is to
differentiate the hESC-derived cells resembling primitive gut into posterior foregut
endoderm, after addition of retinoic acid (RA), FGF10 and KAAD-cyclopamine (an
inhibitor of hedgehog signalling). The posterior foregut expresses at this stage a
combination of high level of Pdx1 and Hnf6 while the level of Hnf1beta and Hnf4A
is maintained or increased. In later stages, cell were cultured with exendin 4, insulin-
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like growth factor 1 and hepatocyte growth factor (HGF) to differentiate the
posterior foregut endodermal cells to pancreatic endodermal cells, pancreatic and
endocrine precursors which give rise to endocrine islet cells expressing insulin,
glucagon, somatostatin, pancreatic polypeptide and ghrelin hormones.
Unfortunately, with this protocol of hESC differentiation the insulin-
producing cells were not glucose responsive, suggesting that those cells were still
immature. However, another protocol of hESC differentiation developed by Jiang et
al. (Jiang et al., 2007a) successfully converted hESCs into glucose-responsive
insulin-secreting cells. They exposed a monolayer of hESCs (a two-dimensional
culture system) with low activin and sodium butyrate to generate definitive
endoderm. The latter was cultured in suspension (a three-dimensional culture system)
with FGF, noggin and EGF to promote the formation of Pdx1 positive cells and their
further differentiation into endocrine cells with addition of nicotinamide, insulin-like
growth factor 2. Also, ductal cells were evident in the final stage of the culture as
well as amylase mRNA, a marker of exocrine cells.
Thus, the spatial arrangement of the cells during the various steps of
differentiation may be an important element to consider to efficiency convert hESCs
to definitive endoderm and later into mature endocrine cells (Spence and Wells,
2007).
The next step to achieve for realistic progress regarding cell-based therapies
is to make certain that the hESC-derived beta-cells are capable of correcting diabetes
in animals after transplantation, and do not have any adverse effects. Indeed, in the
past previous protocols used to derive hESC into insulin-producing cells did not
recapitulate important elements of embryonic pancreatic development. As a result
the insulin-positive cells transplanted in diabetic animals induced by streptozotocin,
failed to restore euglycemia in those mice and furthermore formation of teratomas
was observed (Spence and Wells, 2007).
Kroon and colleagues (Kroon et al., 2008) used an improved protocol of
D’Armour to drive hESCs into definitive endodermal cells. Then, the hESC-derived
definitive endodermal cells were transplanted into immune-compromised mice to
promote their differentiation into mature endocrine cells. Subsequently, the latter
protected the mice from streptozotocin-induced hyperglycaemia, indicating that the
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hESC-derived insulin secreting cells were fully functional. However some mice
developed teratomas due to hESC-derived non-pancreatic endoderm, suggesting the
need of a step of purification to discard such unwanted cells. The formation of
teratomas, if it not prevented, could seriously undermine the utility of such an
approach for clinical application. In another study, the authors (Jiang et al., 2007b)
developed another differentiation protocol for hESC which led to the generation of
hESC-derived glucose responsive insulin-secreting cells in a step-wise process
mimicking embryonic pancreas organogenesis. They showed that the hESC-derived
functional insulin-secreting cells transplanted in streptozotocin-treated nude mice
protected them from hyperglycaemia. Importantly, the mice did not develop a
teratoma. However, the number of engrafted mice investigated in this report was
only nineteen compared to the number of forty-six grafts observed in Kroon’s report
(Kroon et al., 2008).
In conclusion, collectively, these studies underscore the requirement to use a
differentiation process that recapitulates pancreas development to guide hESC
differentiation into fully mature surrogate beta-cells and to eliminate any residual
hESC capable of forming teratomas (Spence and Wells, 2007, Oliver-Krasinski and
Stoffers, 2008, Guo and Hebrok, 2009).
Despite the fact that hESC hold great hope to derive expandable surrogate
beta-cells, a hurdle to its widespread clinical application relates to the problem of
rejection associated to allograft transplantation even though important progress has
been made by continuously optimizing immunosuppressant drugs. However, a
breakthrough that might represent an alternative to hESC, is the reprogramming of
somatic cells into pluripotent stem cells induced by defined transcription factors
(Park et al., 2008), and virus-free (Woltjen et al., 2009). The reprogramming of
somatic cell into induced pluripotent stem cells (iPS) promises to revolutionize
regenerative medicine because the use of patients’ own cells will possibly abrogate
the pitfall of graft rejection that impedes cell-base therapies, and because adult cells
that are easily available and in great amount could be utilized. Importantly, similar to
hESCs, iPS cells can differentiate into the three embryonic germ layers, so it will be
of interest to see whether in the future, differentiation protocols for hESC can be
applicable for iPS cells (Best et al., 2008, Guo and Hebrok, 2009).
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1.3 Transdifferentiation as a potential source for beta-cells
Internal organs such as the liver, gut or pancreas share a common endodermal
origin during development. Based on this observation and others, some groups
intended to transdifferentiate liver or gut cells into a beta-cell fate using mice model
such as Hes1 knockout mice (Burke and Tosh, 2005) or engineering approaches (Nir
and Dor, 2005). In theory an advantage of this strategy is the availability of these
types of autologous cells in patients.
Also in the pancreas, exocrine tissue has long been the centre of attention as a
source for new beta-cells. Bertelli and colleagues (Bertelli and Bendayan, 1997)
reported that after duct ligation in rats, intermediate endocrine-acinar pancreatic cell
phenotype appeared co-expressing insulin and amylase which may represent an
intermediate step in a transdifferentiating process. However, recently, Desai and
colleagues demonstrated by direct lineage tracing experiments that exocrine cells do
not give rise to new beta-cells during regeneration, at least in mice after inducing
various methods of pancreatic injury including duct ligation (Desai et al., 2007).
This result does not signify that exocrine cells are not able to transdifferentiate under
other circumstances. Indeed, Baeyens and colleagues (Baeyens et al., 2005) reported
the conversion of cultured exocrine cells into beta-cells under specific conditions.
This result was confirmed using direct lineage tracing by two other reports (Minami
et al., 2005, Okuno et al., 2007). Furthermore Minami et al. showed that the cultured
acinar cells also expressed markers recapitulating some aspects of pancreas
development, suggesting that the acinar cells in culture were able to revert into
immature pancreatic cells. These results demonstrate that exocrine cells are indeed
capable of sufficient cellular plasticity in vitro when exposed to specific signals. One
must stress, as Minami et al. in a review (Minami and Seino, 2008) reported, that the
acinar cell-derived insulin-producing cells are still immature and so full
differentiation of these insulin-positive cells has yet to be achieved to be really
instrumental for clinical application. In another recent report (Zhou et al., 2008), the
authors succeeded in reprogramming exocrine cells into beta-cells in mice, by
delivering key transcription factors controlling cell fate during pancreas development.
The reprogrammed beta-cells could partially correct hyperglycaemia in
streptozotocin-treated mice. This report is a perfect example of how reprogramming
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of differentiated adult cells might be used in the future to generate beta-cells or other
cell types using accessible patient cells.
1.4 Diffentiated beta-cells as a resource for new beta-cells
Replication of differentiated beta-cell during postnatal period could prove to
be effective either for replacing missing beta-cells in patients or for propagating
donor islet beta-cells ex vivo. The adult pancreatic cell mass was considered for a
long time as quiescent, but recent studies have shown that actually beta-cell mass is
dynamic and can fluctuate under normal and patho-physiological conditions during
postnatal life (Bouwens and Rooman, 2005). There is an abundant literature
dedicated to beta-cell mass regulation during adulthood, in which copious reports
reviewed by Cozar-castellano et al., Heit et al., Vasavada et al., Elghazi et al.,
Bouwens and Rooman, Ackermann and Gannon (Cozar-Castellano et al., 2006a,
Heit et al., 2006, Vasavada et al., 2006, Bouwens and Rooman, 2005, Ackermann
and Gannon, 2007, Elghazi et al., 2006, Lee and Nielsen, 2009) support the view
that beta-cell proliferation is essential for the maintenance and generation of
postnatal beta-cell mass.
Most of these studies used animal models in which cell-cycle machinery or
elements of signalling pathways were altered (Fatrai et al., 2006, Marzo et al., 2004,
Zhong et al., 2007, Zhang et al., 2005a, Buteau et al., 2001, Nguyen et al., 2006,
Rulifson et al., 2007, Cozar-Castellano et al., 2006b, Karnik et al., 2005,
Krishnamurthy et al., 2006, Garcia-Ocana et al., 2000, Kushner et al., 2005,
Lindberg et al., 2005, Georgia and Bhushan, 2004). Kushner et al., Georgia and
Bhushan (cited above) showed that deletion of Cyclin D2 in mice was accompanied
with a dramatic beta-cell mass decrease during the postnatal life. Thus the authors
demonstrated that Cyclin D2, a component of the cell cycle, plays a critical role in
beta-cell mass expansion and maintenance during postnatal life. Marzo et al. showed
how a mutation of the Cdk4 gene encoding for Cdk4 another component of the cell
cycle (Marzo et al., 2004) could also disturb beta-cell mass growth. And many other
studies regarding alterations of other components of the cell-cycle showed similar
effects on the postnatal beta-cell mass development (see references above).
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Collectively these reports, have positioned cycling-beta-cells as the primary
mechanism for maintaining postnatal beta-cell mass and growth. Definitive proof
came from a pulse-chase lineage tracing experiment to follow the fate of beta-cells
during postnatal life, performed by Dor et al. (Dor et al., 2004). The author and co-
workers demonstrated for the first time with a genetic lineage tracing system that
pre-existing beta-cells were the main source for new beta-cells during beta-cell self
maintenance and expansion in adult mice. This lineage tracing experiment result was
reinforced by another study employing a DNA analogue-based lineage tracing
system (Teta et al., 2007). Collectively, these results indicate that pre-existing beta-
cells exhibit a remarkable proliferative capacity that could be exploited as a potential
source for regenerative medicine (Dor, 2006). However, Teta et al. in a study in
which they investigated beta-cell replication turnover in adult mice discovered that
beta-cell of old mice have extremely low rates of replication (Teta et al., 2005),
suggesting that beta-cell replication can be possibly a rare event in mammals and it is
tightly regulated (Kushner, 2006).This result was reinforced by Krishnamurthy et al
(Krishnamurthy et al., 2006) showing that regenerative potential of islets was age-
dependent in mice.
However, in contrast with these observations, there are circumstances in
which cell cycle restriction can be relaxed. For instance, in pregnancy, beta-cells
show remarkable proliferative capacity to expand the maternal beta-cell mass to
accommodate the increased insulin demand (Kargar and Ktorza, 2008). Thus
Karnick et al. and Gupta et al (Karnik et al., 2007, Gupta et al., 2007) demonstrated
that Menin and HNF-4alpa play a critical role in the regulation of beta-cell
replication in response to new metabolic demand characteristic of pregnant states.
The inability of these factors to coordinate the cell cycle pathway results in a failure
of the maternal beta-cell mass to expand properly in response to the increased
metabolic demand. Therefore, taken together, these works suggest that manipulation
of factors providing the right signals to proliferate might be used as a strategy to
force beta-cells to re-enter the cell-cycle and then expand beta-cell mass in diabetic
patients. Consequently this source may be seen as a promising avenue to expand
beta-cell mass in vivo and in vitro for future transplantation. Nevertheless, there are
important concerns that could limit this approach. First the promotion of beta-cell
replication using factors might induce unwanted neoplastic effects in other tissues in
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patients. Therefore these target molecules will have to be thoroughly tested before
any clinical trials. Second, in vitro expansion of islet beta-cells was proven to be
very difficult because of the loss of markers of differentiation over time in cultured
beta-cells (Guo and Hebrok, 2009, Limbert et al., 2008, Weinberg et al., 2007). But,
Ouziel-Yahalom and co-workers (Ouziel-Yahalom et al., 2006) described a culture
condition to propagate adult human pancreatic islets cells ex vivo, and allowing their
subsequent redifferentiation. At the same time Path and co-workers (Path et al., 2006)
reported the successful expansion of human islets over-expressing a nuclear protein
P8, without, in this case evidence of dedifferentiation. Thus, optimization of islet
culture conditions might be decisive for future application of donor pre-existing-
beta-cell propagation.
1.5 Adult pancreatic progenitor or stem cells as a source for new beta-
cells: the debate continues
Researchers have been fascinated during the last two decades by two major
questions related to adult pancreatic progenitor or stem cells. First, do adult
pancreatic progenitor or stem cells exist and second, do they contribute to beta-cell
mass renewal or growth during adulthood? Thus, the elusive progenitor or stem cell
to maintain endocrine lineages in postnatal life is a subject of ongoing debate in this
area of research which moreover does not seem to converge towards a general
consensus (Bonner-Weir, 2000a, Ackermann and Gannon, 2007, O'Neill et al., 2008,
Lee and Nielsen, 2009, Bonal et al., 2008, Xia et al., 2009, Guo and Hebrok, 2009,
Levine and Itkin-Ansari, 2008, Zhang et al., 2005b, Bonner-Weir and Weir, 2005,
Hanley et al., 2008, Limbert et al., 2008, Bonner-Weir et al., 2004).
It is well-established that endocrine lineages during pre-natal development
are the progeny of progenitor cells (neogenesis) within the primitive gut epithelium
that begin to express Pdx1 protein around E.8.5 (Gu et al., 2002). In postnatal
development, on the other hand, the picture is far less clear and the existence of
progenitors giving rise to pancreatic islet or beta-cells in adults is a highly
contentious issue. The first reports suggesting the existence of such a pancreatic
bona fide progenitor are related mostly to models of pancreatic regeneration caused
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by pancreatic injury, and histological observations. Regular analysis of human donor
pancreata examined by Bouwens and Pipeleers (Bouwens and Pipeleers, 1998),
revealed that single beta-cell units are frequently associated with ductules from
which they seemed to emerge by budding, as seen in the foetal and neonate pancreas.
These observations led the authors to suggest that beta-cell neogenesis might be
reliant on duct cell replication and differentiation. In models of pancreatic injury, the
majority of reports if not almost all, strongly suggested the existence of such elusive
progenitors within the duct, exocrine or endocrine compartments. Bonner-Weir and
co-workers developed (Bonner-Weir et al., 2004) solid argumentations in favour of
adult pancreatic ductal progenitors that regress to a less differentiated phenotype
with replication, before functioning as endocrine progenitors. Their results largely
came from the study of a model of ninety percent pancreatectomy, well-known to
induce pancreatic regeneration. Briefly, they showed that twenty four hours after
pancreatectomy, there was an increased proliferation in the duct compartment,
followed forty eight hours later by expression of the transcription factor Pdx1 in this
same component, a molecule has been suggested by others as a marker for adult
progenitor cells. Also analysis of the gene expression profile of isolated pancreatic
ducts, showed that ductal genes were preferentially expressed in newly formed islets
from the focal region of proliferating ducts but not in pre-existing pancreatic islets,
both from regenerated pancreas after partial pancreatectomy. Wang et al (Wang et al.,
1995) reported that partial duct ligation in adult rats resulted in islet cell neogenesis
that could be activated by stimulation of pancreatic ductal cells. In models of
chemical injury inducing specifically beta-cell ablation by toxic agents such as
streptozotocin or alloxan (Bonal et al., 2008), several authors also suggested that the
regenerative process after the insults was in part due to beta-cell neogenesis from
precursors residing in the duct or islet compartment (De Haro-Hernandez et al., 2004,
Yamamoto et al., 1997, Yamamoto et al., 2000, Li et al., 2004, Fernandes et al.,
1997, Guz et al., 2001). Other authors showed similar results in animals infused with
glucose (Lipsett and Finegood, 2002, Jetton et al., 2008), or in adult human
pancreatic islets treated with a combination of EGF (epidermal growth factor ) and
Gastrin in vivo and in vitro (Suarez-Pinzon et al., 2005). Furthermore, authors who
have studied models of transgenic mice expressing IFN-g (interferon-gamma) or
expressing a combination of Gastrin and TGFalpha (transforming growth factor
alpha) also suggest that islet neogenesis could be reactivated in the pancreatic duct
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epithelium of adult mice (Wang et al., 1993, Gu et al., 1994, Gu and Sarvetnick,
1993). What’s more, in vitro studies aiming to isolate and propagate pancreatic
progenitors and culture them in appropriate medium, came to similar conclusions
that a bone fide progenitor might exist in adult pancreas (Suzuki et al., 2004,
Seaberg et al., 2004, Zulewski et al., 2001, Yatoh et al., 2007, Peck et al., 2002).
Collectively, these reports strongly suggest the existence of putative
pancreatic progenitors that could be reactivated in certain circumstances or can be
isolated and propagate in appropriate in vitro setting. Even though these conclusions
are very convincing, none of these studies used a direct lineage tracing approach to
conclusively demonstrate the existence of the elusive adult pancreatic progenitors.
To confirm the existence of such adult pancreatic progenitors suggested by
authors above and others, Dor et al. (Dor et al., 2004), designed an elegant lineage
tracing system for beta-cells in order to trace beta-cell fate in adult mice.
Unexpectedly, they demonstrated that replication of pre-existing beta-cells was the
main mechanism that give rise to new beta-cells during the mouse lifespan and even
after partial pancreatectomy. This publication has had a massive impact in this field
and has cast doubt at its extreme on the existence of putative progenitors residing
within adult pancreas and the contribution of such progenitors during beta-cell
renewal and maintenance in adulthood.
These results were reinforced by two other studies. One, using the same
lineage tracing system in a model of transgenic mouse expressing the diphtheria
toxin in beta-cells after diabetic recovery (Nir et al., 2007). The other employing a
DNA analogue-based lineage tracing system (Teta et al., 2007).
But ultimately, very recently, because this field is moving fast, three reports
and a review, one after the other (Xu et al., 2008, Inada et al., 2008, Collombat et al.,
2009, Liu and Habener, 2009), have reinstated adult pancreatic progenitors on the
map. They have conclusively demonstrated that adult progenitors within the
pancreas do exist, are of ductal origin, and contribute significantly to the formation
of new beta-cells shortly after birth or during beta-cell regeneration after duct
ligation in mouse. First, Xu and colleagues (cited above), used a direct approach to
track down the origin of new beta-cells in response to duct ligation in mice, a well-
establish model of pancreatic injury and regeneration. They showed that new beta-
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cells were the progeny of Ngn3 positive endocrine precursors and the cultured
endocrine precursors were able to differentiate into islet cells in appropriate
conditions. This report was the first to demonstrate incontrovertibly that adult
progenitors do exist and reside in the pancreatic duct. Furthermore, if given the right
signals they could be activated to give rise to endocrine lineages in vivo and in vitro.
Second, Inada and co-workers (cited above), using a distinct direct approach,
demonstrated that ductal cells engender endocrine and exocrine lineages during the
neonate period, and in response to duct ligation, in mice. They generated mice
expressing the Cre-recombinase under the control of an adult ductal marker promoter,
that of the carbonic anhydrase II gene. Third, Collombat et al. (cited above) very
recently published an article in which they reported the certainty of adult progenitors
in pancreas and possibly residing in the ductal component. They demonstrated, using
a lineage tracing system that forced expression of Pax4 in glucagon-deficient mice,
the continual conversion of glucagon-expressing alpha-cells into insulin-expressing
beta-cells. Importantly, the generation of the alpha-cells was dependent of Ngn3-
positive progenitor cells.
Taken together, these reports indicate, in the context of regenerative medicine
that adult pancreatic progenitors could be manipulated in vitro to yield sufficient
surrogate beta-cells suitable for transplantation into diabetic patients. Additionally,
given the right factors, these adult progenitors may be activated to beget new beta-
cells in situ in patients.
In the light of new findings arising from the advent of novel genetic cell-
lineage techniques, undeniably there is a resurgence of the debate regarding the
mechanism by which new beta-cell arise in normal and patho-physiological
conditions. It is reasonable to address the cellular origin of new beta-cells in other
situations involving different types of stimuli. Pregnancy is an appealing model of
beta-cell mass expansion in which the origin for new beta-cells could be specifically
investigated.
1.6 Maternal adaptation in response to pregnancy
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The general mechanisms of maternal adaption to accommodate the new
metabolic demand during pregnancy, were studied by several authors in specific
situations reviewed by Sorenson and Brelje (Sorenson and Brelje, 2009), but none of
these reports used a direct approach to investigate the cellular lineages responsible
for the increased beta-cell mass. Still, it is established that pregnancy is accompanied
by a near doubling of the beta-cell mass (Scaglia et al., 1995, Blondeau et al., 1999,
Avril et al., 2002, Huang et al., 2009, Aerts et al., 1997, Gupta et al., 2007, Karnik et
al., 2007) mostly due to beta-cell cycling (Gupta et al., 2007, Karnik et al., 2007,
Scaglia et al., 1995, Avril et al., 2002, Brelje et al., 1993, Brelje et al., 2008,
Sorenson et al., 1993, Huang et al., 2009, Vasavada et al., 2000, Parsons et al.,
1992). Studies in pregnant rodents have shown that prolactin or placental lactogens
are responsible for up-regulation of islets during pregnancy (Sorenson and Brelje,
2009). The beta-cell mass adaptation to pregnancy seems to be regulated through the
prolactin receptor signal transduction pathways (Figure 5) (Brelje et al., 2004,
Sorenson and Brelje, 2009). Recently, Karnik et al. and Gupta et al. (Karnik et al.,
2007, Gupta et al., 2007) showed that beta-cell proliferation is largely accountable
for the beta-cell mass expansion in response to pregnancy, this through the
repression of the Men1 gene (which encodes a protein component of a histone
methyltransferase) and its targets (Karnik et al., 2007) or Hnf-4alpha (hepatocyte
nuclear factor-4alpha) (Gupta et al., 2007). Other adaptations during pregnancy
include a slight beta-cell hypertrophy (Huang et al., 2009), an increase in glucose-
induced insulin secretion, and a decrease of the threshold of the amount of glucose
that induces insulin secretion (Parsons et al., 1992). Also a substantial increase in
peripheral insulin resistance combined with a slightly lower blood glucose level and
elevated serum insulin level are observed during this state (Sorenson and Brelje,
2009). However, there is little information about whether beta-cell neogenesis takes
place during pregnancy (Parsons et al., 1995). For this reason, it will be of great
interest to use a direct approach to examine the contribution of non-beta-cell
progenitors during the beta-cell mass expansion in response to pregnancy.
1.7 Toxic-genetic model of beta-cell ablation and regeneration to
address origin of new beta-cells in patho-physiological conditions
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Identification of cellular sources capable of generating new beta cells in the
endogenous postnatal pancreas, or for transplantation, could have important
implications for developing new therapeutic strategies to treat diabetes more
efficiently.
In this context we employed a mouse model (pIns-c-MycERTAM) of toxic-genetic
ablation-regeneration of beta-cells, developed by Pelengaris and co-workers
(Pelengaris et al., 2002), to address the origin of new beta-cells after diabetic
recovery. In this model, beta cells are depleted by apoptosis after activation of the c-
Myc protein upon tamoxifen exposure. This results in the development in the mouse
of a diabetic phenotype, which, can be reversed by beta cell regeneration upon
tamoxifen withdrawal. The latter point constitutes the originality of this mouse
model which can be exploited to investigate the cellular sources for new beta-cells
after diabetic recovery, in combination with a cell-lineage tracing system.
1.8 Thesis aim
Thus, since the debate regarding the contribution of adult stem/progenitor
cells as a legitimate cellular source for new beta-cells, is far from being resolved, it
is justifiable to address the origin of new beta-cell in different circumstances where
other types of stimuli might be involved. This is the subject of my thesis. Indeed, we
exploited a Cre/loxP lineage tracing system to efficiently label β-cells to examine, 1) 
the origin of new beta-cells during the beta-cell mass expansion in response to
pregnancy, and 2) in a specific model of pancreatic regeneration, the origin of new
beta-cells after toxic-genetic beta-cell ablation in transgenic mice over-expressing c-
Myc (Pelengaris et al., 2002).
Finally, a further important question relates to the functionality of such newly
formed beta-cells subsequent to beta-cell mass depletion. Therefore, in parallel, we
evaluated the functionality of regenerated beta-cells in a mouse model of toxic-
genetic ablation cited above by single-cell microfluorimetry, in collaboration with Dr
P. Squires.
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Figure 4 During pregnancy, islet mass increases and insulin secretion becomes
increasingly sensitive to glucose stimulation. The figure highlights cellular events
that occur in islet cells as they adapt to pregnancy. These were determined by
comparing the results of lactogen-treated islets with those observed in islets during
pregnancy. This has led to the hypothesis that cell PRL receptors have a central role
in the adaptation of islets to pregnancy. Glut-2, Glucose transporter-2; Jak2, Janus
kinase 2; PI3K, phosphatidylinositol 3-kinase. (Sorenson and Brelje, 2009).
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Materials and Methods
2.1 Animal care
The three single strains, RIP-CreERTAM, pIns-c-MycERTAM, and Z/AP
transgenic mice were maintained by crossing with CBAxC57BL/6 F1 background.
The double transgenic mice (RIP-CreERTAM; Z/AP) were generated by crossing the
two single transgenic mice RIP-CreERTAM and Z/AP, while the triple transgenic
mice (Z/AP; RIPCreERTAM; pIns-c-MycERTAM) were generated by crossing the
double transgenic mice (RIP-CreERTAM; Z/AP) with the single transgenic pIns-c-
MycERTAM. Single and multiple transgenic mice were housed under a 12 hour
light/dark cycle and received food and water ad libitum until sacrifice. Animal care
and experiments were carried out according to UK Home Office regulations.
2.2 Animal genotyping
2.2.1 PCR genotyping
2.2.1.1 DNA extraction from mouse ear disc
First, two reagents are prepared, one (hotshot reagent) at pH 12, made with
25mM NaOH, 0.2mM disodium EDTA and the second (Neutralising reagent) at pH
5, made with 40mM Tris-HCl (Tris-HCl is dissolved in water without adjusting pH).
Of note, a neutral pH should result from a 1:1 mix of the two solutions. Then, 75µl
of hotshot reagent is added to the tube containing the mouse ear disc, after that, the
tube containing the ear disc plus the reagent is heated at 95oC for 10min to 1hour
(30min is sufficient). Afterwards 75µl of neutralising agent is added in the tube with
the ear sample. Subsequently, after cooling at 4oC for 1 hour (for longer term storage,
the sample can be frozen at -20oC), 1 to 5µl of the final preparation of the DNA
extract could be used for PCRing.
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2.2.1.2 PCRing procedure for RIP-CreERTAM strain genotyping
In a PCR tube is added, 5µl of the final preparation of the DNA extract above
from one mouse ear disc or distilled water, followed by 0.75µl of MgCl2 at 50mM
(Invitrogen kit), 2.5µl of 10xPCR reagent (Invitrogen kit), 1µl of each, reverse and
forward primers at 10picomol/ul, 0.25µl of dNTP (deoxyribonucleotide triphosphate)
at 10mM (Invitrogen kit), 0.25µl Taq at 500 units (Invitrogen kit), and finally,
14.25µl of distilled water. The tube with all reagents is then ready to be processed in
a PCR machine using the appropriate PCR program.
2.2.1.3 PCR procedure pINS-c-MycERTAM strain genotyping
In a PCR tube is added, 3µl of the final preparation of the DNA extract above from
one mouse ear disc or distilled water, followed by 0.75µl of MgCl2 at 50mM
(Invitrogen kit), 2.5µl of 10xPCR reagent (Invitrogen kit), 0.5µl of each, reverse and
forward primers at 10picomol/µl, 0.25ul of dNTP (deoxyribonucleotide triphosphate)
at 10mM (Invitrogen kit), 0.25µl Taq at 500 units (Invitrogen kit), and finally,
17.25µl of distilled water. The tube with all reagents is then ready to be processed in
a PCR machine using the appropriate PCR program.
2.2.1.4 PCR product analysis
When the PCR is completed, the PCR product size is analysed, after
migration in a 1 to 1.5% percent of agarose gel containing ethidium bromide
(0.2mg/µl). DNA PCRing products from transgenic, control animals positive and
negative for the target gene and the appropriate DNA ladder are loaded in distinct
wells in the gel at the same time, for subsequent analysis. For this purpose, prior to
loading, 25µl of each DNA PCRing sample is mixed with 5µl of 6X gel-loading
buffer, while 1µl of a 1kb ladder solution (1µg/µl) is mixed with 9µl of distilled
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water and 2µl of 6X gel-loading buffer. Before loading the different samples in the
wells, the gel is place in a tank gel containing 0.5% of TBE (Tris/Borate/EDTA)
buffer.
2.2.1.5 Primers and PCR program used for the RIP-CreERTAM strain genotyping
RIP-CreERTAM strain was genotypes by PCR using the following set of
primers which detect part of the Cre-recombinase gene sequence (forward
5’ACGGCGCTAAGGATGACTCT3’ and reverse
5’CCACCAGCTTGCATGATCTC3’), and PCR program (step 1: 94oC for 30
seconds, step: 2: 57oC for 30 seconds, step: 3: 72oC for 1 minute, then step 1 to 3 are
repeated for 35 cycles). The product size expected is 124 base pairs. The Cre-
recombinase PCR assay using these Cre primers is illustrated in Appendix1.
2.2.1.6 Primers and PCR program used for the pINS-c-MycERTAM strain genotyping
pIns-c-MycERTAM strain was genotypes by PCR using the following set of
primers, the forward MERTM (5’)( 5’ CCAAAGGTTGGCAGCCCTCATGTC
3’)and reverse Myc (3’) (5’ AGGGTCAAGTTGGACAGTGTCAGAGTC 3’) which
detect part of the Mus musculis oestrogen receptor and Homo sapiens c-Myc gene
respectively and PCR program (step 1: 94oC for 2 minutes, step: 2: 94oC for 1
minute, step: 3: 57oC for 1 minute, step 4: 72oC 2 minutes, then step 2 to 4 are
repeated for 30 cycles, and step 6: 72oC for 10 minutes). The product size expected
is 413 base pairs.
2.2.2 Enzymatic genotyping
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The Z/AP double reporter strain was genotyped by enzymatic staining using
ear biopsy from transgenic mice mixed with a solution containing 5bromo-4chloro-
3indolybetagalactopyranoside (X-gal, Sigma). In a tube containing a mouse ear disc,
50µl of a fresh made X-gal solution is added, the mixture is then incubated at 37oC
for 1 and half to 2 hours. Ear discs which turn blue during this period of incubation
will be scored positive for the Z/AP target gene. The X-gal solution is prepared as
follows. In an universal is added, 125µl of potassium ferrocyanide at 100mM
(K4Fe(CN)6, H20), 125µl of potassium ferricyanide at 100mM (K3Fe(CN)6), 5µl of
MgCl2 at 1M, 50µl of X-gal reagent at 50mg/ml which was first dissolved in DMSO
or dimethylformamide (the X-gal stock solution is wrapped in aluminium foil and
kept at -20oC), and finally 2183µl of PBS (phosphate buffered-saline) at 100mM pH
7.3. After gentle homogenising, the solution is ready to use. All the reagents are
prepared with phosphate buffered-saline pH 7.3 (PBS) except the X-gal solution.
2.2.3 Solution content
1l of 10X TBE (Tris/Borate/EDTA) is made with Tris (108g), boric acid
(55g), 40ml of EDTA at 0.5M.
6X gel-loading buffer is made with 0.25% bromophenol blue, 0.25% xylene
cyanol FF, 30% glycerol in water
2.3 Preparation of tamoxifen and 4-hydroxytamoxifen (4-OHT)
Tamoxifen and 4-hydroxytamoxifen (4-OHT) emulsions were prepared by
sonication in peanut oil. The compound or the peanut oil was administrated
intraperitoneally in the animals.
2.4 Intraperitoneal glucose tolerance test (IPGTT)
Subsequent to a 16 hour fast, the animals were injected intraperitoneally with
30% D-glucose in PBS (2mg/g body weight). Blood glucose levels were monitored
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prior to, and 10, 30, 60 and 120 minutes after glucose injection using an Advantage
glucose meter (Roche Diagnostics). For measurement 2 to 3 µl of blood are collected
from the tip of the animals’ tail.
2.5 Tissue processing and immunohistochemistry.
Pancreata from animals were dissected out and fixed in 4%
paraformaldehyde for 2 hours at room temperature, then transferred to 30% sucrose
overnight at 4°C before embedding in OCT mounting medium (Tissue Tek).One
block for each pancreas was sectioned for immunohistochemistry. Five sections per
pancreas, representing different parts of the organ and separated at least by 500 to
1000µm from each other, were immunostained with an insulin polyclonal guinea-pig
anti-swine (DAKO), a polyclonal sheep anti-human placental alkaline phosphatase
(ARP American Research Products, Inc) or a polyclonal rabbit anti-human placental
alkaline phosphatase (Accurate Chemical & Scientific Corporation). Vectashield
mounting medium with DAPI (Vector laboratories) was used to stain the nucleus.
DAPI (diamidino-2-phenylindole) is a blue fluorescent dye that fluoresces brightly
when it is selectively bound to double stranded DNA
The secondary antibodies used to reveal the primary antibodies were Alexa
633-conjugated goat anti-guinea-pig (Invitrogen), FITC-conjugated donkey anti-
sheep (Jackson ImmunoResearch laboratories) and FITC- conjugated goat anti-rabbit
(Vector laboratories). All the antibodies were diluted in phosphate buffered saline
(PBS) containing 0.1% Triton X-100 and 2% normal donkey serum (Jackson
ImmunoResearch laboratories).
The antibody working dilution was 1/100 for the insulin polyclonal guinea-
pig anti-swine, 1/1000 for the sheep and rabbit anti-human placental alkaline
phosphatase, and 1/200 for the secondary antibodies. Briefly, the sections were
stained sequentially with, i) the polyclonal sheep anti-human placental alkaline
phosphatase overnight at 4°C, ii) the FITC labelled anti-sheep for 30min at room
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temperature, iii) the polyclonal guinea-pig anti insulin for 1hour at room temperature,
iv) the Alexa 633 goat anti-guinea-pig for 30min at room temperature.
Then slides were mounted with Vectolab mounting medium with DAPI. The
sections were washed 3 times with PBS containing 0.1% Triton X-100 before adding
the next antibody.
2.6 Morphometric analysis and calculation
The images of the whole pancreatic tissue sections, immunostained and
DAPI-stained, were captured using a x5 objective using a Leica confocal microscope
while the total pancreatic sections immunostained for insulin and HPAP (human
placental alkaline phosphatase) used a x40 objective. Slides were coded and scored
‘blind’ as to their experimental origin. Systematically, all single islets and beta-cell
clusters found in each section were photographed and 5 sections representing
different regions of the pancreas were analysed. After adjusting a threshold
separately for each image, ImageJ was then used to count the number of pixels of
cross-sectional area stained for HPAP and insulin in each picture. Alternatively,
beta-cells positive for HPAP or insulin were counted manually in each picture using
ImageJ. Each such measurement was repeated, to obtain three separate counts for
each image. Most of the time, these images showed only one islet. For the
measurement of the all pancreatic tissue cross-sectional area positive for DAPI we
first processed the pictures using the Gaussian blur option before proceeding with the
count. This option blurs the areas positive for DAPI, so that all nuclear area positive
for DAPI meet and this allow a better estimation of the tissue area.
The beta-cell mass was calculated by forming the ratio of the total number of
pixels of insulin cross-sectional area to the total number of pixels of the pancreatic
tissue cross-sectional area in the five sections in each pancreas, multiplying by the
pancreas weight of the given mouse. Because the pancreatic tissue area was captured
with the 5x objective, its area values were first multiplied by a 64 correction factor
before proceeding with the calculation and comparison with images collected with
40x objective.
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Similarly, the proportion of beta-cell area positive for HPAP or the HPAP
labelling index was calculated by forming the ratio of total number of pixels of
cross-sectional area immunostained for HPAP to total number of pixels cross-
sectional area immunostained for insulin, in all five sections in the given mouse from
the x40 images.
Alternatively, the HPAP labelling index was also calculated by forming the
ration of total number of beta-cells positive for HPAP over total number of beta-cells
positive for insulin in all five sections in the given mouse from the x40 images.
The beta-cell area was calculated by forming the ratio of total number of
pixels cross-sectional area positive for insulin over total number of beta-cell positive
for insulin, in all five sections in the given mouse from the x40 images
2.7 Origin of new beta-cell in response to pregnancy in the double
transgenic (RIP-CreERTAM; Z/AP) mice
2.7.1 Induction of beta-cell labelling and one cycle of pregnancy
The study was performed on eight RIP-CreERTAM; Z/AP double transgenic
female mice, weighing 16.4±1.9g, aged 9 weeks ± 4 days and paired at the time of
their first pulse of tamoxifen. Beta-cell labelling with the human placental alkaline
phosphatase (HPAP) reporter was carried out by injecting in each pair, 5 doses of 4
mg of tamoxifen (Sigma), diluted in peanut oil, over a period of 2.5 weeks.
One animal in each pair was either mated for pregnancy or maintained in a
non-pregnant state. As soon as the females in each pair were fertile again, that is 1.5
to 2.5 months after the last pulse of tamoxifen, they were mated until visibly
pregnant (around 15 to 18 days of pregnancy). Both groups (non-pregnant control
and pregnant females in the same pair) were sacrificed at the same time. Pancreata
were excised for analysis. Tissue processing and analysis were carried out together.
The mean weight of the pups at time of pregnant animal sacrifice was
1.05±0.22g.
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4 pregnant and 4 non-pregnant animals in total were used for the whole
experiment.
2.7.2 Induction of beta-cell labelling and two cycle cycles of pregnancy
The study was executed on 6 double transgenic (Z/AP; RIPCreERTAM)
female animals, age and weight-matched. They were paired and animals in each pair
were injected together with 25mg of tamoxifen to label beta-cells with HPAP, for a
period of 2.5 weeks. They weighed 16.8±1.7g and were aged 9 weeks ± 3 days at the
start of the first tamoxifen injection.
As soon as the females were fertile again, one animal in each pair was either
mated for pregnancy or maintained in a non-pregnant state. After a first pregnancy,
the same animals were mated yet again ten days after giving birth. Then, during the
second pregnancy (around 15 to 18 days), the pregnant animals were euthanized
concurrent with the non-pregnant control females in the same pair and their
pancreata were excised, processed and analysis contemporaneously.
The mean weight of the pups at time of pregnant animal sacrifice was
1.1±0.3g.
Three pregnant and three non-pregnant animals in total were used for the
whole experiment.
One pair of animals was injected with tamoxifen from the same batch as
animals from the experiment above, while the two other pairs of animals were
injected with tamoxifen from a new batch.
2.8 Origin of new beta-cell after diabetic recovery in the triple
transgenic (Z/AP; RIP-CreERTAM ; pINS-c-MycERTAM) mice
2.8.1 Induction of beta-cell labelling and diabetes
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The study was carried out with 9 triple transgenic (Z/AP; RIPCreERTAM ;
pIns-c-MycERTAM) mice about seven weeks of age at the start of the 4-
hydroxytamoxifen (4-OHT) pulse.
4-OHT and tamoxifen compounds have similar effects when injected in
animals, but tamoxifen is far less expensive and easier to prepare in peanut oil. Of
note, at the time I started this experiment, 4-OHT was still used routinely in my
group to treat the single pIns-c-MycERTAM transgenic mice.
Beta-cell labelling with the human placental alkaline phosphatase (HPAP)
reporter, and the toxic genetic beta-cell ablation by activation of c-Myc to induce
diabetes, were carried out by injecting animals daily with 1ml of 4-OHT dissolved in
peanut oil (1mg/ml) for ten consecutive days.
The animals were divided in 3 groups of 3. Both the control vehicle group
(n=3) injected daily with 1ml of peanut oil for 10 days, and 3 animals treated with
the drug, were euthanized 28 days after the last injection, while 3 other animals
treated with the drug were euthanized just after the last day of injection. Pancreata of
all animals were excised for analysis.
The fed blood glucose level was monitored in animals during the course of
the whole experiment i.e. before, during, after 4-OHT injections, and at the time of
sacrifice.
2.9 Beta-cell functionality after diabetic recovery in the single
transgenic (pINS-c-MycERTAM) mice
2.9.1 Diabetic induction
Single transgenic pIns-c-MycERTAM (n=7) and wild-type mice (n=4) about
three months of age were daily injected with 1ml of 4-OHT (1mg/0.2ml) for six
consecutive days, while other pIns-c-MycERTAM mice (n=3) from the same age were
injected with peanut oil, the control vehicle.
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9 months after the last pulse of 4-OHT or peanut oil, pIns-c-MycERTAM mice
were aged 12 months at the time of euthanizing while the wild-type animals were
aged 3 months, but all groups were sacrificed contemporaneously for islets.
The islets from pIns-c-MycERTAM and wild-type mice were isolated, cultured
and analysed to examine their beta-cell functionality using the single-cell
microfluorimetric method performed by Dr Paul E. Squires.
Also, we isolated islets from three month old pIns-c-MycERTAM control (n=3)
and wild-type mice (n=3) that did not received any treatment, for additional control
tests of functionality.
Fed blood glucose levels and glucose tolerance tests were performed on the
animals prior to, during, just after the last 4-OHT injection and before euthanizing
the mice for islet isolation.
2.10 Pancreatic islet isolation
2.10.1 Preparation of solutions
_HBSS 1 medium is made with 500ml HBSS (Hanks Balanced Salt Solution),
2.4ml of NaHCO3 at 7.5%, 10ml of HEPES at 1M pH 7.4 and1.4ml of a mixture of
antibiotics containing Penicillin (10000IU/ml) and Streptomycin (10mg/ml).
_HBSS1-10%FCS medium is made with the medium above with 10% (v/v) of foetal
calf serum (FCS).
_RPMI 1 medium is made with 500mls RPMI 1640 pH7.4, 0.9g of glucose (final
concentration at 10mM), 1.5ml of the same antibiotic solution cited above, BSA
(bovine serum albumin) at 5g/l and 5ml of L-glutamine.
_Collagenase solution is made with 9ml of HBSS 1 medium and 10mg of
collagenase with protease inhibitor (1mg/ml, Type V, Sigma-Aldrich)
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2.10.2 Islet isolation procedure for one pancreas and culture
The islet isolation procedure is described as follow.
1) A sterile universal with 10ml of HBSS1 medium is placed in a waterbath at
37oC prior to pancreas dissection.
2) An empty sterile universal and the collagenase solution are placed on ice.
3) After euthanizing the animal, its abdomen is incised.
4) 2.5mls of the cold collagenase solution is aspirated into 5 ml syringe, and
slowly is injected first into the pancreatic duct then into all the part of the pancreas.
The latter must be inflated.
5) The pancreas is excised gently in one piece and placed immediately in the
empty cold universal. The rest of the procedure should be carried out in a class II
cabinet.
6) 10mls of the warmed HBSS1 medium (in the waterbath at 37oC) is added to
the universal containing the pancreas, then, the latter is placed in a waterbath at 37oC
for 18 minutes to digest the pancreas.
7) The warm HBSS1 is discarded and replaced with 10mls of cold HBSS1
medium (without FCS) to stop the digestion, then the universal containing the digest
is kept on ice.
8) The pancreas tissue is disrupted in the universal by mild hand shaking for 1
min.
9) The digest is poured through a 500µ mesh and the supernatant is collected, the
tissue left on mesh is washed by pouring again 10mls of HBSS1 -10%FCS medium
through the mesh, then supernatant is collected.
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10) The supernatant is equally split into 2 conical 50ml tubes.
11) The conical tube containing the supernatant is centrifuged at 1200rpm for 1
min at 4oC. The medium is discarded and the pellet is resuspended in fresh HBSS1-
10% FCS medium (10mls), then this step is repeated twice.
12) The pellet is resuspended this time in10mls of RPMI 1 medium, then,
centrifuged at 1200rpm for 1 min. The medium is discarded, and fresh medium is
added to resuspend the pellet. This step is repeated a second time.
13) The pellet is resuspended in 10mls of RPMI 1medium, then, pooled in a non-
coated Petri-dish.
14) Islets are purified by hand picking under a dissecting microscope.
Then, subsequent to islet purification, the islets were cultured on 3-
aminopropyltriethoxysilane-coated glass coverslips in a Petri dish containing 10ml
of RPMI 1 medium. They were incubated at 37oC in the presence of 5% CO2 for two
to three days prior to analysis. The calcium microfluorimetric measurements to study
beta-cell functionality were performed by Dr Paul E. Squires according to the
protocol described by Squires et al. (Squires et al., 2000).
2.11 Statistical analysis
The results are presented as MEANS±SD. Pregnant and non-pregnant
animals were derived from pairs of age and weight-matched animals injected with
tamoxifen at the same time, the pairs of animals were killed contemporaneously, and
their pancreata were processed and analysed in pairs. Therefore, the paired 2-tailed
student t test was used for statistical analysis using the GraphPad InStat3 software. A
P value <0.05 was considered as significant. For the other experiments, the unpaired
2-tailed student t test was used for statistical analysis using the GraphPad InStat3
software. A P value <0.05 was considered as significant.
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Origin of new beta-cells during a single pregnancy
3.1 Introduction
One key feature of the multiple physiological changes that characterize the
pregnant state is the near doubling of the maternal beta cell mass, in a short period of
time, to adapt to new metabolic challenges. Therefore, pregnancy is an appealing
condition to understand beta-cell mass regulation, and specifically to examine the
cellular sources that give rise to new beta cells.
To address this question about where new beta cells arise during this normal
physiological situation, we used an inducible Cre/Lox based direct cell-lineage
tracing system developed by Dor et al. (Dor et al., 2004). In double transgenic mice
(Z/AP; RIP-CreERTAM) beta-cells can be heritably marked.
3.2 Genetic cell-lineage tracing for beta cells and experimental design
This Cre/LoxP cell-lineage tracing system in the double transgenic mice
presents three fundamental features. The first property is the ability to actively label
beta-cells in adult mice during a predetermined time-window, called the pulse period.
The two other properties concern the heritability and the constitutive or permanent
expression of the label once the cells are labelled. Put simply, when using this
labelling system, 1) one can fix the appropriate time to induce beta-cell labelling in
vivo, and 2) only beta cells marked during the pulse phase will express the label
subsequently, during the chase period ( time following the pulse), as will their
progeny, even if they arise some time after the pulse period (Nir et al., 2007).
By tracking the fate of labelled beta-cells and their progeny one can use the
system to infer the source of new beta-cells in differing conditions in vivo.
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3.2.1 Genetic construct and mechanism
The pulse chase strains are generated by the simple expedient of crossing the
Z/AP double reporter mice with RIP-CreERTAM mice to yield the necessary double
transgenic mice required. The double transgenic mice carry an inducible Cre/LoxP
system in which the Cre-recombinase (Cre), after its activation excises, at the LoxP
sites, stop signal sequences upstream of a reporter gene. This leads to the expression
of the reporter in beta-cells.
The system to be functional requires two distinct DNA constructs. The first
genetic construct RIP-CreERTAM (Dor et al., 2004) comprises a rat insulin promoter
(RIP) driving the expression of a Cre-recombinase (Figure 5) exclusively in insulin-
secreting cells, but in the absence of tamoxifen the recombinase enzyme is inactive.
The second DNA construct, the double reporter Z/AP (Lobe et al., 1999),
comprises a general CMV/beta-actin promoter (Figure 5), (further details regarding
this DNA construct can be found in appendix 2) driving the expression of either
beta-galactosidase, the first reporter gene (Lac Z), or the human placental alkaline
phosphatase (AP or HPAP), the second reporter gene, which is the label of interest in
our case. The cassette composed of the Lac Z gene and the stop signal sequences, is
flanked by two LoxP sites. As one will see further, the position of the LoxP sites in
the second construct is crucial to the expression of the HPAP label.
How to induce the labelling of beta-cells for HPAP in double transgenic mice
(Z/AP; RIP-CreERTAM)?
The Cre-recombinase is a chimerical protein fused with a truncated form of
the oestrogen receptor (ER). In absence of tamoxifen, (Figure 6), the heat shock
proteins (HSP) bind to the altered oestrogen receptor domain of the enzyme, creating
a steric obstruction that prevents the enzyme being active and translocated into the
nucleus. The Cre-recombinase is confined to the cytoplasmic compartment. As a
result, at this stage (Figure 9A); the HPAP label (green staining) is not expressed in
the beta-cells (red staining) while the beta-galactosidase (Lac Z) is expressed in all
the cells of the rodent, including the beta-cells (Lobe et al., 1999).
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By contrast, in presence of tamoxifen (TAM) (Figure 7), the drug binds to the
altered oestrogen receptor domain of the Cre-recombinase in place of the HSP. This
leads to the activation of the enzyme and its translocation in the nucleus.
Once the active Cre-recombinase is within the nuclear compartment (Figure
8), it catalyses deletion in the second DNA construct. After recognition of two LoxP
sites, the lac Z gene and the stop signal sequences upstream to the HPAP gene are
deleted, by recombination. This simultaneously results in the constitutive expression
of the HPAP label (green staining, Figure 9B) specifically in beta-cells (red staining)
and the abolition of the beta-galactosidase expression in these same beta-cells (Lobe
et al., 1999).
Thereby, the Cre-recombinase-mediated recombination at the LoxP sites has
a binary effect in the second transgene by replacing the Lac Z expression with the
HPAP which is expressed restrictively in beta-cells.
The success of the labelling relies on the ability of the Cre-recombinase to
efficiently remove the stop signal sequence upstream to the HPAP label gene by
recombination. This leads one to anticipate that there should be a positive curvilinear
relationship between the percentage of active Cre-recombinase molecules and the
percentage of beta-cells that become labelled, which is another property of this
system that deserves to be examined.
Figure 5 Lineage tracing system DNA constructions in the double transgenic
mice. The double transgenic mice include a RIP
the rat insulin promoter (RIP) drives the expression of the
mature beta-cells, but it is inactive in absence of tamoxifen. The second DNA
construct includes, Z/AP or the repor
(CMV/beta actin) which leads to the expression either of the beta galatosidase (Lac
Z) or the human placental
Furthermore, in the second transgene, the cassette formed by the Lac Z gene and the
stop signals, is flanked by two LoxP sites.
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Figure 6 Beta-cell labelling mechanism in the double transgenic mice
of tamoxifen, the Cre
inactive due to its sequestration by HSP (heat shock protein). As a result the HPAP
label is not expressed while the beta galactosidase is expressed in the entire animal
including the beta-cells.
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Figure 8 Beta-cell labelling mechanism in the double transgenic mice
migration into the nucleus, the active
the LoxP sites, hence causing the deletion of the
and translational stop signals upstream to the HPAP reporter gene. As a result, the
beta-cells are irreversibly and heritably labelled by HPAP while the expression of the
beta galactosidase (Lac Z) is irreversibly abolished in these same beta
Chapter 3: Origin of new beta-cells during a single
Cre-recombinase mediates recombination at
Lac Z gene and the transcriptional
pregnancy
51
. After
-cells.
Figure 9 Beta-cell labelling mechanism in the double transgenic mice
Pancreatic section of mouse not pulsed with tamoxifen. The image shows no
(green staining) expression in beta
mouse pulsed with tamoxifen. The image shows HPAP expression in the beta
The nucleus is stained with DAPI (blue). The scale bar corresponds to 40 µm.
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3.2.2 Other properties associated with the labelling system which have been
investigated
If the percentage of beta-cell labelled does depend on the rate of the active
Cre-recombinase, one would expect that the tamoxifen dose administered to the
animal might modulate the amount of active Cre-recombinase and, consequently the
proportion of labelled beta-cells.
To test this hypothesis, we injected two female double transgenic animals of
similar age and weight with 20 or 25mg of tamoxifen. The percentage of HPAP
labelled beta-cells was 49% and 66% respectively (Figure 10), leading us to assume
that the labelling is sensitive to tamoxifen or tamoxifen dose-dependent, as originally
suggested by Dor et al. (Dor et al., 2004). ). Previous works carried out by Norhayati,
Ahmad who worked in our group on the same double transgenic mice (Z/AP; RIP-
CreERTAM, the data can be found in her thesis) clearly demonstrated dependency of
recombination frequency on tamoxifen dosage.
On the other hand, in absence of tamoxifen, the proportion of beta-cells
labelled for HPAP was zero, even though we observed, occasionally in older animals,
a few islets containing one to two beta-cells labelled for HPAP.
Moreover, the beta-cell labelling in the pancreas of animals injected with the
same dose of tamoxifen (20mg) but sacrificed after different times, two or eleven
weeks after the tamoxifen pulse (Figure 11) showed no sign of dilution. This
indicates that the labelling of the beta-cells is irreversible. This system is a genetic
lineage tracing system.
Also, preceding work by N. Ahmad showed that a high proportion of labelled
beta-cells in the pancreas could be obtained by pulsing the double transgenic mice
(Z/AP; RIP-CreERTAM) with a total amount of 40mg of tamoxifen. Using this dose
of tamoxifen, we found that 90% of beta-cells in the animal pancreata were labelled
for HPAP.
Unfortunately, for our current experiment it was not feasible to inject a total
amount of 40mg of tamoxifen into our female animals. This tamoxifen dose was
lethal for the majority of them. One explanation may be related to the small size of
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our 9 week old female mice. We could not use older animals because the fertility of
the female mice decreases when they get older.
However, after optimisation of the tamoxifen dose, we found that half of the
amount of tamoxifen (that is 20mg) was sufficient to label efficiently the beta-cells
in the mice without compromising subsequent fertility. Also, using this quantity of
tamoxifen, we observed a significant improvement of the survival rate of the animals.
Consequently, this dose of tamoxifen was used to inject our mice to perform the
present study.
However, despite the fact that many of our mice could tolerate a total
quantity of 20mg of tamoxifen, nonetheless this amount was still high for animals of
low weight. This explains in part, why the number of animals at the end of the
experiment was low and so the number of replicates in the study. Limitations related
to this type of experiment were 1) the permanent loss of the fertility of some female
mice due to the dose of tamoxifen administrated and 2) the low ratio of female
double transgenic mice expected to be of the right genotype.
To sum up, we are confident to state that our lineage tracing system is 1)
specific to beta-cells, 2) the labelling is irreversible 3) heritable and 4) the percentage
of Cre-recombinase induced recombination is tamoxifen dose-dependent.
Consequently, it could be used in pulse-chase experiment to determine the origin of
new beta-cells.
3.2.3 Pulse-chase experiment and analyses of beta-cell origin
The double transgenic mice (Z/AP; RIP-CreERTAM) can be employed in
pulse-chase experiments to predict where new beta-cells arise during pregnancy or
other conditions.
The methodology is presented in Figure 12. The first step is to mark beta-
cells with the HPAP label, in our case by injecting 20mg of tamoxifen in female
double transgenic animal mice for two and half weeks; a period called the pulse.
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It is important to point out that before starting the tamoxifen treatment, age
and weight-matched female mice were paired. Each pair was treated the same way
during the whole experiment. Likewise their pancreas were excised, processed and
analysed contemporaneously.
Importantly, the average percentage of labelled beta-cells after completion of
the pulse of tamoxifen was 44%. Thereafter, during the chase period, in each pair,
pregnancy was induced in one animal while the other female was maintained in a
non-pregnant state. Thenceforth, when the pregnancy was visible, around 15 to 18
days of gestation, the pregnant and non-pregnant control female paired mice were
euthanized contemporaneously and their pancreata collected for analyses.
According to the percentage of labelled beta-cells measured in the pancreas
of pregnant animals, one can deduce the cell origin for newborn beta-cells during
pregnancy. At least three likely possibilities must be considered concerning the
contribution of stem/progenitor cells (neogenesis) and/or pre-existing beta-cells
(mitogenesis) to the formation of new beta-cells in these studies.
Hypothesis 1, the percentage of labelled beta-cells in the pancreas of the
pregnant animal is the same as in the non-pregnant control, suggesting that new beta-
cells originate from pre-existing differentiated beta-cells. Beta-cells give rise to fresh
new beta-cells by self-duplication.
Hypothesis 2, the percentage of label in pregnant animals is diluted,
suggesting that an unlabelled pool of cells of non beta-cell lineage, are contributing
significantly to the formation of new beta-cells, in combination or not with
differentiated beta-cells, hinging on the degree of dilution. These cells can be either
stem/progenitor cells or differentiated cells which are not beta-cells, or simply both.
Hypothesis 3, whole new islets devoid of any marked beta-cells are formed in
the pregnant female pancreas, resulting in an increase of the percentage of these
types of islets. If this happened, one could conclude that these newly formed islets
derive from beta-cells generated from non-beta-cell progenitors.
The quantification of the percentage of the beta-cells labelled for HPAP is an
important question since our conclusions depend on the accuracy of these data. So
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we defined a reliable method to measure the HPAP and insulin area. This is the
subject of the next section and merits further discussion.
3.2.4 HPAP labelling index and quantification
With a view to determining the percentage of labelled beta-cells in the
pancreas of double transgenic mice, we quantified the area positive for HPAP or
insulin in multiple digitally recorded images of pancreatic sections using ImageJ
software. First of all, it was necessary to put into place a method to process the
pancreas and to carry out the HPAP and insulin measurement so as to produce
reliable data.
First, we needed to employ an appropriate protocol to take into account the
complex and heterogeneous organization of islets within the pancreas (Alanentalo et
al., 2007, Avril et al., 2002).
Thus, specific regional adaptation of the rat pancreas has been shown during
pregnancy, which include an increased replication rate in the head of the pancreas
(region adjacent to the duodenum) compared to the tail (region of the pancreas
adjacent to the spleen). Although, this might not necessarily reflect what occurs in
mouse, we decided to roll up the excised pancreas in a flat spiral, and to section it in
the same plane as the flat spiral, namely, along a z-axis (Figure 13). Thus, the
different anatomical parts of the pancreas (tail, body, and head) will be on the same
section and each section will represent different levels of the organ.
Secondly, to avoid bias in sections chosen for analysis, we numbered our
sections sequentially by ascribing the number one to the first microtome section, the
number two to the second and so forth. In total from five to seven hundred sections
per pancreas were cut but only six sections per level were collected. One level
corresponds to ten abutting sections. As the thickness of the section was ten
micrometers, one level represented a thickness of approximately one to two hundred
micrometers, about the size range of a typical intermediate islet (Jo et al., 2007).
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Given the great number of sections produced per pancreas, it was not feasible
to process every single one of them. For this reason, five sections representing
different regions or levels of the pancreas along a z-axis, and separated from each
other by at least five hundred micrometers to minimize the sampling of the same islet
twice, were chosen at random.
To recapitulate, with the objective to extract the greatest amount of
practicable information from the pancreas, first, we embedded the harvested organ in
a flat spiral. Then, it was sectioned along a z-axis and each section was numbered
appropriately to ensure that in the selected analysed sections the same islets were not
scored twice.
The second criterion was to consider the HPAP and insulin area measurement
procedure. In order to quantify the HPAP and insulin area in the section using
ImageJ, we captured images of every immunostained pancreatic cross-sectional area
of single beta-cells, clusters of beta-cells, and islets which were present in each
section. Five sections per pancreas were entirely scanned using a confocal
microscope (Leica, SP2).
An average, two hundred and twenty one photos of islets or beta-cell clusters
per pancreas were captured, but four hundred and forty two images per pancreas or
in the whole five sections were analysed, employing the measurement software,
because the quantification of HPAP and insulin cross-sectional area had to be
performed on separate images after immunostaining (i.e. red and green channels).
Overall, three thousand five hundred and thirty six images were processed for the
whole experiment (eight harvested pancreata in total).
The area evaluation was performed on pancreatic sections immunostained
with anti-HPAP and anti-insulin antibodies (as described in Materials and Methods).
Fluorescein and Alexa fluo 633, which are fluorescent dies bound to secondary
antibodies, were used to reveal the primary antibodies respectively.
Using ImageJ, the HPAP and insulin area can be measured either
automatically or manually after adjusting an image intensity threshold with a slider.
In our case, the threshold was set manually for each picture, as it proved more
accurate for distinguishing positive HPAP or insulin immunoreactivity
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from“background”. After adjusting the threshold, the HPAP or insulin area was
measured. The adjustment of the threshold was repeated three times on the same
object, so that three counts per object were carried out and the three computed values
were averaged.
It is of interest to point out that ImageJ measures the area by counting the
number of pixels constituting the object on the picture. Thus, the HPAP and insulin
area determination represent the total number of pixels counted.
Importantly, all such measurements were conducted blind. The images used
to quantify the HPAP or insulin area were all anonymously coded. The experimenter
had no knowledge of the condition being observed, meaning if the pictures analysed
were from a pregnant or non-pregnant animal or from a given replicate.
Using this tool (ImageJ), we were able to evaluate the HPAP and insulin area
in each beta-cell cluster and islet, and to calculate the proportion of HPAP labelled
beta-cells, the “HPAP labelling index” in the pancreas of each mouse. The HPAP
labelling index was computed by forming the ratio of the total pixel cross-sectional
area positive for HPAP over the total pixel cross-sectional area positive for insulin in
the whole five sections of each animal. We applied the same method to measure the
cross-sectional area for insulin and the pancreatic tissue to calculate the beta-cells
mass in the pregnant and non-pregnant mice (Huang et al., 2009).
Figure 10 Lineage tracing system is tamoxifen dose dependent
sections from mice pulsed with 25mg (A) or 20mg (B) of tamoxifen. The sections
were immunostained for HPAP (green), insulin (red staining) and the nucle
stained by DAPI (blue).
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Figure 12 Analysing the origin of new beta
transgenic female mice (Z/AP; RIP
their beta-cells. Then during the chase period, pregnancy was induced in only one
group of mice while the other animals were assigned to the non
group. After the chase period, if the percentage of beta
pancreas of the pregnant animals is identical to the non
conclude that new beta
1). However, if there is a dilution of the percentage of HPAP
the pregnant animals, we conclude that a non
cells, possibly in combination with a contribution from pre
(Hypothesis 2). Finally
higher in pregnant animals than in the controls, one can deduce that whole new islets
arise from non-beta-cell progenitors (Hypothesis 3).
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Figure 13 Pancreas orientation before embedding and sectioning
is a heterogeneous organ which is divided in three regions, the head, body and tail. In
order to extract information from this organ with little bias, the pancreata were rolled
up in flat spiral before embedding and sectioning in the same plane as the flat spiral,
i.e. along the z-axis.
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3.3 Results
3.3.1 Experiment outline
The Cre/LoxP lineage tracing system was exploited to analyse the origin of
new beta-cells induced by a single cycle of pregnancy. In transgenic animals (Z/AP;
RIP-CreERTAM) beta-cells and their progeny were marked with HPAP in response to
tamoxifen-induced activation of the Cre-recombinase in beta-cells.
To maximize the potential of the lineage tracing system technique for
detecting any dilution of the labelling during the chase period, we aimed to use a
dose regime of tamoxifen that gave a relatively high proportion of labelling in the
range of 40-50% in the transgenic animals, without compromising subsequent
fertility.
For this purpose age and weight-matched female animals were paired and
injected together with a total of 20mg of tamoxifen, about 9 weeks of age, over a
period of two and half weeks, to label beta-cells for HPAP. Thereafter, one female
animal in each pair was either mated for pregnancy or maintained as a virgin in a
non-pregnant state. Pregnant animals between fifteen to nineteen days of gestation
and non-pregnant controls from the same pair, were euthanized contemporaneously
for examination of the pancreata. Each pair (a total of four pairs were set up for the
whole experiment) was treated the same way, and their pancreata processed and
analysed similarly and at the same time.
We suspected (see below) that a variable in the lineage-tracing is the
preparation of the tamoxifen solution for injection, and the paired design should
minimize this source of variation, as both animals were injected with the same
preparation of the drug. This is consistent with our observations on the sensitivity of
the dose-response to tamoxifen.
3.3.2 Response to pregnancy
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In line with another study, pregnancy was associated with an increase of the
body weight (Karnik et al., 2007) and pancreas weight. At the time of the experiment
we observed a 45% increase of the mean body weight (Figure 14A) and a 51%
increase of the mean pancreas weight (Figure 14B) in pregnant animals compared
with the age-matched non-pregnant controls. In the same way, we determined the
beta-cell mass by morphometric analysis as described in Materials and Methods, in
the animals. We observed a 91% increase of the beta-cell mass in the pregnant
animals compared to the age-matched non-pregnant controls (Figure 14C). This
result corroborates previous studies (Scaglia et al., 1995, Aerts et al., 1997, Huang et
al., 2009, Avril et al., 2002, Blondeau et al., 1999, Karnik et al., 2007, Parsons et al.,
1995, Parsons et al., 1992, Teta et al., 2007) indicating that maternal adaptation to
pregnancy was accompanied by a substantial beta-cell mass increment of about fifty
to a hundred percent, compared to non-pregnant control animals. Importantly, the
authors above have demonstrated that increase in beta-cell numbers was mainly
responsible for the maternal beta-cell mass increase with slightly or no contribution
from beta-cell hypertrophy (i.e. increase in beta-cell size). Therefore, we could
deduce that the increased beta-cell mass observed in pregnant animals in our study,
was the result of an increase of the beta-cell population. Consequently, our next
question was to examine where the newly formed beta-cells arose.
3.3.3 Dilution of HPAP labelling index during a single cycle of pregnancy
The double transgenic female mice were paired for age and weight, and
injected with tamoxifen. At the start of the study, 17 animals were involved, but due
to the experimental difficulties mentioned above, only 8 animals could be analysed.
Following the pulse, after the mice recovered their fertility, pregnancy was induced
in one animal in each pair while the other one in the same pair was maintained in a
non-pregnant state. At the end of pregnancy, the pancreata were collected for
analysis.
We observed that the mean HPAP labelling index (Figure 15A) in the non-
pregnant control group was greater (0.44±0.05) than in the pregnant group
(0.33±0.06). Also, we draw attention to the fact that the HPAP labelling index, when
Figure 14 Responses to pregnancy
increased by 45% (A), and the mean pancreas weight by
their age-matched non
pregnant animals increased by 9
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analysed individually shows a dilution of the label systematically in the
pregnant animal within each pair (Figure 15C). It is worth reminding that animals in
each pair were treated and analysed identically and contemporaneously to minimize
variations other than differences between animals. The difference between the two
groups was statistically significant (P=0.021, paired two-tailed t-test).
This dilution leads to rejection of hypothesis 1 and indicates for the first time,
the contribution to new beta-cells from a non-beta cell source during the beta cell
mass expansion in response to pregnancy. Accordingly, the data are consistent with
hypothesis 2.
One potential mechanism for beta-cell expansion is the creation of new islets.
To investigate this possibility, we focused on determining the frequency of islet or
beta-cell clusters whose sectioned area appeared totally devoid of any HPAP label,
in pancreata of pregnant and non-pregnant animals.
The appearance of beta-cell clusters or small sized-islets after certain types of
pancreatic injury or under specific conditions is frequently reported as neogenic
beta-cells or islets (Wang et al., 1995, Yamamoto et al., 1997, Yamamoto et al.,
2000, Lipsett and Finegood, 2002, Aerts et al., 1997, Blondeau et al., 1999, Huang et
al., 2009, Parsons et al., 1995).
To validate hypothesis 3, that is if new whole islets are formed by neogenesis
during pregnancy, we counted islet cross-sectional area for islets appearing as totally
negative for HPAP in pancreatic section of non-pregnant control and pregnant
animals.
We noted in our studies that amongst small islet cross-sections, several did
not contain any labelled beta-cells, whereas, by contrast, intermediate and large islets
cross-sections always contained HPAP labelled beta-cells.
This observation regarding the small islets cross-sections devoid of HPAP
immunoreactivity, supports the idea that small islets sizes or beta-cell clusters might
represent formation of new islets by neogenesis.
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Alternatively, these label-free small islets cross-sections, might represent
glancing sections or edges of larger islets (Figure 16).
The proportion of islet cross-sectional area HPAP negative in the two groups
was computed by forming the ratio of total number of islet cross-sectional area
negative for HPAP over the overall number of islet cross-sectional area positive or
not for HPAP, in the whole five sections for each pancreas.
We found that the mean proportion of islets negative for HPAP (Figure 15B)
was greater (0.19±0.06) in the pregnant mice compared to this in the control non-
pregnant group (0.11±0.04). Likewise, the analysis of the proportion of islets HPAP
negative in each animal (Figure 15D), shows a rise of these specific islets or beta-
cell clusters, systematically in the pregnant animals in each pair. The difference
between the two groups was not statistically significant (P=0.093, paired two tailed
t-test).
It is still tempting to speculate that there might be formation of whole new
islets during pregnancy. Yet, small islet cross-sections might represent glancing
sections of larger islets and not solely representative sections of genuine islet of
small mass.
Numerous reports showed that during pregnancy, islets grew bigger (Aerts et
al., 1997, Blondeau et al., 1999, Parsons et al., 1995), So it is possible that the
dilution within such enlarged islets will increase the number of small cross-sections
lacking HPAP immunoreactivity in pregnant animals. Eventually, the increased
number in label-free small cross-sections in pregnancy, supports our results above
regarding the diminution of the HPAP labelling index in this condition.
To conclude, we have demonstrated for the first time that non-beta-cell
progenitors contributed significantly to the beta-cell mass expansion during
pregnancy. The next question is: where do these new beta-cells come from?
Thus, we next sought to examine the identity of the cell-lineage contributing
to beta-cell neogenesis. Based on extensive literature surrounding the beta-cell
differentiation, obvious candidates were progenitors associated with the pancreatic
duct epithelium
Figure 15 Lineage tracing in pregnancy
pregnant control and pregnant female animal pancreata was calculated by forming
the ratio of total number of pixels of cross
to total number of pixels cross
Image J. The mean labelling index in the pancreata of non
(0.44±0.05) than in the pregnant mice (0.33±0.06). (B) The proporti
sections completely negative for HPAP is calculated by forming the ratio of the
HPAP-negative islet cross
whole of 5 sections for each pancreas. The mean proportion of islet sections
negative in the pregnant group is (0.19± 0.06) is higher than in their age
non-pregnant control counterparts (0.11±0.04) as seen in the graph. (C) and (D)
represent the HPAP labelling index and the frequency of HPAP negative beta
cluster or islets in pregnant and non
designates a P-value <0.05 by the paired two
Pregnant (P).
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Figure 16 Beta-cell clusters negative for HPAP
sections from pregnant animals stained for insulin (red), HPAP (green), and nuclei
(blue, DAPI). Small islet sections are either partly or wholly HPAP
completely HPAP-negative (dashed circle, B). Small islet
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3.3.4 Beta-cell clusters associated with the pancreatic duct
In numerous studies, the pancreatic duct epithelium has been identified as a
potential location for islet beta-cells progenitors in adult pancreas both during
normal growth and beta-cell regeneration.
A program of beta-cell neogenesis that might be activated in the adult
pancreatic ductal epithelium has been well-documented in the literature. Studies
analysing beta-cell regeneration, subsequent to pancreatic injury (Wang et al., 1995,
Waguri et al., 1997, Thyssen et al., 2006, Yamamoto et al., 1997, Yamamoto et al.,
2000, Sharma et al., 1999), in transgenic mice over-expressing INFα (Gu and 
Sarvetnick, 1993) or TGFα and gastrin (Wang et al., 1993), showed that regenerated
beta-cell mass was associated with an increase of single beta-cells, beta-cell clusters
or small sized-islets closely in contact with the ductal structure.
Furthermore, the studies revealed that the activation of this intricate program
of neogenic beta-cells required, in this sequence, a burst of proliferation in the
pancreatic ductal component, then the expression of endocrine markers within this
compartment (Wang et al., 1995, Yamamoto et al., 2000, Bonner-Weir et al., 2004,
Bouwens and Pipeleers, 1998, Suarez-Pinzon et al., 2005, Holland et al., 2005,
Dutrillaux et al., 1982, Gu et al., 1994, Sharma et al., 1999).
These observations led the authors to conclude that the actual adult
pancreatic ductal epithelium might contain islet cell precursors that could be re-
activated in specific situations.
More recently Inada et al. (Inada et al., 2008) demonstrated, using a duct
cell-lineage tracing system, that duct progenitors were indeed accountable for the
generation of new islet-cells and acinar cells shortly after birth, and after pancreatic
injury induced by duct ligation.
Also, the abundant literature concerning putative islet progenitors residing in
the ductal epithelium, reported by studies above and reviewed in others reports
Figure 17 Insulin-positive cells associated with the ductal epithelium
sections from pregnant female animals, stained for insulin (red), HPAP (green), and
nuclei (blue, DAPI), show examples (yellow arrows) of HPAP
(A), or HPAP-negative beta
correspond to 20µm (A) and 40µm
Figure 18 Beta-cells do not transdifferentiate into other cell
sections from non-pregnant control females animals stained for insulin (red), HPAP
(green), and nuclei (blue, DAPI), showing that the HPAP label is restricted to beta
cells, at two and half months following the pulse of tamoxifen. Scale bar corresponds
to 40µm.
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(Zhang et al., 2005b, Levine and Itkin-Ansari, 2008, Bonner-Weir, 2000b, Bonner-
Weir et al., 2004, Banerjee et al., 2005, Xia et al., 2009), led us to postulate that
beta-cell precursors in the ductal compartment might also be re-activated in
pregnancy. In other words, cells associated with the ductal system might represent a
preferred source for new beta-cells. If this assumption is true one should expect a
decrease of the proportion of beta-cells labelled for HPAP in the ductal structure
with respect to the islet compartment.
To investigate if this is the case, first we examined the presence of cells
positive for insulin within the pancreatic ductal system in pancreata of pregnant
animals. We observed, as reported in others studies, increased numbers of insulin-
producing cells abutting or within the ductal epithelium (Figure 17). We counted the
number of the insulin-producing cells positive or not for HPAP, located in, or
adjacent to the duct and in islets in the same pancreatic section, to derive the HPAP
labelling indices for the islets and ductal compartment. For comparison, the labelling
index for insulin-producing cells in the duct was 0.21 (n=57 cells, representing 4
replicates) and for the islets 0.31 (n=7053 cells, representing 4 replicates). We note
in passing that the labelling index (0.31) determined by cell counting is close to the
value noted above (0.33) which was obtained by morphometric analysis based upon
cells areas determined by pixel numbers. The labelling indices of insulin-positive
ductal cells and islets are not significantly dissimilar (2x2 contingency table, the chi-
square approximation, two-sided, P= 0.15).
On the assumption that the number of insulin-positive cells in the ductal
component increases substantially during pregnancy, the similar HPAP labelling
indices in the ductal component and in the islets are not consistent with the duct
being a “ preferential” source of new beta-cells during pregnancy.
3.3.5 Beta-cells do not transdifferentiate into other cell types.
An interesting aspect of cell plasticity is the ability to transdifferentiate into
other cell types. Having confirmed that the HPAP-labelling was initially specific for
beta-cells, we examined whether beta-cells are able to transdifferentiate into other
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(insulin-negative) cells in the endocrine or exocrine components of the pancreas
during pregnancy. We therefore looked for cells positive for HPAP, and negative for
insulin, in the pancreata of pregnant and non-pregnant animals after the chase period
(about two and half months after the last pulse of tamoxifen). We did not find any
example of cells positive for HPAP and negative for insulin in the pancreatic
sections of pregnant and non-pregnant female mice (Figure 18).
This analysis indicates that during this time-window, beta-cells do not fully
lose differentiation or transdifferentiate into other cell types of either endocrine or
exocrine tissue. This is similar to conclusion reached after induction of acute
pancreatitis (Strobel et al., 2007).
However, we cannot exclude that transdifferentatiation could take place
during a much longer period following the tamoxifen pulse, or self-evidently under
different conditions not examined here, for example following pancreatic injury and
regeneration.
3.3.6 Conclusion
We investigated the origin of new beta-cells in response to a first cycle of
pregnancy using a cell-lineage tracing for beta-cells in pulse-chase experiments.
We first showed that the labelling system in the double transgenic mice
(Z/AP; RIP-CreERTAM) was 1) specific to beta-cells, 2) irreversible and heritable and
3) tamoxifen dose-dependant.
Secondly, we showed that in response to pregnancy, 1) the mean body and
pancreatic weight increased about 45 and 51% respectively in pregnant animals
compared to the aged-matched non-pregnant control animals, 2) the mean beta-cell
mass increased around 91% in pregnant mice compared with the age-matched non-
pregnant control mice.
The analysis of the proportion of beta-cells labelled for HPAP, showed that
the labelling index of the non-pregnant animals (0.44±0.05) was greater than in the
pregnant group (0.33±0.06). The difference between the two groups was statistically
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significant (P=0.021, paired two-tailed t-test). This result is consistent with
hypothesis 2 and indicates that non-beta-cell progenitors contribute significantly to
the increase of the beta-cell mass in response to pregnancy.
The analysis of the proportion of the beta-cell clusters or small sized-islets
devoid of HPAP, showed that the means of the beta-cell clusters or small islets
negative for HPAP was greater in the pregnant group (0.19±0.06) than in the non-
pregnant controls (0.11±0.04). The difference between the two groups was not
statistically significant (P=0.093, paired two tailed t-test). However, there is a trend
suggesting that either new islets are formed during pregnancy or alternatively, these
results might reflect the dilution of the label in expanded islets.
The analysis of the HPAP labelling indices in the beta-cells in the lining of
the ductal component (0.21, n=57 cells, representing 4 replicates) and in the islet
compartment in the same sections (0.31, n=7053 cells, representing 4 replicates)
showed that the two indices are not significantly dissimilar (2x2 contingency table,
chi-square approximation, two-sided, P= 0.15) These results indicate that the duct
compartment is not “a preferential” source for new beta-cells during the beta cell
mass expansion occurring to adapt to the new insulin demand during pregnancy.
Finally, we did not observe any examples of cells positive for HPAP and
negative for insulin in the pancreatic sections of non-pregnant and pregnant animals,
indicating that even after a lengthy chase period, beta-cells do not fully lose
differentiation or transdifferentiate into other lineages of either endocrine or exocrine
compartment.
In conclusion, using a cell-lineage tracing system for beta-cells, we
demonstrated, for the first time, that non-beta-cell progenitors contribute
significantly to the beta-cell mass increment in response to pregnancy, in addition to
the role of pre-existing beta-cells in beta-cell duplication.
What might be the other potential lineages of the non-beta-cell progenitors
during pregnancy?
It is a question that we will discuss in the last discussion chapter.
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In this chapter we demonstrated that non-beta-cell precursors can
differentiate into insulin-producing cells during a first pregnancy. We aimed to
repeat this experiment during a second cycle of pregnancy after the beta-mass
reversed subsequent to the parturition period, to reinforce our previous finding. Thus,
we wish to ask if there is a more pronounced dilution of the HPAP label in the
pancreas of pregnant animals that have undergone two consecutive pregnancies,
compared to those that undergo only one cycle of pregnancy. This is the subject that
we have explored in the following chapter.
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Origin of new beta-cell in two pregnancies
4.1 Introduction
Heretofore, we showed that the proportion of beta-cells positively labelled
for HPAP decreased significantly during a first cycle of pregnancy. This dilution led
us to conclude that a substantial population of new beta-cells were the progeny of
non-beta-cell progenitors in pancreas of pregnant animals. We wished to explore this
result and ask whether non-beta-cells progenitors contribute significantly to the beta-
cell mass expansion occurring in pregnant animals, but this time during two cycles
of pregnancy. We employed the same cell-lineage tracing system for beta-cells to
address the role of non-beta-cell precursors during two pregnancies.
4.2 Experimental design
For this purpose, age and weight-matched double transgenic female animals
(Z/AP; RIP-CreERTAM),were paired and injected together with 25mg of tamoxifen to
mark beta-cell with HPAP, around nine weeks of age for a period of two and half
weeks. At the start of the study, 14 animals were involved, but due to the
experimental difficulties mentioned in the previous chapter, only 6 animals could be
analysed. Thereafter, one animal in each pair was either mated for pregnancy or
maintained in a non-pregnant state. After a first pregnancy, the same animals were
mated yet again ten days after giving birth. Then, during the second pregnancy,
between fifteen to nineteen days of gestation, the pregnant animals were euthanized
concurrent with the non-pregnant control females and their pancreata were excised
for analysis.
Three pairs of animals were studied for the whole experiment and their
pancreata were processed and analysed, as previously described, to determine the
proportion of HPAP labelled beta-cells by using cross sectional area and also by
determination of cell numbers positive for insulin or HPAP.
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The counting of labelled or non-labelled beta-cells in sections were
performed manually and the HPAP labelling index related to this analysis, was
derived by forming the ratio of total number of beta-cells positive for HPAP over the
total number of beta-cells positive for insulin in the whole five sections per pancreas
and per animal. The counting of number of beta-cells or the measurement of area
positive for HPAP or insulin was carried out simultaneously on the same set of
sections for subsequent comparison.
Overall, five sections per pancreas and animal were analysed and selected
according to the criteria that have been discussed in the preceding chapter, in the
same way pancreata were processed and sectioned following the method presented
previously. The images of all islets, single beta-cells or beta-cell clusters within
sections were captured using a confocal microscope.
In total two thousand one hundred and ninety eight images were analysed for
the entire experiment, and all were examined anonymously.
4.3 Results
4.3.1 Response to pregnancy
As reported in Chapter 3, pregnancy is accompanied by multiple
physiological and physical changes to accommodate to the new metabolic demand.
Similarly to a first pregnancy (Karnik et al., 2007), in a second pregnancy,
we observed a 60% increase of the mean body weight in pregnant animals compared
to that of non-pregnant controls, similarly the mean pancreas weight increase about
43% in pregnant animals in comparison to non-pregnant female animals (Figure 19
A and B). We calculated the beta-cell size in both groups by forming the ratio of
total pixel number of cross-sectional area positive for insulin (detailed in chapter 3)
over the number of beta cells counted, in the whole five sections per pancreas and
per animal. We observed that the mean beta-cell area in pregnant animals
(147±18.89 pixels) was slightly larger compared to that of non-pregnant controls
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(131±12.45 pixels, figure 19C). The beta-cell area increased about 12% in pregnant
animals, close to Avril et al. report (Avril et al. 2002).
Equally, during a first round of pregnancy (Scaglia et al., 1995, Aerts et al.,
1997, Huang et al., 2009, Avril et al., 2002, Blondeau et al., 1999, Karnik et al.,
2007, Parsons et al., 1995), we found that the beta-cell mass doubled in the pancreas
of pregnant animals during the second pregnancy, compared to that of age-matched
non-pregnant controls (Figure 19D).
Therefore, in line with other reports, in our animals, the beta-cell mass
increased, observed in response to pregnancy must be due to an augmentation of
number of the beta-cell population, with little contribution of increased beta-cell
volume. Therefore, the next question was to investigate the origin of the new beta-
cells.
4.3.2 Analysis of beta-cell origin during two cycles of pregnancy
The experimental design has been explained above and is also succinctly
presented in Figure 20. The particularity of this experiment is to test the activation of
progenitors from a lineage different from beta cells during two pregnancies,
following beta-cell mass involution in the pancreas induced by apoptosis after a first
pregnancy, in the post-partum period (Scaglia et al., 1995).
We have showed that a non-beta-cell source contributes to the beta-cell mass
expansion during a first pregnancy. Based on the assumptions that the involution of
the beta-cell mass occurs at random by beta-cell apoptosis and non-beta-cell
progenitors contribute to the beta-cell mass increment during a second pregnancy,
we would expect a further dilution of the HPAP labelling index during two cycles of
pregnancy.
The first assumption does imply that unlabelled and labelled beta-cells are
equally ablated by apoptosis, without any distinction between both populations.
In the same way, the second assumption does imply that the mechanism of
the beta-cell mass expansion is similar to that in a first pregnancy (Figure 20).
Chapter 4: Origin of new beta-cells in two pregnancies
80
Based on the assumptions above and inasmuch as Φ1 defined as the ratio of
the mean HPAP labelling index of non-pregnant animals over pregnant animals
during a first pregnancy, is 1.37 (Chapter 3), Φ0, the quotient of the mean HPAP
labelling index of non-pregnant animals over pregnant animals at the end of the
tamoxifen pulse, is 1, we estimated that the ratio Φ3 of the mean HPAP labelling
index of non-pregnant animals over the age-matched pregnant animals during two
cycles of pregnancy, should be 1.88.
The HPAP labelling indices ( Figure 21 A and B) in pancreata of non-
pregnant and age-matched pregnant animals was calculated using data generated
from both area measurement (Figure 21A) in pixel number, using ImageJ and
manual cell counting (Figure 21B).
First, we confirmed that the HPAP labelling index values calculated from
data produce by area measurement or generated by manual cell counting, for the
same animal, are numerically similar.
Secondly, we observed that the HPAP labelling indices display large
variations between animals of same group, namely between as well as the non-
pregnant animals as compared all together that the animals in pregnant group.
This is likely due to an unanticipated problem with one batch of tamoxifen
required to activate the labelling. Indeed, the animals from pair 1 received tamoxifen
from the same batch used in studies in Chapter 3 and the proportions for beta-cells
HPAP positive in animals from a first pregnancy were very similar ( see Figure 15 in
chapter 3). And, the rate of labelling, in animals injected with 25 and 20mg using
this same batch of tamoxifen, showed that the marking was tamoxifen dose-
dependent (see Figure 10 in chapter 3).
By contrast, the HPAP labelling indices in animals of pair 2 and 3 showed
values clearly lower to that expected for the dose of tamoxifen injected. Pairs 2 and 3
were given tamoxifen from a new batch, as the original one had to be replaced.
This suggests that the tamoxifen quality can be variable from one batch to
another or less likely that the animals from pair 2 and 3 might be different from the
other animals used.
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Nevertheless, these results demonstrate the importance of animal pairing to
minimize variations other than those related to individual animals.
Statistical analysis of these data is limited, due to the great variation between
pairs, but we can still use comparison between the paired designs, to examine the
assumptions above.
To extract the information needed, we derived the ratio of the HPAP
labelling indices of non-pregnant animal over pregnant animal, determined by cross-
sectional area measurement in each pair for each experiment, namely, animals from
experiment described in Chapter 3 (experiment 1, i.e. a single pregnancy) and in this
Chapter (experiment 2, i.e. two pregnancies).
Figure 21C represents the mean ratio of the HPAP labelling indices in
pancreata of non-pregnant controls over pregnant animals derived from the results of
experiment 1 and 2 separately.
We observed that the mean ratio of the HPAP labelling index in pancreas of
non-pregnant control over pregnant animals from experiment 1 (a single pregnancy,
1.37±0.209) is close to that of animals from experiment 2 (two pregnancies,
1.34±0.004). The difference between the two groups is not significant (P=0.53, two
tailed, paired t-test).
According to the assumptions discussed above, namely, if ablation of
unlabelled or labelled beta-cells occurs at random during the parturition period after
a first pregnancy, and if the mechanism governing beta-cell mass expansion in a
second pregnancy is similar to that of a first pregnancy, then the ratio expected for
experiment 2, should be 1.88.
Given that the ratio obtained for experiment 2 (1.34±0.004) is different to
that expected (1.88), accordingly, we cannot support both hypotheses.
We cannot conclude about the contribution of non-beta-cell progenitors
during a second cycle of pregnancy.
The comparison of the proportion of labelled-free small islet sections
between pregnant and non-pregnant animals shows that this ratio is systematically
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greater in pregnant animals compared to that of the non-pregnant animals within the
same pair (Figure 22D) despite the large variation between replicates of same group.
As shown during a first pregnancy, we observed, during a second pregnancy,
small islet cross-sections positive or negative for HPAP immunoreativity, while
intermediate or big islet cross-sections were always marked with the reporter (Figure
22 A, B and C).
In principle, one could have tested hypothesis 3, concerning the formation of
whole new islets during two cycles of pregnancy, or alternatively tested the effect of
a dilution in larger islets on the proportion of free-label small islet cross-sections, but
because of the large variation between replicates, it was not possible to perform a
robust statistical analysis to test the veracity of such propositions.
4.3.3 Beta-cell clusters associated with the pancreatic duct
Pancreatic duct epithelium in numerous reports is presented as a potential
source for new beta-cells during normal growth in adult pancreas or after certain
types of pancreatic injury. Consequently, our attention was directed specifically to
this compartment. Unfortunately, the comparison of HPAP labelling indices in
ductal and in the islets compartment in the pancreas of pregnant animals was not
possible in this situation owing the large variation which was discussed above.
Figure 19 Responses to pregnancy
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Figure 22 Beta-cell clusters negative for HPAP during a second pregnancy
Photomicrographs of pancreatic sections from pregnant animals stained for insulin
(red), HPAP (green), and nuclei (blue, DAPI). Small islet
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Thus, instead of focusing on the HPAP labelling index as done in the preceding
chapter, we examined the incidence of insulin-positive ductal cells in pregnant and
non-pregnant animals during a second and first pregnancy (Figure 23A and B).
The data are presented in Figure 24. The scrutiny of insulin-containing cells
in the ductal lining (Figure 24A), indicated an increase numbers of these cells, both
during a first or two cycles of pregnancy. We also noticed that the numbers of ducts
containing insulin-positive cell increased (Figure 24B). The analysis was carried out
on five sections per pancreas, four and three replicates were viewed for the
experiments conducted during a first and two cycles of pregnancy correspondingly.
The difference between the two groups, for both analyses was not significant.
Combining the data from the experiment of one and two pregnancies (Figure 24A
and B) did alter the P-value (paired, two-sided student t-test), but the difference is
still not significant.
These tentative results suggest that during pregnancy, more ducts expressing
insulin-positive cells may accommodate the new insulin load but the numerical
analysis indicates that dramatic activation of this mechanism does not in fact occur.
Nonetheless, more experiments need to be performed to conclude about the
extent of the contribution of the duct compartment.
Furthermore, we combined the results of the HPAP labelling indices obtained
from paired animals in one and two pregnancies. We observed that the combined
mean HPAP labelling index in the non-pregnant animals (0.44±0.12) is higher than
that in pregnant animals (0.33±0.09), and the difference between the two groups is
considered extremely significant (paired, two-sided student t-test, P-value 0.0007).
Similarly, the combined results of the proportion of small islets or beta-cell
clusters negative for HPAP obtained from paired animals in one and two pregnancies,
showed an increase in this proportion in pregnant animals (0.25±0.12) as compared
with the non-pregnant group (0.14±0.08). The difference between the two groups is
considered very significant (paired, two-sided student t-test, P-value 0.006). The
latter indicates that either new islets are formed during pregnancy or alternatively,
there is a dilution of the label in larger islets during this state.
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4.3.4 Beta-cells do not transdifferentiate into other cell-lineages
In the previous chapter, we showed that beta-cells do not transdifferentiate
into other pancreatic cell-lineages or do not fully loss differentiation two and half
months after the last tamoxifen pulse. Here, we had a further opportunity to ask if
this was still the case in animals three and half months following the last tamoxifen
injection. We screened pancreatic sections for cells positive for HPAP and negative
for insulin in non-pregnant and pregnant animals (Figure 25 A and B), we did not
see any examples of cells remaining positive for HPAP without expressing insulin.
We can confirm that beta-cells do not transdifferentiate into other lineages or
fully lose differentiation. It remains to be seen if this type of event can still take
place in much longer time point that is six or twenty four months after the last
tamoxifen pulse or in other circumstances.
Once again our examination corroborates results from studies on pancreatitis
showing that beta-cell do not transdifferentiate into other cell types (Strobel et al.,
2007)
Figure 23 Insulin-positive cells associated with the ductal epithelium
pregnancies. Pancreas sections from pregnant female animals (panel A) or non
pregnant female animals (panel B) stained for insulin (red), HPAP (green), and
nuclei (blue, DAPI), show examples of beta
with duct epithelium. Scales bar correspond to 40µm.
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Figure 25 Beta-cells do not transdifferentiate into other cell
labelling remains restricted to beta
from non-pregnant control (panel A) and pregnant (panel B) females animals stained
for insulin (red), HPAP (green), and nuclei (blue, DAPI), showing that the HPAP
label is restricted to beta
tamoxifen. Scale bar corresponds to 40µm.
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4.4 Conclusion
In conclusion, using the same lineage tracing system employed to trace the
fate of beta-cells during a first cycle of pregnancy, we have undertaken a similar
experimentation to explore whether during two cycles of pregnancy, non-beta-cell
progenitors contribute to the same extent to the formation of newly formed beta-cells.
We observed a 60% and 43% increase of the mean body weight and pancreas
weight correspondingly in pregnant animals compared to non-pregnant controls.
Similarly, we confirmed an increment of two fold of the beta-cell mass in
response to pregnancy to adapt to the new insulin load with little contribution of
beta-cell hypertrophy.
Secondly, the comparison of the HPAP labelling index in non-pregnant
controls over pregnant animals in one and two cycles of pregnancy led us to reject
our hypothesis that, the HPAP labelling index would be markedly lower in the
pregnant animals during two cycles of pregnancy compared to a first cycle.
The variation in the beta-cell labelling in the three replicates put a limitation
to the analysis. Nonetheless, we observed both a small increase of the occurrence of
insulin-positive cells in the ductal compartment and the number of ducts associated
with these cells in a one and two pregnancies. These tentative results might suggest
that duct progenitors could be activated to form de-novo beta-cells in pregnancy, but
it was evident that this must be a minor mechanism.
However, the combined results of the HPAP labelling indices and the
proportions of small islets or beta-cell clusters negative for HPAP from experiment 1
(a single pregnancy) and experiment 2 (two pregnancies), reinforce our conclusion
regarding the contribution of non-beta-cell progenitors during the beta-cell mass
expansion in response to pregnancy.
Lastly, we did not find any example of beta-cells that had transdifferentiated
into other lineages, or fully lost differentiation in pregnant and non-pregnant animals
even three and half months after the last pulse of tamoxifen.
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As discussed at the beginning of this chapter, we expected that during two
cycles of pregnancy, the dilution of beta-cells labelled for HPAP should be greater
than in a first pregnancy, this if the beta-cell apoptosis process took place at random.
And, the results obtained led us to reject that hypothesis. This unexpected outcome
prompts more questions, which will be debated in the discussion chapter.
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Origin of new beta-cells after diabetic recovery
5.1 Introduction
The search for new therapies to cure diabetes and understanding tissue
homeostasis has prompted researchers to investigate the origin of new beta-cells
during postnatal growth, maintenance or beta-cell regeneration (Like and Chick,
1969). Studies from models of pancreatic injury in adult rodents, mooted for a long
time the existence of progenitors within the adult pancreas playing an active role
during beta-cell regeneration, and possibly during beta-cell renewal and maintenance
in postnatal life (Nir and Dor, 2005, Bonner-Weir and Weir, 2005, Levine and Itkin-
Ansari, 2008). In 2004, a first application of an inducible cell-lineage tracing for
beta-cells performed by Dor et al. (Dor et al., 2004) has had an enormous impact in
this field. For the first time they provided, with direct evidence, that pre-existing
beta-cells were progenitors for new beta-cells and subsequently contributed
essentially to beta-cell growth and maintenance during mouse postnatal development,
and even after partial pancreatectomy.
The existence of putative pancreatic progenitors residing within adult
pancreas or even the contribution of such progenitors to form de-novo beta-cells in
adulthood has been seriously questioned since this publication.
However very recently, three reports (Inada et al., 2008, Xu et al., 2008,
Collombat et al., 2009), have reinstated adult pancreatic progenitors on the map, by
offering with direct proof ultimately that progenitors within adult pancreas do exist,
are of ductal origin, and contribute significantly to the formation of new beta-cells
shortly after birth or during beta-cell regeneration after duct ligation in mouse.
Undoubtedly there is a resurgence of the debate regarding the mechanism by
which new beta-cell arise in normal and patho-physiological conditions with the
advent of novel genetic cell-lineage techniques.
The dispute regarding whether stem/progenitor cells in the adult pancreas
could be considered as legitimate cellular sources for newly formed beta cells under
multiple situations is far from being resolved. It is justifiable to address the origin of
Chapter 5: Origin of new beta-cells after diabetic recovery
96
new beta-cell in different circumstances where other types of stimuli might be
involved to better understand the mechanisms of these two complementary processes.
For this reason, we aimed to use a direct approach in a specific model of pancreatic
regeneration, to examine the origin of new beta-cells after toxic-genetic beta-cell
ablation in transgenic mice over-expressing c-Myc (Pelengaris et al., 2002).
5.2 Experimental design
With the view to explore the cellular source giving rise to new beta-cells after
diabetic recovery, we generated triple transgenic mice in which the inducible cell-
lineage tracing system for beta-cells has been introduced in a mouse model of
pancreatic regeneration (pIns-c-MycERTAM).
First, the Z/AP mouse line was crossed with the RIP-CreERTAM line to obtain
double transgenic mice (Z/AP; RIP-CreERTAM), the beta-cell lineage tracing system.
Then, the latter were crossed with the toxic-genetic beta-cell ablation mouse line
(pIns-cMycERTAM) to generate the triple transgenic animals (Z/AP; RIP-CreERTAM;
pIns-c-MycERTAM).
Using this strategy, one mouse out of eight was expected to be of the right
genotype. The cell-lineage tracing in the bigenic mice (Z/AP; RIP-CreERTAM) has
been described in chapter 3, therefore we will describe only the transgenic line of
beta-cell regeneration (pIns-c-MycERTAM) in this section.
5.2.1 Toxic-genetic model of beta-cell ablation and regeneration in the single
pINS-c-MycERTAM mice
In the pIns-c-MycERTAM monogenic mice, the switchable human basic helix-
loop-helix leucine zipper (bHLH-LZ) transcription factor c-Myc, under the control
of a preproinsulin promoter (pIns) is expressed restrictively in insulin-secreting beta-
cells.
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In this system the transcription factor c-Myc is in fact a chimerical protein
which is fused with a truncated form of an oestrogen receptor (ERTAM). In absence of
4-hydroxytamoxifen (4-OHT), the chimerical transcription factor domain is inactive
owing to its binding to heat shock proteins (HSP) on its ERTAM (Figure 26A).
The untreated animal presents a normal blood glucose level. However, upon
tamoxifen or 4-hydroxytamoxifen (4-OHT) exposure, the c-MycERTAM is activated
(see below) due to its binding to this synthetic drug in place of the HSP. As a result,
the activated chimerical protein c-MycERTAM ablates specifically beta-cells by
apoptosis. This apoptosis follows a short burst of proliferation (Pelengaris et al.,
2002, Cano et al., 2008), leading to islet involution and the development of a
diabetic phenotype in the transgenic animals.
By contrast, inactivation of c-Myc upon tamoxifen or 4-hydroxytamoxifen
withdrawal, results in gradual beta-cell regeneration and diabetic recovery
characterized by normalization of the glycaemia in the animals, as originally
reported by Pelengaris et al. and Cano et al. (Pelengaris et al., 2002 and Cano et al.,
2008).
Figure 26, panel B, shows islet morphology in pancreatic sections in the
pIns-c-MycERTAM transgenic animals. The microphotography (Figure 26Bi) shows a
representative islet in an untreated animal (note the regular shape of the islet), but
upon 4-OHT exposure, acute beta-cell apoptosis results in islet involution evident as
islets of small mass with irregular contours (Figure 26Bii). Conversely, withdrawal
of 4-OHT, leads to beta-cell regeneration (see discussion of this later) and islets
grow back virtually to their original size (Figure 26Biii, Pelengaris et al., 2002, Cano
et al., 2008).
In this model of beta-cell regeneration, we introduced the cell-lineage tracing
system for beta-cells to study (in triple transgenic mice) the origin of new beta-cells
following the toxic-genetic beta-cell ablation induced by c-Myc.
The active process of beta-cell regeneration after diabetic recovery, in the
single pIns-c-MycERTAM mice, demonstrated by the authors above, might not occur
in the triple transgenic (Z/AP; RIP-CreERTAM ; pIns-c-MycERTAM) mice at the time
point investigated.
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5.2.2 Methodology applied to study beta-cell genesis after diabetic recovery
We generated multiple transgenic mice (Z/AP; RIP-CreERTAM; pIns-c-
MycERTAM) to study in pulse-chase experiments the cellular source giving birth to
de-novo beta-cells during beta-cell regeneration subsequent to beta-cell depletion
induced by c-Myc.
The animals were split into three groups of three (Figure 27). The first group
represents untreated control animals (group 1, 3 animals), in which beta-cells are not
labelled for HPAP and the fed blood glucose level is normal.
The second one (group 2, 3 animals), animals were pulsed with the drug 4-
OHT for ten consecutive days (the pulse period) and euthanized the following day
after the last drug injection, at the time where the mice were overtly diabetic.
The last group (group 3, 3 animals) corresponds to animals also pulsed with
4-OHT for ten days but euthanized four weeks after the last day of the drug injection
and after diabetic recovery (the chase period).
Thus, after daily injection of 1mg/0.2ml of 4-OHT for ten days each mouse about
seven weeks of age, received after the end of the last pulse, 10mg of the drug in total.
Then, animals from group1 (control untreated mice) and 3 (mice recovered from
diabetes) were sacrificed contemporaneously, while animals from group 2 (diabetic
mice) were sacrificed four weeks earlier before diabetic recovery. Pancreata of all
animals were collected for analysis.
The fed blood glucose level was monitored in animals during the course of
the whole experiment i.e. before, during, after 4-OHT injections, and at the time of
sacrifice. Our animals were considered diabetic when their fed blood glucose level
was above 12mM. After induction of diabetes in our mice, they did not require
insulin treatment to recover for diabetes.
Figure 26 Toxic-genetic model of beta
single pIns-c-MycER
c-Myc is inactive due to its binding to heat shock proteins (HSP) on its ER
domain. Upon 4-OHT exposure, the c
in place of the HSP. As a result, the c
apoptosis, leading to islet involution. By contrast, inactivation of c
OHT withdrawal, results in gradual beta
pancreatic sections in the pIns
microphotography (i) shows a representative islet in an untreated animal, but upon 4
OHT exposure (ii), acute beta
islets of small mass. Conversely, withdrawal of 4
regeneration.
Chapter 5: Origin of new beta-cells after diabetic recovery
-cell ablation and regeneration in the
TAM mice. (A) In the absence of 4-hydroxytamoxifen (4
-Myc is activated due to its binding to 4
-Myc ablates specifically beta
-cell regeneration. (B) Islet morphology in
-c-MycERTAM transgenic animals. The
-cell apoptosis results in islet involution e
-OHT (iii) leads to beta
99
-OHT),
TAM
-OHT
-cells by
-Myc upon 4-
-
vident as
-cell
Figure 27 Pulse-chase experiment in triple transgenic mice (Z/AP;
CreERTAM; pIns-c-MycER
mice are euglycemic and no expression of HPAP in their beta
4-OHT exposure (the pulse period), beta
labelled for HPAP by removal of stop codon sequences upstream of
cre-recombinase. Beta
a diabetic phenotype (group
the last pulse of 4-OHT (the chase period), the animals recover from diabetes and
become euglycemic due to beta
Chapter 5: Origin of new beta-cells after diabetic recovery
TAM) mice. In absence of 4-OHT the triple transgenic
-cells (group
-cells are ablated by c-Myc activation and
-cell ablation leads to islet involution and the animals develop
2). Conversely, upon 4-OHT withdrawal, 4 weeks after
-cell or islet regeneration (group 3).
100
RIP-
1). Upon
HPAP gene by
Chapter 5: Origin of new beta-cells after diabetic recovery
101
It is important to emphasise that in the triple transgenic mice, upon 4-OHT injection,
beta-cells are both labelled for HPAP resulting from removal of stop signal
sequences upstream of the HPAP reporter gene catalyzed by the Cre-recombinase,
and are also ablated by apoptosis following c-Myc activation.
Thus, during the 4-OHT treatment, the two events occur concurrently,
leading to the marking of the surviving beta-cell population that escaped apoptosis
induced by c-Myc activation. Thenceforth, at the end of the last pulse of 4-OHT, the
mice develop a diabetic phenotype due to beta-cell depletion. Our initial expectation
was that upon 4-OHT removal, the triple transgenic mice (Z/AP; RIP-CreERTAM;
pIns-c-MycERTAM) recover from diabetes due to formation of new beta-cells by
regeneration in the same way as the single transgenic pIns-c-MycERTAM mice, after
diabetic recovery to replenish the missing beta-cells in their pancreas.
By which mechanism are new beta-cells produced in the triple transgenic
mice after diabetic recovery subsequent to selective beta-cell ablation and labelling?
To answer to this question, triple transgenic mice were generated and injected
with 4-OHT for ten consecutive days to ablate and label their beta-cells, then upon 4-
OHT withdrawal, they were allowed to recover from diabetes before excising their
pancreata for analyses.
Pancreata were processed and analysed in a systematic way to avoid any
forms of bias, as described in chapter 3 and Materials and Methods. ImageJ was used
for performing pixel counts on captured images of sectioned islets, single and
clusters of beta-cells stained for HPAP or insulin.
Overall, one thousand seven hundred and six images were analysed for the
whole experiment comprised of nine mice. In total an average of seventy eight beta-
cell clusters or islets were analysed per mouse in group 2 (diabetic animals), seventy
four beta-cell clusters or islets were analysed per mouse in group 3 (animals after
diabetic recovery) and one hundred and thirty two beta-cell clusters and islets were
analysed per mouse in group 1 (untreated control mice).
The HPAP labelling index and beta-cell mass for each animal were
calculated as detailed previously.
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5.2.3 Interpretation of possible lineage-tracing outcomes
Using the triple transgenic mice bearing the ablation-tracing system in a
pulse-chase experiment, we could examine the origin of new beta-cells after diabetic
recovery and beta-cell regeneration.
The analysis of the lineage tracing results and the strategy described above
are presented succinctly in Figure 28. In the absence of 4-OHT, the beta-cells in the
multiple transgenic animals are unlabelled for beta-cells, and exhibit normal fed
blood glucose level.
Upon 4-OHT addition, during the pulse period, beta-cells in the animals are
ablated and labelled for HPAP simultaneously, resulting in the development of a
diabetic phenotype.
Withdrawal of 4-OHT leads to diabetic recovery and beta-cell regeneration
during the chase period.
Comparisons of the HPAP labelling indices in animals at the end of the pulse
period (when the mice are diabetic) and in animals four weeks after the last 4-OHT
pulse, after diabetic recovery during the chase period, should allow deductions about
the mechanism by which newly formed beta-cells arise.
We must consider three hypotheses. First, the percentage of beta-cells
labelled for HPAP in animals after diabetic recovery or beta-cell regeneration in the
chase period is similar to that in diabetic animal shortly after the last pulse of 4-OHT.
One concludes that new beta-cells are produced by mitogenesis (Hypothesis 1).
Secondly, if there is a diminution of the proportion of beta-cells positive for
HPAP in animals after diabetic recovery compared to the proportion of labelled beta-
cells in diabetic animals, one deduces that new beta-cells are the progeny of non-
beta-cell progenitors in combination or not with pre-existing beta-cells (Hypothesis
2).
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At last, if the percentage of islets devoid for the HPAP label is higher in
animals after diabetic recovery than in the diabetic animals, one can infer that new
whole islets are formed from non-beta-cell progenitors (Hypothesis 3).
5.3 Results
5.2.1 Induction of diabetic by activation of c-myc in the triple transgenic mice
In order to study the origin of new beta-cell after diabetic recovery in the
triple transgenic mice, the mice were pulsed with 10mg of 4-OHT, to ablate and
labelled their beta-cells, then euthanized four weeks following the pulse.
The fed blood glucose was monitored at the three time points presented in
Figure 29A. Untreated animals and animals before treatment present a normal fed
blood glucose level. The mean fed blood glucose in those animals was 4.7±1.5mM.
After the last pulse of 4-OHT, treated animal developed a diabetic phenotype,
the mean fed blood glucose level was 21.6±6.0mM.
The difference between the two groups was significant (One-way Analysis of
Variance (ANOVA), P-value <0.001).
Then four weeks after the last 4-OHT injection, the last time point on the
graph, the mice partially recovered from diabetes, illustrated by a mean fed blood
glucose level about 10.5±2.6mM.
The difference of mean fed blood glucose level between diabetic animals and
animals after diabetic recovery was significant (One-way Analysis of Variance
(ANOVA), P-value <0.01), whereas the difference between untreated animals and
animals after diabetic recovery was not (One-way Analysis of Variance (ANOVA),
P-value >0.05).
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Following the 4-OHT treatment the mice developed a diabetic phenotype as
expected, suggesting that the beta-cell mass in the pancreas of the treated mice was
depleted by apoptosis induced by c-Myc activation. This treatment was also expected
to mark the remaining beta-cells for HPAP.
Were the beta-cell mass ablated and the survival beta-cells marked for HPAP
during the drug treatment?
In order to answer those questions, we collected pancreas from untreated
animals and animals at the end of the pulse and also pancreata after diabetic recovery.
The HPAP labelling index and beta-cell mass were determined. We observed
that the mean beta-cell mass of untreated animal is higher (0.83±0.20) than that of
the diabetic animals after the end of the treatment (0.16±0.07mg). The difference
between the two groups was statistically significant (One-way Analysis of Variance
(ANOVA), P-value<0.01). We also compared the three groups altogether, see below.
Thus, we found that the diabetic phenotype observed in triple transgenic mice
was due to beta-cell ablation induced by apoptosis subsequent to c-Myc activation by
4-OHT. These data corroborate Pelengaris et al. and Cano et al. results (Pelengaris et
al. and Cano et al.).
Another important point to verify was the labelling of the remaining beta-
cells after activation of the Cre-recombinase. Therefore, we immunostained for
insulin and HPAP as described in Materials and Methods, pancreatic sections of
triple transgenic animals treated or not for 4-OHT. The results are presented in
Figure 30. In the absence of 4-OHT (Figure 30A), the overall islets were largely
unlabelled for HPAP in all three untreated animals, even though, we observed
limited labelling scattered in few islet sections. On the other hand, beta-cells of
animals treated with 4-OHT (Figure 30B and D), expressed the HPAP reporter. The
islets shown in Figure 30 are representative of the overall islet population observed
in the pancreatic sections of animals for each time point.
We observe that the activation of the Cre-recombinase upon 4-OHT exposure
induced expression of the label exclusively in the beta-cells of treated triple
transgenic animals.
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Also Figure 31 shows examples of paired post-mitotic cells positive for
HPAP in treated animals which must be the progeny of pre-existing beta-cells as
evidenced by the HPAP label. These examples are relatively rare but the overall
labelling index in the triple transgenic mice is also low. It is not unreasonable to state
that the dose of 4-OHT injected in the mice do not ablate all their beta-cells as
evident in Figure 30B, and so one can expect in the same way, that a proportion of
surviving beta-cells not to be labelled as well.
5.2.2 Analysis of origin of new beta-cell after diabetic recovery
With the view to determine the source for new beta-cells after diabetic
recovery in the triple transgenic mice, we calculated the HPAP labelling index in
animals of each group. The results are presented in Figure 29B.
The HPAP labelling index in the untreated mice (group1) is close to zero as
compared with that of treated animals.
The mean HPAP labelling index of the diabetic mice (0.047±0.028, group 2)
and mice after diabetic recovery (0.06±0.026, group 3) are not dissimilar (two-tailed,
unpaired t-test, P-value=0.587).
This result might be taken to that new beta-cells after diabetic recovery arise
mainly from pre-existing beta-cells (hypothesis 1). This is consistent with the
examples of paired post-mitotic beta-cells positive for HPAP in pancreata of treated
animals.
However to validate Hypothesis 1, one must prove that new beta-cells were
produced during diabetic recovery. Therefore, we measured the beta-cells mass in
diabetic animals in which beta-cells were ablated (group 2) and in animals after
diabetic recovery (group 3), the results are presented in Figure 29C.
The mean beta-cell mass of diabetic mice (0.16±0.07mg) is not dissimilar to
the mean beta-cell mass of mice after diabetic recovery (0.13±0.06mg). The
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difference between the two groups was not statistically significant (One-way
Analysis of Variance (ANOVA), P-value>0.05.
Surprisingly, from these data, after diabetic recovery, there is no evidence
that new beta-cells were produced despite the fact that the fed blood glucose of the
mice returned to normal values.
Large scale regeneration can be excluded by these data, but limited
regeneration giving rise to new beta-cells cannot be ruled out in the context of the
beta-cell mass remaining low.
5.4 Conclusion
In conclusion, in the triple transgenic mice we showed that c-Myc and the
Cre-recombinase were activated upon 4-OHT exposure, leading to the development
of a diabetic phenotype, and the labelling of remaining beta-cells for HPAP.
We also showed that the labelling was 4-OHT-dependent, heritable and
specific for beta-cells.
Unfortunately, we were unable to demonstrate in the triple transgenic that
diabetic recovery was associated with beta-cell regeneration, as was previously
reported in the single transgenic mice model of beta-cell regeneration (pIns-c-
MycERTAM). Therefore we could not examine the cellular source giving rise to new
beta-cells after diabetic recovery in this model. However we have seen examples of
paired post-mitotic cells positive for HPAP which must be the progeny of pre-
existing beta-cells in treated animals.
The similar labelling indices before and after recovery are specifically
consistent with the observation that new beta-cells are not formed from progenitors.
What is the mechanism for glucose homeostasis in this model? This will be
discussed in Chapter 7.
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By contrast to the triple transgenic mice, in the pIns-c-MycERTAM mice, we
and others (Pelengaris et al., 2002 and Cano et al., 2008), have shown that the
activation of c-Myc induced massive beta-cell loss by apoptosis, resulting in
development of a diabetic phenotype in the animals. And more importantly, that after
4-OHT withdrawal, the mice recover from diabetes due to active beta-cell
regeneration.
A pertinent question to address, after the beta-cell regenerative process
occurred in these single (N.B. not triple transgenic) transgenic mice, relates to the
properties of such regenerated beta-cells. Namely, if they still have the ability to
completely match the functionality of true beta-cells such as the capability to
maintain blood glucose level within a narrow physiological range particularly after a
meal.
This is the subject of the next chapter.
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Figure 31 HPAP labelling in the triple transgenic mice after 4OHT treatment
(A) and (B) represent pancreatic sections from two different animals that were
treated with 20mg of 4
weeks later respectively (scale bar, 40µm). (B) and (D) are an enlargement of
micrographs A and C re
stained by immunohistohemistry for HPAP (green) and DAPI for the nucleus (blue).
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Beta-cell functionality after diabetic recovery
6.1 Introduction
In physiological situations such as pregnancy, beta-cell mass expansion is
generally associated with beta-cell function enhancement to accommodate the new
insulin requirement particular to the pregnant state (Sorenson and Brelje, 1997).
Similarly during obesity, an augmentation of both beta-cell number and beta-cell
responsiveness is also observed to compensate for the insulin resistance induced by
this state, a key trait of this condition (Kargar and Ktorza, 2008).
However, in specific models of pancreatic injury associated with
hyperglycaemia, such as 90% subtotal pancreatectomy (Laybutt et al., 2007) or
selective beta-cell ablation induced by activation of caspase 8 (Wang et al., 2008),
the regenerative process characterised by an increase beta-cell mass was not
correlated with an improvement of the beta-cell functionality. Similar features were
observed in the Kir6.2G123S transgenic mice, a spontaneous model of beta-cell
regeneration (Oyama et al., 2006). In those models, the regenerated beta-cells are not
fully functionally mature (Kargar and Ktorza, 2008).
Consequently, in our system in which beta-cells do regenerate after massive
ablation by c-Myc (Pelengaris et al., 2002, Cano et al., 2008), it is also of interest to
address the properties of new beta-cells and determine to which extent their
functional capacity matches that of original beta-cells.
Using single cell microfluorimetry, we examined the beta-cell function after
diabetic recovery in the pIns-c-MycERTAM mice. We stress that the mice studied
here are singly and not triply transgenic.
6.2 Experimental design
We analysed the beta-cell responsiveness in islets isolated from pIns-c-
MycERTAM mice after diabetic recovery using calcium microfluorimetry.
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Single transgenic pIns-c-MycERTAM and wild-type mice about three months
of age were daily injected with a dose regime of 1mg/0.2ml of 4-hydroxytamoxifen
(4-OHT) for six consecutive days, while control pIns-c-MycERTAM mice were
injected with peanut oil, the control vehicle.
At the end of the pulse, the pIns-c-MycERTAM mice upon 4-OHT withdrawal
were allowed to recover. Nine months after 4-OHT withdrawal, the islets from mice
after diabetic recovery, from wild-type and control pIns-c-MycERTAM mice were
isolated for analysis.
It is important to point out that pIns-c-MycERTAM mice, at around three
months of age at the beginning of the experimentation, were injected
contemporaneously with peanut oil with or without 4-OHT, and nine months after
the last pulse of 4-OHT or peanut oil were euthanized concurrently at the end of the
experiment to isolate their islets. The wild-type mice, on the contrary, were injected
with 4-OHT at different times, at three months of age, but their islets were also
isolated at the same time as those of the single transgenic mice for consistency.
Three to four replicates were used per group for the experiment and islets
were isolated from each individual animal. Also, we isolated islets from three month
old pIns-c-MycERTAM control and wild-type mice that did not received any
treatment, for additional control tests of functionality.
Islets were isolated from three mice per group. Fed blood glucose levels and
glucose tolerance tests (see Materials and Methods for further details) were
performed on the animals during the experiment before euthanizing the mice for islet
isolation.
The islets were isolated using the collagenase digestion procedure, then the
purified islets were cultured on 3-aminopropyltriethoxysilane-coated glass coverslips
in a standard RPMI medium and incubated at 37oC in the presence of 5% CO2 for
two to three days until analysis (details of these procedures are described in
Materials and Methods).
The calcium microfluorimetric measurements to study beta-cell functionality
were performed by Dr Paul E. Squires according to the protocol described by Squires
et al. (Squires et al., 2000).
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What is the mechanism that allows beta-cells to tightly regulate the release of insulin
in mammals and how can the single-cell microfluorimetric method be used to
evaluate the efficiency of this process?
Beta-cells can be compared to a micro-factory that manufactures insulin that is
stored in secretory vesicles or granules before its release into the medium by
exocytosis. Insulin secretion is highly regulated and depends on intricate intracellular
signalling in response to a variety of stimuli. The process involved in glucose-
induced insulin release by beta-cells, is succinctly presenting in Figure 32 and it
follows the following steps.
First, an increase of glucose concentration in the extracellular medium leads
to glucose uptake by the beta-cells, catalysed by the glucose transporter-2 (Glut2).
Then, the metabolic breakdown of the sugar that ensues results in the increase of the
intracellular ATP concentration at the expense of ADP (or the increase of the
ATP/ADP ratio) which induces the closure of an ATP-dependent potassium channel
(KATP-channel). The closing of this channel causes a progressive depolarisation of
the plasma membrane and the initiation firing of action potentials. These in turn open
voltage-sensitive, L-type Ca2+ channels and provoke the influx of Ca2+ in the beta-
cells. This results in an increase of the intracellular free Ca2+ concentration ([Ca2+]i)
that can be considered as the key stimulus that triggers insulin-containing granules to
fuse with the plasma membrane and release insulin into the medium by exocytosis
(Rutter, 2004, Rorsman and Renstrom, 2003).
Glucose-stimulated insulin release by beta-cells, is in fact ultimately due to
the Ca2+ influx. Accordingly, one can quantify this specific part of the process to
appraise the efficiency of the beta-cell functionality by measuring a change in [Ca2+]i
in the cells after appropriate treatments known to induce insulin release
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Figure 32 Mechanism of glucose induced insulin release in beta cells. The entry
of glucose via the glucose transporter-2 (Glut2) in the beta-cells results in the
glucose metabolic breakdown that leads to the generation of ATP at the expense of
ADP. The change in the ratio of ATP/ADP results in the closure of the ATP-
dependant potassium channel (KATP channel). Subsequently a membrane
depolarization occurs; this opens voltage-gated Ca2+ channels initiating electrical
activity and Ca2+ influx in the cells. The consequent rise in intracellular Ca2+ ([Ca2+] i)
triggers the insulin release process. Secretory granule (SG), membrane potential (Ψ 
↓), ion potassium (K+), inhibition (-), stimulation (+), increase (↑) or decrease 
(↓).(Rorsman and Renstrom, 2003). 
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The single cell fluorimetric technique is based on the measurement of a change in
[Ca2+]i by using a Ca2+-fluorophore fura-2A/M (Squires et al., 2000).
Upon binding calcium the maximum excitation wavelength of the fura-2A/M
undergoes a blue shift from 380nm (when it is calcium free) to 340nm (when it is
saturated with calcium). By detecting the intensity of the emitted light (wavelength
of 510nm) coming from the fluorophore after illumination alternatively with the
excitation wavelength of 340nm and that of 380nm, the increase of [Ca2+]i due to the
influx of calcium into the beta-cells will be characterized (Palmer and Moore, 2000).
Changes in [Ca2+]i is represented by the ratiometric values of the intensity of
fluorescence emitted by fura-2A/M after excitation with the 340nm wavelength over
the intensity of fluorescent emitted by fura-2A/M after excitation with the 380
wavelength. This emission ratio can be written as 340/380nm.
To trigger insulin release from the beta-cells in vitro, the cells maybe
incubated with high concentrations of glucose, about 20 to 30mM, but other
components can be used to elicit the release of insulin. Potassium chloride at 20mM
depolarises the membrane and forces the voltage-sensitive, L-type Ca2+ channel to
open, which in turn leads to the influx of extracellular Ca2+ in the cells and insulin
release by exocytosis. Tolbutamide (100µM), actives the sub-unit Sur1 of the KATP-
channel, which also results in depolarisation of the membrane, which in turn induces
the opening of the voltage-sensitive, L-type Ca2+ channel and so forth. Finally, ATP
(100µM) which binds to P2-purinoreceptors, in turn leads to the formation of IP3
(inositol-3phosphates) resulting in the release of Ca2+ from the endoplasmic
reticulum to the cytoplasm of the cell. In this situation the Ca2+ is released from
inside the cells.
An important point regarding this technique is that the fluorescence
measurement is carried out only in regions (called region of interest (RIO)) located
at the periphery of the islets because only these areas are in focus under the binocular
microscope, so that the fluorescence coming from fluorophore fura-2A/M can be
recorded.
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6.3 Results
6.3.1 Metabolic measurements
6.3.1.1 Fed blood glucose and glucose tolerance tests in pIns-c-MycERTAM and wild-
type animals.
Wild-type and transgenic pIns-c-MycERTAM mice were injected with 4-OHT
or a control vehicle for six consecutive days to induce diabetes by ablation of beta-
cells upon c-Myc activation.
Figure 33 presents the fed blood glucose (a) in wild-type animals, (b) in pIns-
c-MycERTAM mice injected with control vehicle (c-MycERTAM off), (c) in pIns-c-
MycERTAM mice on the last day of c-Myc activation by 4-OHT (c-MycERTAM on),
and (d) in pIns-c-MycERTAM mice in which c-Myc was activated and then
deactivated upon 4-OHT removal after nine months (c-MycERTAM on-off). The
values were, (a) 7.3±1mM, (b) 4±0.4mM, (c) 30±3mM and (d) 4.1±.5mM
respectively.
The difference between all the groups was statistically significant (One-way
Analysis of Variance (ANOVA) P-value <0.05), except for the mean fed blood
glucose of pIns-c-MycERTAM mice after diabetic recovery (4.1±.5mM, c-Myc on-off)
and that of control pIns-c-MycERTAM (4±0.4mM, c-Myc off).
These results indicate that upon activation of c-Myc by 4-OHT, the mice
developed a diabetic phenotype (30±3mM) but following removal of 4-OHT, the
transgenic mice recovered from diabetes (4.1±.5mM). The difference between the
two groups is highly significant (One-way Analysis of Variance (ANOVA) P-value
<0.0001). These results corroborate Pelengaris et al. (Pelengaris et al., 2002) and
Cano et al. (Cano et al., 2008) reports.
Also, the data show that the mean fed blood glucose is higher in wild-type
mice in general (7.3±1mM) than in pIns-cMycERTAM mouse line (4±0.4mM), (One-
way Analysis of Variance (ANOVA) P-value <0.05).
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We carried out glucose tolerance tests by injecting intra-peritoneally, glucose
(2g/kg ) in animals after overnight fasting. The blood glucose level was recorded
prior to and at 10, 30, 60 and 120 minutes after glucose administration.
Figure 34 presents the intra-peritoneal glucose tolerance test (IPGTT) results
in non-treated wild-type (n=4) and pIns-c-MycERTAM (n=3) mice aged three months,
and also pIns-c-MycERTAM mice (n=4) treated with control vehicle, aged twelve
months.
Following the IPGTT, one can see that 120min after the glucose challenge,
the blood glucose level of animals of each group returns to normal. Only at the time
point prior to and 120 min after glucose administration, the wild-type animals show
a glucose level different from the two other groups. The difference was significant
(One-way Analysis of Variance (ANOVA) P-value <0.05).
Also the calculation of the area under the curve (AUC), (prism 4, University
of Warwick) of the glucose tolerance test curve for each individual mouse in each
group, showed that the difference of the mean AUC between non-treated wild-type
(1541±276), pIns-c-MycERTAM (1359±285) mice, both aged three months and pIns-
c-MycERTAM mice aged twelve months (1015±326) was not statistically significant
(One-way Analysis of Variance (ANOVA) P-value >0.05).
First, these results indicate that the age of the transgenic pIns-c-MycERTAM
mice, does not affect the capacity of their beta-cells to respond properly to a glucose
challenge. Second, the mice of each group were glucose tolerant, suggesting that
their beta-cells were functional. Third, it is of interest to note that the fed blood
glucose of wild-type animals is higher than that of our transgenic animals.
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Figure 33 Fed blood glucose. Blood fed glucose of 3 month old wild-type animals
treated with 4-OHT, 3 month old pIns-c-MycERTAM mice before treatment (c-Myc
off), 3 month old pIns-c-MycERTAM mice shortly after the last pulse of 4-OHT (c-
Myc on), and 12 month old pIns-c-MycERTAM mice nine months after 4-OHT
withdrawal (c-Myc on-off).
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Figure 34 Intra-peritoneal glucose tolerance test (IPGTT)
recorded prior to, 10, 30, 60 and 120min
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6.3.1.2 Glucose tolerance tests in pINS-c-MycERTAM mice after diabetic recovery
Three pIns-c-MycERTAM mice about three months of age, were treated with
4-OHT for six consecutive days, and then allowed to recover from diabetes upon 4-
OHT removal.
IPGTT was carried out on the same mice during the course of the experiment,
that is before 4-OHT treatment, shortly after the end of the treatment (that is when
the mice were overtly diabetic) and nine months after the last 4-OHT treatment (that
is when the mice recovered from diabetes). The results are recorded in Figure 35.
The analysis of the IPGTT in the animals shortly after 4-OHT treatment (c-
MycERTAM on) indicates clearly that the mice were glucose intolerant and 120 min
after the glucose challenge they were still not able to normalise their blood glucose
level.
The IPGTT values of animals shortly after treatment compared with those of
both the mice before treatment and after diabetic recovery, were significantly
different at all the time points (One-way Analysis of Variance (ANOVA) P-value
<0.05).
In stark contrast, IPGTT curves of animals before treatment (c- MycERTAM
off) and after diabetic recovery (c- MycERTAM on-off) were not significantly
dissimilar from each other. Thus, analysis of IPGGT curves in these two groups
indicates that the animals were able to normalise their blood glucose level 120min
after the glucose challenge.
Also, the calculation of the AUC of the glucose tolerance test curve of each
individual mouse shows that the difference of the mean AUC of animal before
treatment (1197± 273) and after diabetic recovery (1010±466) was not statistically
significant (One-way Analysis of Variance (ANOVA) P-value >0.05).
By contrast, comparison of the mean AUC of the animals during treatment
(2661±359) with that of animals before treatment or after diabetic recovery, indicates
that the difference between the two groups was statistically significant (One-way
Analysis of Variance (ANOVA) P-value <0.001).
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It is noteworthy that the same animal was glucose tolerance tested prior to, at
the end of and after the 4-OHT treatment, in this experiment.
Collectively, these results indicate that upon 4-OHT treatment, pIns-c-
MycERTAM mice develop a diabetic phenotype (become glucose intolerant), but after
4-OHT removal, namely nine months after the drug pulse, the animals recover from
diabetes, as evidenced by normalisation of their fed blood glucose and by becoming
glucose tolerant again.
In addition, the fact that the animals after diabetic recovery were glucose
tolerant again, suggested that their regenerated beta-cells were functional.
6.3.2 Analysis of beta-cell functionality using single-cell microfluorimetry
Using single-cell microfluorimetry we studied islet beta-cell functionality of
pIns-c-MycERTAM mice before and after diabetic recovery. The study was performed
in collaboration with P. Squires.
For this experiment, wild-type animals were treated with 4-OHT prior to islet
isolation. pIns-c-MycERTAM mice were treated with 4-OHT or control vehicle and
islets were isolated nine months after 4-OHT or control vehicle administration. In
each group, islets were isolated from three different animals. Figures 36, 37 and 42
represent graphs of the islet beta-cell functionality of islets from wild-type animals.
Each figure represents the result of the beta-cell functionality test of an islet from an
individual animal. The islets were incubated, first with glucose (20mM) then with
different components not in a particular order, tolbutamide (100µm), ATP (100µm)
or K+Cl- (20mM). The y-axis, corresponds to the changes in [Ca2+]i symbolised by an
increase of the ratio 340/380nm, whilst the x-axis to the time in seconds. Series or
RIO (region of interest) represents a region in the islet that was examined. At least
eight different regions of interest were concurrently monitored per islet, for
stimulated changes in [Ca2+]i. Each oscillatory curve characterizes changes in [Ca2+]i
for each RIO or series tested. The three graphs show unequivocally an increase of
the ratio 340/380nm, indicating an augmentation of the [Ca2+]i, due either to an
influx of Ca2+ release into the cells or the cytoplasm, after the islets were stimulated
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with nutrient and non-nutrient. These results indicate clearly that the islet beta-cells
from wild-type animals were completely functional.
By contrast, the islet beta-cells from pIns-c-MycERTAM mice after diabetic
recovery (Figures 38 and 39) show very little increase of the ratio 340/380nm or
change in [Ca2+]i after stimulation by glucose or other components. This indicates a
marked impairment of the beta-cell functionality of mice after diabetic recovery.
To verify that the impaired beta-cell functionality was a feature of the beta-
cells after diabetic recovery, we checked the islet beta-cells functionality in pIns-c-
MycERTAM mice treated with control vehicle (Figures 40 and 41). Surprisingly, after
stimulation of the islets with glucose, tolbutamide or K+Cl-, little increase in change
in [Ca2+]i was observed, similar to islets of animals after diabetic recovery.
To rule out the fact that the age of the pIns-c-MycERTAM animals might
affect their beta-cell responsiveness, we examined the islet beta-cell functionality of
pIns-c-MycERTAM (Figure 43 and 44) and wild-type (Figures 45 and 46) animals
aged three months.
The graphs of the islets from wild-type animals, once again, show a higher
amplitude of the increase of the [Ca2+]i compared to those from pIns-c-MycERTAM
mice.
Collectively, the profound attenuation of the beta-cell responsiveness in pIns-c-
MycERTAM mice either in untreated controls or after diabetic recovery shows
explicitly that beta-cell functionality is abnormal in this transgenic line.
Also, the finding that the fura-2M/A uptake was similar in wild-type and
pIns-c-MycERTAM islets, characterized by comparable dye base line, indicates that
the beta-cells were viable at the start of the experiment.
The graphs of islets from pIns-c-MycERTAM mice untreated controls and after
diabetic recovery, show no evidence that the beta-cell functionality after diabetic
recovery is different from that of untreated control pIns-c-MycERTAM mice (albeit
abnormal).
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6.4 Conclusion
Based on the results of the glucose tolerance test, we concluded that the
transgenic pIns-c-MycERTAM mice prior to c-Myc activation were glucose tolerant.
This indicates that their beta-cells are functional in maintaining glucose homeostasis,
and the age of the transgenic mice did not affect this property.
By contrast, upon 4-OHT treatment, pIns-c-MycERTAM mice developed a
diabetic phenotype, becoming glucose intolerant, but upon 4-OHT removal, the
animals recovered eventually from diabetes and became glucose tolerant again,
suggesting that regenerated beta-cells are at least partially functional after diabetic
recovery.
To explore whether beta-cell function was normal after diabetic recovery, we
tested their functionality using single-cell microfluorimetry.
Based on the results of calcium microfluorimetry, we concluded that the islet
beta-cells from control wild-type animals were completely functional.
In stark contrast, the profound attenuation of the beta-cell responsiveness in
pIns-c-MycERTAM mice untreated controls and after diabetic recovery, demonstrated
that the mechanism of the beta-cell functionality in this line was altered.
In addition, the comparison of the profile in the change of intracellular
Ca2+concentration between islets from pIns-c-MycERTAM mice untreated controls
and after diabetic recovery, showed no evidence that beta-cell functionality after
diabetic recovery was different from the (albeit abnormal) functionality of untreated
control pIns-c-MycERTAM mice.
The discrepancy observed between the physiological responsiveness of
transgenic animals and the beta-cell responsiveness in vitro in the pIns-c-MycERTAM
line is quite intriguing and will be discussed in the next chapter.
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Discussion
7.1 Origin of new beta-cells under normal physiological condition
We investigated the origin of new beta-cells in response to one and two
cycles of pregnancy using a cell-lineage tracing for beta-cells in pulse-chase
experiments. We first showed that the labelling system in the double transgenic mice
(Z/AP; RIP-CreERTAM) was 1) specific to beta-cells, 2) irreversible and heritable and
3) tamoxifen dose-dependant.
7.1.1 Origin of new beta-cells during a first round of pregnancy
Secondly, we showed that in response to a first cycle of pregnancy, 1) the
mean body and pancreatic weight increased about 45 and 51% respectively in
pregnant animals compared to the aged-matched non-pregnant control animals, 2)
the mean beta-cell mass increased around 91% in pregnant mice compared with the
age-matched non-pregnant control mice.
The analysis of the proportion of beta-cells labelled for HPAP, showed that
the labelling index of the non-pregnant animals (0.44±0.05) was greater that in the
pregnant group (0.33±0.06). The difference between the two groups was statistically
significant (paired two-tailed t-test, P-value 0.021).
Furthermore the combined results obtained from paired animals during one
and two pregnancies reinforce this result, by indicating that the difference between
the two groups was extremely significant (paired, two-sided student t-test, P-value
0.0007).
Taken together, Theses results are consistent with hypothesis 2 and indicate
that non-beta-cell progenitor contribute significantly to the increase of the beta-cell
mass in response to pregnancy.
The analysis of the proportion of the beta-cell clusters or small sized-islets
devoid of HPAP, showed that the means of the beta-cell clusters or small islets
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negative for HPAP was greater in the pregnant group (0.19±0.06) than in the non-
pregnant controls (0.11±0.04). The difference between the two groups was not
statistically significant (P=0.093, paired two tailed t-test). There is a trend indicating
that new islets are formed during pregnancy or alternatively, these results might
reflect the dilution of the label in expanded islets.
However, the combined results of these proportions in paired animals in one
and two pregnancies strongly indicate that new islets are formed during pregnancy or
there is a dilution of the label in larger islets during the pregnant state. Inasmuch, the
difference between the pregnant and non-pregnant groups is considered very
significant (paired, two-sided student t-test, P-value 0.006).
The analysis of the HPAP labelling indices in the beta-cells in the lining of
the ductal component (0.21, n=57 cells, representing 4 replicates) and in the islet
compartment in the same sections (0.31, n=7053 cells, representing 4 replicates)
showed that the two indices are not dissimilar (2x2 contingency table, the chi-square
approximation, two-sided, P= 0.15).
On the assumption that the number of insulin-positive cells in the ductal
component increases substantially during pregnancy, the similar HPAP labelling
indices in the ductal component and in the islets are not consistent with the duct
being a “ preferential” source of new beta-cells during pregnancy.
Finally, we did not observed any example of cells positive for HPAP and
negative for insulin in the pancreatic sections of non-pregnant and pregnant animals,
indicating that during this time window beta-cells do not fully lose differentiation or
transdifferentiate into other lineages of either endocrine or exocrine compartment.
In conclusion, using a cell-lineage tracing system for beta-cells we
demonstrated, for the first time, that the beta-cell mass increase in response to a first
cycle of pregnancy is associated not only with pre-existing beta-cells duplication but
more importantly with the activation of non-beta-cell progenitor sources.
We need to exclude alternative explanations, most critically, whether the rate
of proliferation of pre-existing beta-cells labelled for HPAP is slowed down with
regard to beta-cells devoid of the label, i.e. the label may alter the beta-cell
replication process. This is unlikely to happen, since Nir et al. (Nir et al., 2007),
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previously demonstrated, using the same cell lineage tracing system, that the
proliferation rate of beta-cells labelled for HPAP was similar to that of the non
marked beta-cells. What is more, the authors did not observe any dilution of the label
during the beta-cell mass regeneration after diabetic recovery. In line with this result,
Dor et al. (Dor et al., 2004) also reported no dilution of the label during both normal
growth and after pancreatectomy, strongly suggesting that it is unlikely that the label
affects the replication rate of beta-cells containing the reporter.
We cannot give an exact number of the non-beta-cell progenitor contribution
during the beta cell mass expansion. Yet, on the other hand, we can give an estimate
of this precursor involvement. In principle, if the beta-cell mass doubles in mice
during pregnancy, as reported by us and others (Huang et al., 2009, Karnik et al.,
2007), and if the non-beta-cell progenitors are exclusively accountable for this beta-
cell mass population increment, then, the HPAP labelling index in pregnant animals
should be half of that of the non-pregnant animals. In non-pregnant controls, we
observed a HPAP labelling index about 0.44, consequently, we would expect a
proportion of the labelled beta-cells for HPAP around 0.22 in pregnant animals. The
observed number is 0.33, suggesting that approximately, 50% of new beta-cells arise
from pre-existing beta-cells by replication, while the other half must come from the
activation of a non-beta-cell progenitor. Our finding validates results from previous
authors suggesting that beta-cell mitogenesis is responsible for the beta-cell mass
increment during pregnancy (Karnik et al., 2007, Teta et al., 2007, Scaglia et al.,
1995, Avril et al., 2002, Parsons et al., 1992). But using a cell-lineage tracing for
beta-cells, we were able to demonstrate that pre-existing beta-cells are not the only
lineage to contribute to this process, and non-beta-cell precursor source plays an
active role in this beta-cell mass increase as well.
Our finding does not contradict Teta et al. conclusions (Teta et al., 2007)
regarding the absence of contribution of non-beta-cell specialized progenitors during
pregnancy. Those authors used DNA analogue-based lineage tracing technique to
detect multiple cycles of cell division in vivo to assess if progenitors that divided
rapidly give rise to new beta-cells. We can estimate that if there are 3% of
progenitors residing in the pancreas of animals, the progenitors will need to undergo
only three to four rounds of division to increase the beta-cell mass about 50%, in
response to pregnancy. This suggests that the progenitors do not need to go through
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many rounds of replication, consistent with Teta’s finding. Additionally, the
technique used by those authors to co-label the cells with the two different thymidine
analogs, can easily underestimate the number of cycles of replication that the
precursors can actually undergo.
Karnik et al. and Huang et al. (Karnik et al., 2007, Huang et al., 2009)
reported that the over-expression of Menin specifically in beta-cells, or the loss of
expression of prolactin receptor in the whole organism, both abolished the beta cell
mass increment during pregnancy in mice. These results led the authors to conclude
that pre-existing beta-cells were the major lineage contributing to the beta cell mass
increase. If the over-expression of Menin or the lack of prolactin receptors affect
profoundly the duplication of beta-cells, they could also affect the replication of
potential precursors of beta cells, and this would account for their observation.
What might be the identity of the non-beta-cell progenitor lineages during a
first cycle of pregnancy? Strong candidates must be ductal progenitors. In this area,
three groundbreaking recent reports demonstrated, using a direct lineage tracing
system that the ductal compartment indeed contains islet cell progenitors. The first
report used the ductal marker carbonic anhydrase to follow the fate of duct cells
during neonatal period, and after pancreatic injury induced by duct ligation (Inada et
al., 2008). The second report concerns isolated ductal lining cells expressing a
master switch gene Ngn3, involved in embryonic islet cell differentiation, in the
ligated part of adult pancreas (Xu et al., 2008). And in the third report, the authors,
using a lineage tracing system, showed that forced expression of Pax4 in glucagon-
deficient mice, results in the continual conversion of glucagon-expressing alpha-cells
into insulin-expressing beta-cells from Ngn3 precursors associated with the duct
(Collombat et al., 2009). The authors showed that these ductal cells, given that they
were able to differentiate into beta-cells, held progenitor properties. Even though, the
progenitors identified by the authors might represent two different subsets of duct
cells.
To investigate if similar events could take place during pregnancy, we
compared the HPAP labelling indices of insulin-containing cells in contact or within
the duct lining with visible lumen with the islets in the same sections. The labelling
indices of both compartments were not significantly dissimilar, and led one to
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conclude that the ductal component was not a “preferential source” for new beta-cell
during pregnancy. An interesting question will be if these insulin-positive cells or
progenitors produced in the duct compartment could be detached and migrate away
from the ductal component to populate the islet compartment, as it has been already
suggested by Xu et al. (Xu et al., 2008). This is an open question. Should insulin
producing cells adjacent to the duct or part of the lumen lining have to be also
considered as genuine beta-cells or the result of endocrine differentiation as reported
by Bertelli and Bendayan (Bertelli and Bendayan, 2005). This is also another open
question.
In addition Bertelli et al. (Bertelli et al., 2001) reported that, contrary to the
commonly held view, there was an extensive connection between islets and the
ductal tree. In the rat they showed that at least 73% of the islets were in contact with
the duct, about 93% of those were associated with centroacinar cells or small sized
duct. Unfortunately, the latter are easily overlooked by conventional histology
staining, as mentioned by Bertelli et al. and Bouwens (Bertelli et al., 2001, Bouwens,
1998). This suggests that only a minority of insulin-positive cells can be detected
using conventional histology staining, because they appear connected to medium and
large sized-ducts with an observable lumen. Since it was not feasible to score insulin
secreting cells in contact with duct without evident lumen and the counting of such
cells was done at the end of pregnancy when the beta-cell mass expansion process
had already occurred, our analysis must have underestimated the correct number of
insulin secreting cells associated with the ductal tree. Therefore, we should qualify
our previous statement and leave open the possibility that duct progenitors might be
in a certain extent a source of new beta-cells during pregnancy.
Studies in rodents which aimed to isolate putative adult pancreatic precursors
in vitro or to understand the mechanism by which newly formed beta-cell arise in
vivo, during normal growth just after birth, beta-cell renewal and after pancreatic
injury, compellingly suggest the existence of progenitors within islets which can
differentiate into insulin-containing cells (Seaberg et al., 2004, Kodama et al., 2005,
Guz et al., 2001, Li et al., 2004, Gu and Sarvetnick, 1993, Fernandes et al., 1997, Gu
et al., 2002). Indeed, Kodama et al. (Kodama et al., 2005) reported the induction of
Ngn3 mRNA in islet-like cell clusters after streptozotocin-induced diabetes in mice.
Likewise, Gu et al. (Gu et al., 2002) has provided evidence using a direct cell
Chapter 7: Discussion
144
lineage tracing system that the Ngn3 positive cells are islet progenitors in adult mice.
In addition, Guz et al. (Guz et al., 2001) reported the occurrence of two presumptive
intra-islet precursors in the regenerating islets following massive beta cell death
induced by streptozotocin, one expressing the glucose transporter-2(Glut2) and the
other co-expressing insulin and somatostatin. This result corroborates the conclusion
of Pang et al. (Pang et al., 1994) postulating that beta-cells arise from Glut2-positive
cells in the epithelium during rat development. Likewise Wang et al. (Wang et al.,
2008) also reported an increased population of Glut2-positive, insulin-negative, cells
during beta-cell regeneration, which might serve as beta-cell precursors in a
transgenic mouse model called “PANIC-ATTAC”. In this system beta-cells are
ablated specifically and in an inducible fashion by apoptosis after activation of
caspase 8 protein. The authors observed a novel population of Glut2 cells that might
either represent a curiosity of this model or a bona fide beta-cell precursor, but more
investigations have to be done to confirm its precursor status. However, this result is
in line with another model of beta-cell regeneration, the pancreatic duct ligation
system, in which an increased proliferation of these cells was also reported during
the regenerative process (Wang et al., 1995). Another group reported in the
Kir6.2G132S transgenic mouse model of spontaneously recovery from diabetes
(Oyama et al., 2006), the occurrence of DBA-labelled cells expressing insulin in
regenerated islets, which may represent potential ductal cell progenitors in this
system. DBA (the lectin Dolichos biflorus agglutinin) is used for staining ductal
cells. They also observed in the regenerated islets, at a lower degree, the incidence of
PGP9.5 cells expressing insulin that might also contribute in part to beta-cell
regeneration in this transgenic strain. PGP9.5 has been reported to be potential
progenitor marker during beta-cell regeneration. In the light of these studies, we
could also hypothesize that this potential intra-islet progenitor might also be
activated during a first cycle of pregnancy and differentiate into insulin-producing
cells to accommodate the new insulin demand, particularly, the Ngn3-positive
progenitors described in adult mice during normal growth.
In conclusion, in the light of previous reports, we can postulate that non-beta-
cell progenitors of ductal or/and intra-islet origin might be activated during a first
cycle of pregnancy. Further experiments using positive cell-lineage tracing system
for duct, exocrine or embryonic islet cell markers, such as carbonic anhydrase,
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amylase, or Ngn3, respectively, should be employed to further explore our findings.
Our data are compatible with the common view that beta-cell self-duplication plays
an active role in the beta-cell mass expansion to adapt the new insulin load during a
first cycle of pregnancy, but we also showed for the first time that this process
occurred in combination with non-beta-cell progenitors.
7.1.2 Origin of new beta-cells during two rounds of pregnancy
Thirdly, to extend the results obtained in a first pregnancy, we wished to
address the same question as to where new beta-cells arise during two pregnancies
using the same cell-lineage tracing system and experimental design.
In response to two cycles of pregnancy, we observed a 60% and 43%
increase of the mean body weight and pancreas weight compared to age-matched
non-pregnant controls.
Similarly, we observed a doubling of the beta-cell mass induced by
pregnancy to adapt the new insulin load, with little contribution of beta-cell
hypertrophy.
The comparison of the ratio of the HPAP labelling index in pregnant controls
over pregnant animals after one and two cycles of pregnancy showed that the two
ratios were not dissimilar. This led us to reject our hypothesis that the HPAP
labelling index was expected to be markedly lower in the pregnant animals during a
second round of pregnancy compared to a first pregnancy.
The hypothesis assumed that the beta-cell apoptosis occurred at random
during the parturition period.
The variability of the beta-cell marking at a similar rate in the three replicate
pairs, precluded conclusion about both the formation of new whole islets, and
whether duct progenitors are a preferential source for new beta-cells in a second
pregnancy.
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Nonetheless, we observed both an increase of the occurrence of insulin-
positive cells in the ductal compartment, and increase of the number of ducts
associated with these cells in a first and second pregnancy. These results suggest that
duct progenitors could be activated to form de-novo beta-cells in pregnancy. To be
conclusive, further analysis is required.
Lastly we did not observe any example of beta-cells that had
transdifferentiated into other lineages, or fully lost differentiation, in pregnant and
non-pregnant animals three and half months after the last pulse of tamoxifen. But we
cannot rule out that this phenomenon could take place at a longer time point.
The rejection of our hypothesis because the ratio of the HPAP labelling index
in pancreata of non-pregnant over pregnant animals in a second pregnancy was
similar to that in a first pregnancy, is interesting per se.
To recapitulate, we posited that if during pregnancy non-beta-cell progenitors
contributed substantially to the beta-cell mass increment, and if the beta-cell
apoptosis process was indifferent with respect to labelled versus unlabelled cells
following parturition, then during a second cycle of pregnancy, the proportion of
beta-cell labelled for HPAP should be lower than in a first pregnancy.
We estimated that the ratio of the HPAP labelling index in pancreata of non-
pregnant over pregnant animals in a second pregnancy should be 1.88, but 1.37 was
the value observed. This led us to reject our hypothesis.
What assumption(s) was incorrect? Our first proposition to explain our
results, would be that indiscriminate beta-cell apoptosis following parturition might
be not true.
Actually, during the parturition period various events could take place. One
could be a selective ablation of unlabelled beta-cells during the post-partum period.
Furthermore, this ablated beta-cell population might be the progeny of the non-beta-
cell progenitors.
This hypothesis will fit well with our results and is a very tantalizing
explanation.
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A second proposition would accept that beta-cell apoptosis process occurs at
random, but the mechanism by which new beta-cells arise during a second
pregnancy is different from that in a first pregnancy.
In this situation, the model of duplication of pre-existing beta-cells as the
only process for producing new beta-cells fits our results.
Additional experimentation needs to be done to assess these two models. To
test these assumptions, one could evaluate the proportion of beta-cells labelled for a
marker of DNA synthesis to reflect the duplication of beta-cells, during pregnancy
and the post-partum period.
Thus, one could verify if the percentage for this marker is similar, or not, at
both time points. Or one could verify at both time points if the HPAP labelling index
stays stable or not.
To confirm our previous results regarding the involvement of non-beta-cell
progenitors in the formation of new beta-cells, we have conjectured that multiple
rounds (i.e. more than two) of pregnancy could be examined. Our data show that the
outcomes of these types of experiments are more complex than expected, and
suggest that during the parturition period other intricate events might also take place.
To date no report has addressed the question of beta-cell expansion during
several rounds of pregnancy. This is the first time that this was done.
Additionally our results prompt investigations of events in the immediate
post-partum period when physiology of the non-pregnant state is re-established.
Finally, pregnancy is a normal physiological condition in which origins of
new beta-cells can be studied because the adaptation is natural, rapid, substantial,
reversible and repeatable over several rounds of pregnancy in the same animal. Also,
the finding that non-beta-cell progenitors are involved in pregnancy makes this
condition an appealing one for studying beta-cell mass expansion and reversal, the
cells and the pathways involved, and hence the mechanisms by which these cells are
generated.
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7.2 Origin of new beta-cells under patho-physiological condition
Pelengaris et al. (Pelengaris et al., 2002) developed a mouse model of
pancreatic regeneration (pIns-c-MycERTAM) in which beta-cells can be ablated by
apoptosis following c-Myc activation induced by 4-OHT. This results in the
development of a diabetic phenotype in the animals. Upon 4-OHT removal, the
single transgenic pIns-c-MycERTAM mice recover from diabetes due to substantial
beta-cell regeneration (Cano et al., 2008, Pelengaris et al., 2002).
To investigate the nature of the cells responsible of the formation of the new
beta-cells after diabetic recovery in this regenerative system, we generated triple
transgenic mice (Z/AP; RIP-CreERTAM; pIns-c-MycERTAM) in which the inducible
cell-lineage tracing system for beta-cells was introduced in the mouse model of
pancreatic regeneration.
In the triple transgenic mice bearing the tracing-regenerative system, we
observed that upon 4-OHT exposure, beta-cells are both labelled for HPAP and
ablated. Indeed, the mean beta-cell mass in the untreated and diabetic triple
transgenic mice was 0.83±0.20 and 0.1±0.06mg respectively, indicating that 88% of
beta-cells were depleted upon activation of c-Myc, leading to the development of a
diabetic phenotype observed in animals.
Inactivation of c-Myc allowed the mice to recover from diabetes. In this
respect the triple transgenic animals follow the example of the single transgenic
pIns-c-MycERTAM mice. Therefore, we investigated in the triple transgenic mice the
origin of new beta-cell after diabetic recovery.
We found that the mean HPAP labelling index in the diabetic mice and mice
after diabetic recovery was 0.047±0.028 and 0.06±0.026 respectively. This let us to
contemplate the possibility that we should accept hypothesis 1, namely mitogenesis
might be the full mechanism giving birth to new beta-cells after diabetic recovery, as
reported by Nir et al. (Nir et al., 2007) after toxi-genetic beta-cell ablation induced
by expression of the diphtheria toxin specifically in beta-cells.
Chapter 7: Discussion
149
Surprisingly, the difference of the mean beta-cell mass between the diabetic
triple transgenic mice (0.1±0.06mg) and in the triple transgenic mice after diabetic
recovery (0.1±0.03mg) was not dissimilar.
There was no evidence of beta-cell regeneration and so we could not
conclude as to where new beta-cells come from in this model of pancreatic
regeneration induced by c-Myc, after diabetic recovery.
However, we observed examples of post-mitotic paired cells labelled for
HPAP in treated multiple transgenic mice which must be the progeny of pre-existing
beta-cells.
Could we take this observation as a revealing attempt to produce new beta-
cells by beta-cell self-duplication to replenish the missing beta-cells?
It is known that activation of c-Myc in the single transgenic (pIns-c-
MycERTAM) mice, induced beta-cell apoptosis following a short burst of beta-cell
proliferation (Pelengaris et al., 2002). Consequently the post-mitotic paired cells
labelled for HPAP observed in the triple transgenic animals after diabetic recovery,
might also be the progeny of residual beta-cells that underwent mitosis during the
short wave of proliferation activated by c-Myc.
Unfortunately, we could not let the animals recover for longer time points
and wait to see significant beta-cell mass recovery, because they developed tumours
in their pancreata when they got older. This was also reported by Pascal et al. (Pascal
et al., 2008) in old single transgenic mice (pIns-c-MycERTAM).
We also observed that the treated triple transgenic mice did recover from
diabetes without significant beta-cell mass augmentation, and that is intriguing.
What is the mechanism for glucose homeostasis in the triple transgenic mice?
One plausible explanation can be related to the effect of c-Myc on the expression of
markers important for beta-cell functionality. In this context, Laybutt et al. (Laybutt
et al., 2002), reported that over-expression of c-Myc in transgenic mice results in
down regulation of insulin and glucose transporter 2 (Glut2) gene expression. Cano
et al. (Cano et al., 2008) reported similar features in the residual beta-cells of the
single transgenic (pIns-c-MycERTAM) mice upon activation of c-Myc. Yet, the author
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also observed that this phenotype was reversible upon c-Myc inactivation in beta-
cells of the single transgenic (pIns-c-MycERTAM) mice. Namely, sixty days after
tamoxifen removal, when the mice recovered from diabetes and after significant
beta-cell mass increment, beta-cell markers cited above, displayed normal expression.
So, it is reasonable to state that similar to what occurs in the single transgenic
(pIns-cMycERTAM) mice upon c-Myc activation, beta-cell gene markers might also
be down regulated, in addition of the beta-cell loss, in the residual beta-cells of the
triple diabetic transgenic mice following 4-OHT exposure.
At the time point examined, twenty eight days after inactivation of c-Myc,
the triple transgenic mice recovered form diabetes in absence of a large scale beta-
cell mass recovery. To explain the normalisation of the blood glucose level, it is
sensible to postulate that similar to the single transgenic mice, beta-cell marker
expression might also reverse to normal level in the residual beta-cells of the triple
transgenic mice after diabetic recovery. This might in part, contribute to the
glycaemia normalisation, in the triple transgenics, without excluding the possible
contribution of limited beta-cell regeneration.
In the end, the result observed in the triple transgenic mice after diabetic
recovery suggests that the mechanism of diabetic recovery might be complex in this
system. The anatomical beta-cell mass recovery on its own cannot be considered as
an exclusive determinant parameter in this process.
7.3 Beta-cell functionality after hyperglycaemia recovery in single
transgenic (pINS-c-MycERTAM) mice
To study beta-cell functionality after beta-cell regeneration and diabetic
recovery in single transgenic (pIns-c-MycERTAM) mice, we analysed the beta-cell
responsiveness in islets isolated from the transgenic animals using calcium
microfluorimetry.
Based on the results of the glucose tolerance test, we concluded that the
transgenic pIns-c-MycERTAM mice prior to c-Myc activation were glucose tolerant
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indicating that their beta-cells are functional and that the age of the transgenic mice
did not affect this property.
By contrast, upon 4-OHT treatment, pIns-c-MycERTAM mice developed a
diabetic phenotype and became glucose intolerant. Upon 4-OHT removal the
animals recovered from diabetes and became glucose tolerant again, indicating that
regenerated beta-cells might be functional after diabetic recovery.
Second, to formally demonstrate that regenerated beta-cells were functional
after diabetic recovery, we tested their functionality using single-cell
microfluorimetry.
We concluded that the islet beta-cells from control wild-type animals were
completely functional. In stark contrast, the profound attenuation of the beta-cell
responsiveness in pIns-c-MycERTAM controls and mice after diabetic recovery,
demonstrated that beta-cell functionality in this line is altered.
In addition, comparison of the profiles of intracellular Ca2+concentration
between islets from pIns-c-MycERTAM controls and mice after diabetic recovery
shows no evidence that beta-cell functionality after diabetic recovery (albeit
abnormal) was different from that of untreated control pIns-c-MycERTAM mice. The
impaired beta-cell functionality that we report here, in the pIns-c-MycERTAM line by
calcium fluorimetry has also been observed, recently by Pascal et al. (Pascal et al.,
2008).
This result is interesting because our transgenic mice display a normal fed
blood glucose level and respond properly to a glucose challenge in vivo.
What could explain this discrepancy?
A first possibility would be that the islet beta-cells isolated from the pIns-c-
MycERTAM mice might be more susceptible to damage during the isolation
procedure. This can be ruled out since the fura-2A/M basal line for the transgenic
and the wild-type animals, was similar indicating that the cells were viable.
If in the transgenic line the mechanism of the beta-cell responsiveness is
altered, then how do the mice exhibit a normal glucose tolerance test?
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One can postulate that the impaired functionality displayed by the transgenic
mice can be compensated by a group effect of all the beta-cells present in the animal
pancreas. Thus, if all beta-cells in the pancreas of the transgenic animals secrete a
small quantity of insulin in concert, this may be enough to allow the mice to
maintain a normal glucose homeostasis. Put another way, there is over-capacity of
beta-cell function, or redundancy, in wild-type animals.
Another possibility would be that the population of beta-cells in this line is
heterogeneous meaning that functionality within the beta-cell population is not
uniform.
In either case, the altered beta-cell functionality in this line may due to the
slight leakiness of c-Myc expression in absence of 4-OHT or tamoxifen, resulting in
beta-cell impairment. Or the altered function may be related to the introduction of
the transgene which might have altered other genes in the mouse genome related to
beta-cell functionality.
7.4 General conclusion
We examined the origin and the functionality of beta-cells after diabetic
recovery in a toxic-genetic beta-cell ablation mouse model (pIns-c-MycERTAM). We
showed that the beta-cell functionality in this line was abnormal. Our initial aim was
to determine the origin of new beta-cells after diabetic recovery in this model in
which a cell lineage tracing system for beta-cells was introduced (the triple
transgenic mice). However, there was no evidence of large scale beta-cell
regeneration at the time point investigated in the triple transgenic mice despite their
evident recovery from diabetes.
We examined the origin of new beta-cells during the beta-cell mass
expansion occurring in pregnancy to accommodate the increase metabolic demand,
using the cell-lineage tracing system for beta-cells. We showed that new beta-cells
were the progeny of pre-existing beta-cells, but more importantly, for the first time,
we also demonstrated that non-beta-cell progenitors contribute significantly to the
formation of new beta-cells during pregnancy. We also found that during two
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successive pregnancies, the beta-cell dynamics were unexpected. We conclude that
either the mechanism for beta-cell loss following the first parturition is not random,
and/or the subsequent mass increase in response to a second pregnancy occurs
differently from a first pregnancy.
Identification of the non-beta-cell progenitors (of ductal, intra-islet or other
origin) of beta-cells and the pathway giving birth to new beta-cells in pregnancy will
be of great interest in our desire to better understand tissue homeostasis, and factors
that command beta-cell regulation. Knowledge gained from these studies ultimately
it may help design new strategies to generate unlimited sources for new beta-cells for
cell-based therapy to treat diabetes or stimulate an endogenous beta-cell mass in
diabetic patients.
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Gel electrophoresis of PCR products for genotyping Z/AP; RIP
primers.
-CreERTAM mice for the identification of the Cre-recombinase transgene using the Cre
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APPENDIX 2
CHAPTER 3
ORIGIN OF NEW BETA-CELLS IN THE DOUBLE TRANSGENIC (Z/AP; RIP-CreERTAM) MICE IN ONE PREGNANCY
HPAP and Insulin area in pregnant and non-pregnant animals in five coded sections per animal
Pair 1
Pregnant mouse
3940-1 HPAP area Insulin area
PQx=L51-3940-
1 34285.33333 90296.33333
Kyx=L113-3940-
1 50772.33333 125315.6667
SSx=L231-
3940-1 69830.33333 208869.6667
VVx=L271-
3940-1 68016.33333 234907.6667
LGx=L315-
3940-1 59451 184937.3333
Non-pregnant
mouse
3940-2 HPAP area Insulin area
TSx=L36-3937-1 53625.33333 97525.16667
HJx=L81-3937-1 78306.33333 138059.6667
NBx=L141-
3937-1 139420 286030
DJx=L221-3937-
1 92839.66667 195960
JMx=L293-
3937-1 128100.3333 272590.6667
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Pair 2
Pregnant mouse
3900-1 HPAP area Insulin area
AAX=L61-3900-1 30139.33333 96970.66667
RWx=L130-3900-
1 44919.33333 132727.6667
KMx=L211-3900-
1 26604.66667 163459.6667
MRx=L283=3900-
1 81869.33333 346472.1667
FCx=L310-3900-
1 30106 119787.3333
Non-pregnant
mouse
3900-2 HPAP area Insulin area
BZx=L23-3900-2 41391.66667 85278
NGx=L83-3900-2 88581 210243
ZPx=L180-3900-
2 107820 240334.6667
Pox=L243-3900-2 119978.6667 381051.6667
WPx=L304-3900-
2 30933 70040.66667
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Pair 3
Pregnant mouse
3974-1 HPAP area Insulin area
Dax=L51-3974-1 41492 121731.6667
DSx=L111-
3974-1 170808.3333 364063.1667
XDx=L163-
3974-1 95998.33333 325545
Ojx=L234-3974-
1 123781 434645.3333
HRx=L334-
3974-1 36672.66667 116785.6667
Non-pregnant
mouse
3974-2 HPAP area Insulin area
Ycx=L31-3974-2 118341.3333 274959.3333
BTx=L81-3974-2 88366.33333 209352.6667
CVx=L144-
3974-2 48160.33333 131770.6667
Wax=L211-
3974-2 64325 163922
WSx=L264-
3974-2 37543 102509
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Pair 4
Pregnant mouse
3866-1 HPAP area Insulin area
Abx/L221-3866-
1 100834.3333 268309.3333
FXx=L54-3866-1 62334.66667 168298
RDx=L105-
3866-1 141908 370420.6667
Aqx=L172-3866-
1 300651.6667 712194.6667
CRx=L272-
3866-1 54808.66667 140986.6667
Non-pregnant
mouse
3866-2 HPAP area Insulin area
BHx=L111-
3866-2 50829.33333 92658.33333
SWx=L165-
3866-2 68449.66667 167785
Rox=L222-3866-
2 108338.3333 229977
GGx=L312-
3866-2 105145.3333 202245
Acx/L3-3866-2 17270.66667 79556
Appendix
160
HPAP labelling index
HPAP labelling index in pregnant mice
REPLICATE 1 3866-1 0.40
REPLICATE 2 3940-1 0.33
REPLICATE 3 3900-1 0.25
REPLICATE 4 3974-1 0.34
HPAP labelling index in non-pregnant mice
REPLICATE 1 3866-2 0.48
REPLICATE 2 3940-2 0.50
REPLICATE 3 3900-2 0.39
REPLICATE 4 3974-2 0.40
Proportion of small islets and beta-cell clusters negative for HPAP in pregnant and non-pregnant animals
Proportion of small islets or beta cell clusters negative for HPAP
REPLICATE 1 3866-2 0.215152
REPLICATE 2 3940-2 0.154696
REPLICATE 3 3900-2 0.140187
REPLICATE 4 3974-2 0.261589
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HPAP labelling index in islets over ductal compartment in pregnant animals
Pregnant mice
beta-cell number positive for HPAP in
ducts beta-cell number negative for HPAP in duct
L51-3974-1 0 3
L201-3974-1 Test 2 0 3
L234-3974-1 0 4
L95-3866-1 Test2 0 4
L105-3866-1 1 3
L172-3866-1 3 1
L191-3866-1 extra 1 3
L330-3866-1 Test 2 0 1
L214-3866-1 extra 0 6
L231-3940-1 1 2
L251-3940-1extra 3 2
l351-3940-1 extra 2 0
L361-3940-1 0 12
L113-3900-1 Test 2 0 1
L250-3900-1 test 2 1 0
sum 12 45
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Pregnant mice
beta-cell number positive for HPAP in
islets
beta-cell number positive or not for HPAP in
islets
L51-3974-1 74 284
L201-3974-1 Test 2 90 359
L234-3974-1 264 1035
L95-3866-1 Test2 117 334
L105-3866-1 458 1310
L172-3866-1 197 605
L191-3866-1 extra 90 229
L330-3866-1 Test 2 102 249
L214-3866-1 extra 118 350
L231-3940-1 57 175
L251-3940-1extra 54 202
l351-3940-1 extra 219 721
L361-3940-1 183 548
L113-3900-1 Test 2 129 548
L250-3900-1 test 2 16 104
sum 2168 7053
Ratio of HPAP labelling index of non-pregnant animals over that of pregnant animals in same pair
Pair 1 1.21
Pair 2 1.51
Pair 3 1.58
Pair 3 1.18
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Beta-cell mass in pregnant and non-pregnant animals
Beta-cell mass ( g)
Non-pregnant mice pregnant mice
REPLICATE 1 3866 0.0005 0.00139
REPLICATE 2 3900 0.0004221 0.00052
REPLICATE 3 3940 0.00046 0.00059
REPLICATE 4 3974 0.000453 0.001
Body weight in pregnant and non-pregnant animals
Body weight (g)
Non-pregnant mice pregnant mice
REPLICATE 1 3866 20.8 34.2
REPLICATE 2 3900 21.6 33.4
REPLICATE 3 3940 23 32.7
REPLICATE 4 3974 25.8 32.1
Pancreas weight in pregnant and non-pregnant animals
pancreas weight (g)
Non-pregnant mice pregnant mice
REPLICATE 1 3866 0.2394 0.387
REPLICATE 2 3900 0.2076 0.3088
REPLICATE 3 3940 0.1958 0.3372
REPLICATE 4 3974 0.2629 0.3344
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CHAPTER 4
ORIGIN OF NEW BETA-CELLS IN THE DOUBLE TRANSGENIC (Z/AP; RIP-CreERTAM) MICE IN TWO PREGNANCIES
HPAP and Insulin area in pregnant and non-pregnant animals in five coded sections per animal
Pair 1
Pregnant mouse HPAP area
Insulin
area cell count for HPAP cell count for insulin
de=314L4083-3132 15265 22448 123 228
hg=41L4083-3132 25734 53513 177 371
mx=171L4083-3132 85064 200348 653 1526
nb=94L4083-3132 47896 89660 372 767
yr=232L4083-3132 90106 171969 532 1080
Non-pregnant
mouse HPAP area
Insulin
area cell count for HPAP cell count for insulin
fd=302L4083-3135 4061 5824 48 73
lf=181L4083-3135 86931 124130 664 977
ob=105L4083-3135 57378 97551 535 877
vc=241L4083-3135 34644 55309 275 451
vw=34L4083-3135 81476 116084 638 1022
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Pair 2
Pregnant mouse HPAP area
Insulin
area
cell count for
HPAP cell count for insulin
ah=275L4124-3312 48361 290520 258 1656
as=25L4124-3312 28596 56602 184 402
gw=298L4124-3312 39177 178159 242 1115
hk=405L4124-3312 16427 78607 108 638
ty=104L4124-3312 84637 420310 472 2254
Non-pregnant
mouse HPAP area
Insulin
area
cell count for
HPAP cell count for insulin
kl=25L4124-3414 9989 53550 70 408
pb=294L4124-3414 26012 105676 209 786
qw=204L4124-3414 53462 179136 378 1309
rf=394L4124-3414 15173 43787 100 232
rt=101L4124-3414 45960 146692 290 1008
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Pair 3
Pregnant mouse HPAP area Insulin area cell count for HPAP cell count for insulin
dg=181L4173-3434 70063 244820.6667 542 1810
bn=31L4173-3434 15339 37768.66667 124 322
hb=321L4173-3434 32725 112133 241 837
mu=401L4173-3434 12402 90465 104 721
wx=94L4173-3434 22758.3333 72602.66667 146 384
Non-pregnant mice HPAP area Insulin area cell count for HPAP cell count for insulin
br=314L4173-3621 54809.6667 129142.3333 353 984
ce=401L4173-3621 12342.6667 32973.33333 100 242
cv=81L4173-3621 37273.6667 107751.3333 277 833
kd=21L4173-3621 22062.6667 65754.33333 172 541
az=171L4173-3621 37744 107616.3333 268 680
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HPAP labelling index
PREGNANT ANIMALS
total pixel number of area positive for HPAP/ total beta-cell number positive for HPAP/
total pixel number of area positive for insulin total beta-cell number positive for insulin
REPLICATE 1 4083 0.49 0.47
REPLICATE 2 4124 0.21 0.21
REPLICATE 3 4173 0.27 0.28
NON-PREGNANT ANIMALS
total pixel number of area positive for HPAP/ total beta-cell number positive for HPAP/
total pixel number of area positive for insulin total beta-cell number positive for insulin
REPLICATE 1 4083 0.66 0.64
REPLICATE 2 4124 0.28 0.28
REPLICATE 3 4173 0.37 0.36
Ratio of HPAP labelling index of non-pregnant animals over that of pregnant animals in same pair
HPAP labelling index in non-pregnant mouse /
HPAP labelling index in pregnant mouse
count area
1.36 1.35
1.34 1.34
1.35 1.26
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Beta-cell mass in pregnant and non-pregnant animals
Pregnant mice Non-pregnant mice
beta cell mass (mg) beta cell mass (mg)
REPLICATE 1 4083 0.38 0.21
REPLICATE 2 4124 0.87 0.30
REPLICATE 3 4173 0.46 0.34
Proportion of small islets and beta-cell clusters negative for HPAP in pregnant and non-pregnant animals
proportion of small islets or beta-cell clusters HPAP negative
Pregnant mice Non-pregnant mice
REPLICATE 1 4083 0.16 0.07
REPLICATE 2 4124 0.47 0.26
REPLICATE 3 4173 0.35 0.24
Body weight in pregnant and non-pregnant animals
Pregnant mouse Non-pregnant mouse
body weight (g) body weight (g)
REPLICATE 1 4083 28.7 18.4
REPLICATE 2 4124 34.8 22.5
REPLICATE 3 4173 38.2 22.7
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Pancreas weight in pregnant and non-pregnant animals
Pregnant mouse Non-pregnant mouse
pancreas weight (g) pancreas weight (g)
REPLICATE 1 4083 0.3035 0.2194
REPLICATE 2 4124 0.4254 0.3054
REPLICATE 3 4173 0.5124 0.3426
Beta-cell area in pregnant and in non-pregnant animals
total pixel number of cross-sectional beta-cell area
Pregnant mice Non-pregnant mice
REPLICATE 1 4083 135.4326116 117.3228
REPLICATE 2 4124 168.8701292 141.2879
REPLICATE 3 4173 136.9145803 135.1334
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Insulin-positive cell number in ductal compartment and number of ducts containing insulin-positive-cells in one pregnancy
Insulin-positive cell number in ductal compartment
One pregnancy Pregnant mouse Non-pregnant mouse
replicate 1 6 7
replicate 2 7 0
replicate 3 14 0
replicate4 0 4
Number of ducts associated with insulin-positive
cells
One pregnancy Pregnant mouse Non-pregnant mouse
replicate 1 3 5
replicate 2 5 0
replicate 3 6 0
replicate 4 0 1
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Insulin-positive cell number in ductal compartment and number of ducts containing insulin-positive-cells in two pregnancies
Insulin-positive cell number in ductal compartment
Two pregnancies Pregnant mouse Non-pregnant mouse
replicate 1 8 0
replicate 2 6 6
replicate 3 4 1
Number of ducts associated with insulin-positive
cells
Two pregnancies Pregnant mouse Non-pregnant mouse
replicate 1 3 0
replicate 2 3 2
replicate 3 2 1
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Combined results of insulin-positive cell number in ductal compartment and number of ducts containing insulin-positive-cells in one
and two pregnancies
Insulin-positive cell number in ductal compartment
Pregnant mice Non-pregnant mice
6 7
7 0
14 0
0 4
8 0
6 6
4 1
Number of ducts associated with insulin-positive
cells
Pregnant mice Non-pregnant mice
3 5
5 0
6 0
0 1
3 0
3 2
2 1
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Combined results of HPAP labelling indices in one and two pregnancies
COMBINED RESULTS OF HPAP LABELLING INDICES OF ONE AND TWO PREGNANCIES
Group Pregnant non-pregnant
two pregnancies
Pair 1 0.49 0.66
Pair 2 0.21 0.28
Pair 3 0.27 0.37
one pregnancy
Pair 1 0.40 0.48
Pair 2 0.33 0.50
Pair 3 0.25 0.39
Pair 4 0.34 0.40
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Combined results of proportion of small islets and beta-cell clusters in one and two pregnancies
Proportion of small islets or beta-cell clusters negative for HPAP
One pregnancy
Non-pregnant mice Pregnant mice
PAIR 1 0.15 0.22
PAIR 2 0.14 0.15
PAIR 3 0.07 0.14
PAIR 4 0.08 0.26
Two pregnancies
Non-pregnant mice Pregnant mice
PAIR 1 0.07 0.16
PAIR 2 0.26 0.47
PAIR 3 0.24 0.35
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CHAPTER 5
ORIGIN OF NEW BETA-CELLS AFTER DIABETIC RECOVERY IN TRIPLE TRANSGENIC MICE (Z/AP; RIP-CreERTAM; pIns-
c-MycERTAM) MICE
HPAP labelling index and beta-cell mass results
Mice after Diabetic recovery
Replicate HPAP area Insulin area
HPAP area/Insulin
area tissue area
Insulin area/tissue
area
pancreas weight
(g)
beta-cell mass
(g)
3899-2 8967.6667 196960.6667 0.04 279807552 0.000703915 0.1901 0.00013
3662-7 16174.8 170826.4 0.09 428332480 0.000398817 0.276 0.00011
3662-8 13258.2 262798.6 0.05 274762368 0.000956458 0.2251 0.00022
Diabetic mice
Replicate HPAP area Insulin area
HPAP area/Insulin
area tissue area
Insulin area/tissue
area
Pancreas weight
(g)
beta-cell mass
(g)
3899-1 9451 114378.6667 0.08 320789760 0.000356553 0.1991 7.09898E-05
3662-2 7500 283237.4 0.03 374769536 0.000755764 0.2622 0.00020
3662-3 8602.8 257035.4 0.03 352900480 0.000728351 0.159 0.00012
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Untreated control mice
Replicate HPAP area Insulin area
HPAP area/Insulin
area tissue area
Insulin area/tissue
area
pancreas weight
(g)
beta-cell mass
(g)
D02 2190.3333 1357328 0.002 238185536 0.005698616 0.1717 0.0010
D05 516 1274149.667 0.0004 144463296 0.008819885 0.0994 0.00088
3662-4 790 729482.6667 0.001 189581312 0.003847862 0.2361 0.00091
Fed blood glucose results
Mice after Diabetic Fed glucose (mM) Fed glucose (mM) Fed glucose (mM)
recovery before 4OHT pulse
after last pulse of
4OHT
4weeks after last pulse of
4OHT
Mouse number 3899-2 5.1 17 11.8
Mouse number3662-7 4.9 22.2 12.2
Mouse number3662-8 3.5 25.6 7.5
Diabetic mice
Mouse number3899-1 4.5 19.1
Mouse number3662-2 5.7 30.7
3662-3 3.2 14
Untreated control mice
Mouse numberD02 4.1
Mouse number D05 3.3
Mouse number 3662-4 8
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CHAPTER 6
BETA-CELL FUNCTIONALITY IN THE SINGLE TRANSGENIC (pIns-c-MycERTAM) MICE AFTER DIABETIC RECOVERY
Fed blood glucose results
Fed blood glucose (mM)
3 month old wild type mice 3 month old pIns-cMycERTAM 3 month old pIns-cMycERTAM mice 12 month old pIns-cMycERTAM mice
treated with 4-OHT mice before treatment shortly after 4-OHT pulse 9 months after the last 4-OHT pulse
8.7 3.6 29.4 3.9
6.8 3.7 27.3 3.8
6.5 4.8 33.2 2.6
7.1 3.7 6.3
4.5
3.9
3.8
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Intraperitoneal glucose tolerance test (IPGTT) results
IPGTT in 3 month old untreated wild-type mice
replicate 1 2 3 4
Time (min) blood Glucose (mM) blood Glucose (mM) blood Glucose (mM) blood Glucose (mM)
0 6.9 8.9 6.2 7.0
10 9.8 10.4 20.4 19.4
30 16.8 18 15.4 23.2
60 12.4 14.3 9.2 16.4
120 7.8 7.7 5.9 9.7
IPGTT in 3 month old untreated pIns-cMycERTAM mice
replicate 1 2 3
Time (min) blood Glucose (mM) blood Glucose (mM) blood Glucose (mM)
0 2.8 4.5 4.2
10 6.5 6.1 11.0
30 16.9 16.9 13.5
60 13.6 19.4 9.4
120 5.1 8.7 5.4
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IPGTT in 12 month old pIns-c-MycERTAM mice treated with peanut oil
replicate 1 2 3 4
Time (min) blood Glucose (mM) blood Glucose (mM) blood Glucose (mM) blood Glucose (mM)
0 3.4 2.4 2.6 1.5
10 13.8 10.4 11.3 7.7
30 17.7 11.5 16.8 10.2
60 13.8 6.9 8.0 5.3
120 5.7 2.6 2.8 3.2
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